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 ABSTRACT 
A PSD95/Dlg/ZO-1(PDZ)-binding motif (PBM) in the E6 protein of high-risk, cancer-
causing human papillomaviruses (HPV) targets a subset of cellular PDZ domain-containing 
proteins involved in diverse regulatory processes including cell polarity and proliferation, for 
proteasome-mediated degradation.  Interaction with this select group of PDZ domain-
containing proteins is negatively regulated by cAMP-dependent protein kinase (PKA) 
mediated phosphorylation of the E6 PBM.  This thesis has sought to address the hypothesis 
that the PBM of E6 plays an important role within the HPV life cycle.  This study has shown 
that deletion of the E6 PBM from HPV18 genomes affects the morphology and growth of 
viral episome-containing human keratinocytes and furthermore links E6 PBM function to 
viral episome replication (maintenance replication and differentiation-dependent 
amplification).  Loss of negative regulation of the E6 PBM by mutation of the PKA 
recognition motif was associated with increased cell growth and indeed the growth of 
wildtype HPV18 genome-containing cells responded to changes in PKA signalling.  
Constitutive E6 PBM function was also associated with invasion of cells suggesting that 
malignant progression of HPV-infected cells may be linked to changes in PKA signalling.  
Modulation of the E6 PBM function in the viral genome-containing cells was associated with 
a change in protein levels of the PDZ domain-containing protein discs large (hDlg) and 
changes in the non receptor protein phosphastase PTPN13 specific species.  
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Infectious agents and cancer 
The link between human cancers with viral origin was made nearly half a century ago with 
the discovery of the association between Epstein-Barr virus (EBV) and Burkitts Lymphoma in 
1965 (Javier & Butel, 2008).  Since then it has become apparent that a number of viruses play 
significant roles in the multistage development of human cancers.  Approximately 15-20% of 
cancers are associated with viral infections (zur Hausen, 2001; Parkin, 2006).  Oncogenic 
viruses can contribute to different steps of the carcinogenic process, and the association of a 
virus with a given cancer can be anywhere from 15 to 100% (Parkin, 2006).  
Human tumour viruses belong to a number of different families, including the RNA virus 
families Retroviridae and Flaviviridae and the DNA virus families Hepadnaviridae, 
Herpesviridae and Papillomaviridae.  These viruses have been associated with the 
development of a range of cancers including human papillomavirus (HPV) with anogenital 
cancers and head and neck cancers; hepatitis B virus (HBV) and hepatitis C virus (HCV) with 
hepatocellular carcinoma; human T-cell leukaemia virus (HTLV-I) with adult T-cell 
leukaemia and Kaposi’s sarcoma herpes virus (KSHV), also referred to as human herpes virus 
type 8 (HHV-8), associated with Kaposi’s sarcoma and Castelmans disease (McLaughlin-
Drubin & Munger, 2008).   More recently, a human polyomavirus has been linked to the 
development of Merkel cell polyomavirus (MCV); a rare but aggressive form of skin cancer 
(Shuda et al., 2008).  Besides viruses, other pathogens have been identified as oncogenic 
agents.  These include the bacterium Helicobacter pylori which are associated with gastric 
cancer and the parasite Schistosoma hematobium which has been associated with bladder 
cancer (zur Hausen, 2009). 
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Even though human oncogenic viruses belong to different virus families and utilise different 
strategies to cause cancer, these viruses do share a common trait of chronicity.  Each of these 
viruses are capable of establishing a long-term latent or chronic infection in humans, 
increasing exposure time to viral oncogenic pressures and the risk of developing cancer.  
DNA viruses such as HPV, EBV, HBV and KSHV usually persist by either integrating into 
the host genome or remaining episomally.  Whilst these viruses act directly to promote 
carcinogenesis, for other viruses such as the human immunodeficiency virus (HIV) the 
mechanism of action is indirect.  By inducing immunosuppression, HIV acts to permit 
secondary infections with other viruses including HHV-8 (Feller et al., 2007), HPV (Palefsky, 
2009) and EBV (Tran et al., 2008), which can subsequently result in associated cancers.  
The study of oncogenesis is difficult because it is a slow and uncertain process in a living 
organism, and when transformed tissue is found, oncogenesis has already occurred and the 
process remains unobserved (McLaughlin-Drubin & Munger, 2008).  It is further complicated 
by the enormous diversity in forms of cancer and oncogenic mechanisms available.  The use 
of human Adenoviruses (Ads) has somewhat enhanced our understanding of this process.  
Adenoviruses lack an association with human cancers, however they have the ability to 
transform rodent cells (Sawada et al., 1988) and a subset of the viruses can induce tumours in 
experimentally infected rodents (Graham et al., 1984).  As such, the use of these viruses 
serves as excellent models for better understanding the process of tumourogeneisis.  
Oncogenic viruses have given us an insight into cancer biology as well as cell biology 
through their transforming properties and served as experimental models to investigate the 
discovery of oncogenes and tumour suppressors as well as processes that govern cellular 
pathways (McLaughlin-Drubin & Munger, 2008; Carrillo-Infante et al., 2007).  The 
revelation that a subset of human cancers are caused by viruses presents a means by which the 
burden of cancer may be reduced and viruses are now attractive targets on which to base 
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preventative therapeutics.   It is proposed that future research is likely to uncover further links 
between human cancers and infectious agents and this will further increase our understanding 
of carcinogenesis (zur Hausen, 2009). 
1.2 Human papillomaviruses and cancer 
The papillomaviruses of the family Papovaviridae are viruses with many distinctive 
properties.  They are small double stranded DNA viruses, which replicate vegetatively in the 
nucleus of epithelial cells such as the keratinocytes of the skin.  At present more than 120 
distinct HPV types have been characterised based on DNA sequence analysis (Bernard et al., 
2010).  Variations in restriction enzyme digest pattern have led to further division into 
different subtypes.  The two main HPV genera are the Alpha and the Beta papillomaviruses, 
with approximately 90% of currently characterised HPVs belonging to one or other of these 
groups (Doorbar, 2006).  Differences in the regulatory sequences and the coding potential 
within the viral genome are likely to explain the significant differences that are apparent in 
the biology of different papillomaviruses (Doorbar, 2005).  Alpha papillomaviruses constitute 
the mucosal or genital species and can be further classified according to their oncogenic 
potential, into low-risk and high-risk subtypes dependent upon their propensity to cause 
cancer. Within the group of muscoal HPVs, “high-risk” types are distinguished from “low 
risk” types depending upon the risk of an infected individual to develop carcinogenic lesions.  
Low risk HPV types, of which HPV6 and 11 predominate, are associated with the formation 
of benign hyperproliferative lesions including condyloma acuminata, which clinically 
manifests as genital warts and rarely progress to malignancy (Longworth & Laimins, 2004).  
The association between HPV and human cancer was first proposed more than 30 years ago 
by Harald zur Hausen (zur Hausen et al., 1975; zur Hausen, 1976).  Since then, HPV 
genotypes have been shown to account for more than 99.7% of cervical cancers (Walboomers 
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et al., 1999).  Twelve HPV types have been classified as high-risk, and infections with these 
subtypes of HPV, have a higher propensity to progress to cervical carcinoma (Bouvard et al., 
2009), with HPV16 and 18 being the most common types.  The most common member of the 
high-risk group is HPV16 which accounts for more than 60% of all cervical cancers.   
A meta-analysis of HPV type specific prevalence data worldwide from 1990-2010 showed 
that infection with HPV types 16 and 18 accounted for between 70 and 76% of all global 
cervical cancer infections, with prevalence rates of HPV16 and HPV18 at 57% and 16% 
respectively (Li et al., 2011).  Whilst HPV16 is the predominant HPV type of squamous cell 
cervical carcinomas, HPV18 predominates within adenocarcinomas (Bulk et al., 2006).  
Cervical cancer is the second most common cancer for women worldwide, accounting for 
274,000 deaths per annum (World Health Organisation, 2008).  A meta-analysis of 194 
studies from 1995 to 2009 with more than 1 million women with normal cytological findings 
found a global prevalence of 11.7% and the highest HPV prevalence rates in Sub-Saharan 
Africa (24.0%), Eastern Europe (21.4%), and Latin America (16.1%) (Bruni et al., 2010).   
Cancers of the uterine cervix are classified into two major histological forms, dependent upon 
the cell type from which the cancer originated, with squamous cell carcinoma (SSC) 
constituting around 80-85% of these malignancies, whilst adenocarcinomas, derived from 
adenomatous glandular cells are more infrequent, occurring in only 15-20% of cases (Green et 
al., 2003).   
In addition, papillomaviruses are also able to infect exo-genital and oral epithelial cells and 
cause lesions ranging in severity from benign to malignant.  It is estimated that 40% of penile, 
vulva, and vaginal cancers are attributed to HPV infection whilst 90% of anal cancers are 
predicted to be a result of infections with this virus (Parkin & Bray, 2006).  Infection with 
HPV has also been suggested to be an aetiological factor for oral and oro-pharyngeal cancer 
(Gillson & Shah, 2003).   The incidence of the overall HPV prevalence in oro-pharyngeal 
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cancers has increased over the past 10 years (Chaturvedi et al., 2011; Mehanna et al., 2011), 
rising from 40.5% before 2000 to 72.2% between 2005 and 2009, whilst HPV prevalence at 
non-oropharyngeal sites has not increased during the same time frame (Mehanna et al 2011; 
Chaturvedi et al., 2011).  
HPVs that infect the gential tract are sexually transmitted and it is estimated that around two 
thirds of individuals who have sexual relations with an infected partner will become infected 
(Bekkers et al., 2004).  However the majority of these infections are sub clinical and 
infections cleared (Singer et al., 1995).  Whilst the majority of infections are transient, 
persistent infection with a high-risk HPV type is the greatest risk factor for cervical cancer 
(zur Hausen, 2006).  Additional risk factors include multiple sexual partners, use of the 
contraceptive pill, co infection with human immunodeficiency virus (HIV) and cigarette 
smoking (Kjellberg et al., 2000).  Whilst the exact mechanisms are unknown, these cofactors 
are proposed to influence progression to carcinogenesis through suppression of the immune 
system, resulting in increased viral persistence, or through elevating levels of cellular DNA 
damage. 
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1.3 Preventative and Therapeutic strategies 
Disparities exist in mortality rates of cervical cancer worldwide, and a significant burden is 
imparted upon the developing world, with 85% of deaths occurring within low income 
countries (World Health Organisation, 2008).  Within developed countries the incidence and 
mortality rates of cervical squamous cell carcinoma have significantly reduced by as much as 
80% over the past four decades, due largely to the widespread implementation of effective 
screening programmes which enable detection and early treatment of pre-cancerous changes 
within the cervix (Parkin & Bray, 2006).   
Whilst development of low grade lesions is frequent within young women, development of 
cervical cancer is more prevalent within older women, with an average age of around 45 years 
for diagnosis of cervical cancer (Schiffman et al., 2007).  Often progression from the initial 
infection to malignancy can take many years and even decades.  Therefore the use of 
screening programmes can be effective at detection of pre-cancerous lesions (Bekkers et al., 
2004).   
The Papanicolaou test or Pap smear is used routinely to screen women for the detection of 
abnormal changes to the cervical epithelium resulting from a high risk HPV infection, which 
may have the propensity to progress to invasive cervical cancer (Bekkers et al., 2004). 
Although the use of Pap tests has reduced both the incidence and the associated mortality of 
cervical cancer by over 70% (Safaeian & Solomon, 2007), many women still go untreated 
because they do not routinely undergo Pap test screening.  An analysis of the CDCs 1998 
National Health Interview Survey of more than 100,000 individuals revealed that only 83% of 
women aged 40 to 64 years reported Pap testing in the previous 3 years (Selvin & Brett, 
2003).  Screening rates are lower among women who are uninsured, younger, poorer, and less 
educated, probably contributing to the higher cervical cancer mortality in minority groups 
such as African Americans (Jemal et al., 2007).  Even among women who undergo screening, 
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approximately 40% of those with abnormal Pap test results fail to return for additional testing 
(Kupets & Paszat, 2011; Felix et al., 2009).  These statistics show that although cervical 
cancer screening is effective, many individuals are still not receiving preventive measures. 
For this reason, an HPV vaccine has become another important means for physicians to help 
reduce the risk of cervical cancer and other diseases associated with the HPV virus. 
The ability of the HPV to self-assemble virus like particles (VLPs) by the synthesis and 
assembly of its major L1 capsid protein formed the basis of the prophylactic vaccine currently 
in use.  Early experimental studies showed immunogenicity and efficacy with L1 VLP 
vaccines in three animal models: the dog (Suzich et al., 1995), cow (Kirnbauer et al., 1996) 
and rabbit (Breitburd et al., 1995).  In these studies, immunisation with L1 VLPs induced 
circulating neutralising antibody to the L1 capsid protein and the animals were completely 
resistant to challenge with large amounts of the virus.  
To date, two prophylactic vaccines have been granted licences by the European Union, the 
bivalent Cervarix® vaccine (GlaxoSmithKline) and the quadravalent Gardasil® vaccine 
(Merck).  Currently, the HPV quadrivalent recombinant vaccine is approved for the 
prevention of HPV types 6, 11, 16, and 18.  The vaccine requires 3 doses, with the second and 
third doses at 1 to 2 months and then 6 months, respectively.  The Gardasil® vaccine is 
approved for use in boys, girls, men, and women between the ages of 9 and 26 years (CDC, 
2010). A second type of vaccine, the HPV bivalent Cervarix® recombinant vaccine, is 
approved by the US Food and Drug Administration (FDA) for females age 10 to 25 years to 
prevent HPV types 16 and 18 (CDC, 2010).  Vaccination is currently recommended for all 
girls and women aged 9 to 26 years whether or not they have ever tested positive for any HPV 
infection.  The Gardasil® vaccine is beneficial for at least 5 years, and studies have been 
carried out to determine overall long-term efficacy (Harper, 2007).  Results from vaccine 
studies for the Gardasil® and Cervarix® vaccines have shown that both vaccines are highly 
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effective (FUTURE II, 2007; Paavonen et al., 2007; Hendrix, 2008).  In a study of 5455 
women, in which 2723 women received the Gardasil® vaccine, 98% of the women who were 
given the vaccine were protected against precancers (cervical intraepithelial neoplasia [CIN] 2 
or 3, adenocarcinoma) cause by HPV for at least 3 years (CDC, 2010).  
It is important to note that these vaccines are preventative.  Women already infected with 
these HPV types are not protected and vaccination must therefore be received prior to the 
onset of sexual activity (Kahn, 2009).  In the UK, a Cervairx® immunisation programme has 
been approved for use in girls aged 12-13 since September 2008.  Although some evidence of 
cross protection of HPV types has been observed, there is a continual need for cervical 
screening alongside the programme of vaccination, incurring significant costs.  Furthermore, 
the high cost of the vaccine and its cold chain delivery, in addition to poor healthcare 
infrastructure, may prevent implementation of vaccination programmes within developing 
countries where the disease burden is greatest (Agosti & Goldie, 2007).  As such, work has 
begun on finding new alternatives to the L1 VLP vaccine currently in use.  One approach 
currently under development is the use of the minor capsid protein L2 for immunotherapy.  
Protection studies in naïve cattle and rabbits and in-vitro neutralisation assays suggest that 
unlike L1 vaccines, L2 vaccines might provide broad spectrum protection (Gambhira et al., 
2006; Gambhira et al., 2007a; Gambhira et al., 2007b).  The challenge now for this potential 
vaccine is to produce neutralising antibody titres at levels comparable to L1 vaccines (Roden 
et al., 2000).   
Recent studies have identified synthetic long peptides as a potential therapeutic vaccine 
against HPV.  Vaccination studies with synthetic long peptides spanning the complete HPV16 
E6 and E7 proteins have been shown to induce an HPV16 specific CD4
+ 
and CD8
+
 t-cell 
response in 100% of patients with advanced vulvar intraepithelial neoplasia (Kenter et al., 
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2009).  This work provides the first evidence of a therapeutic vaccine against HPV for which 
there is currently none.  
1.4 Genome Organisation 
The HPV virus is a small non-enveloped virus (~55nm in diameter) with an icosahedral 
capsid (Longworth & Laimins, 2004).  Between papillomaviruses the overall genomic 
organisation is highly conserved.  Viral genomes are composed of ~8 kb of double-stranded 
circular DNA which can be divided into three main regions: a long coding region (LCR) and 
early (E) and late (L) regions (Figure 1.1).  The LCR, sometimes referred to as the upstream 
regulatory region (URR) is a non-coding region which contains transcriptional, post-
transcriptional and replicative cis-regulatory elements (Graham, 2008; Thierry, 2009).  
Located within this region is the viral origin of replication (ori), the early promoter and 
overlapping binding sites for transcriptional activators and repressors (Thierry, 2009).  The 
viral genome is composed of eight open reading frames (ORF) which encode for proteins 
which can be categorised into early and late proteins according to their expression during the 
virus life cycle (Longworth & Laimins, 2004).  The early region of the viral genome consists 
of genes designated E1-E7 which are responsible for transcription, viral genome replication 
and transformation of the host cell, whilst the late region contains the L1 and L2 genes which 
encode the structural capsid protein.  The L1 protein is the primary structural element, with 
infectious virions containing 360 copies of the protein organised into 72 capsomeres (Modis 
et al., 2002).  
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1.4.1 Regulation of viral transcription during the HPV life cycle  
Viral genes are transcribed from a single DNA strand into polycistronic mRNA from two 
main promoters: an early and late promoter, with usage dependent upon the differentiation 
state of the cell which divides the viral life cycle into early and late stages (Kalantari & 
Bernard, 2006).  Aside from these two main promoters, further promoters are also likely to be 
utilised, and may play important roles in the virus life cycle (Ozbun & Myers, 1998; Milligan 
et al., 2007).  A process of alternative splicing mechanisms are known to regulate the 
combination of proteins expressed (Longworth & Laimins, 2004).   
1.4.2 Regulation of transcription from the early promoter 
During the early phase of the HPV life cycle the viral DNA is transcribed from the early 
promoter referred to as P97 in HPV type 16,  P99 in HPV type 31 and P105 in HPV18 (Francis 
et al., 2000; Wang et al., 2011), lying immediately upstream of the E6 ORF within the LCR.  
Transcripts terminate at polyadenylation sites within E5 and L1 (Stubenrauch & Laimins, 
1999).  Polycistronic transcripts encoding the E1, E2, E6 and E7 proteins are derived from the 
early viral promoter with coding potential for the  E5 and E1^E4 proteins (Figure 1.1).  
However these latter proteins are not detectable within undifferentiated cells and are likely to 
be expressed at low levels (Longworth & Laimins, 2004).  HPV transcription is regulated by 
cis-responsive elements within the LCR and involves the E1 and E2 viral proteins in addition 
to a number of cellular factors (Longworth & Laimins, 2004).  The LCR contains the binding 
sites for a number of cellular transcription factors including SP1 (Longworth & Laimins, 
2004) (Figure 1.1).  The E2 protein is well characterised as a viral transcription factor and has 
been shown to function as both a transcriptional activator and repressor dependent upon the 
levels of this protein within the cell (Bouvard et al., 1994).  The E2 protein has four binding 
sites (E2BS 1-4) which have a conserved arrangement between HPV types (Kalantari & 
Bernard, 2006).  At low levels E2 binds only to the E2BS4, for which the protein has the 
Introduction 
11 
highest affinity and activates transcription (Steger & Corbach, 1997).  However, as the levels 
of E2 accumulate within the cell as a result of enhanced transcription, the other E2BS become 
occupied by E2 such as E2BS1 and E2BS2 (Steger & Corbach, 1997).  HPV transcription is 
therefore regulated by a negative feedback loop whereby levels of transcription are regulated 
by the abundance of E2 within the cell (Steger & Corbach, 1997).  As such, regulation of 
HPV transcription from the early promoter acts to modulate expression of the early proteins. 
1.4.3 Regulation of transcription from the late promoter 
Within the stratum spinosum of the epithelium, viral transcription is induced from the late 
promoter sequence located within the E7 ORF, designated P742 in HPV31, P670 in HPV16 and 
P811 (Graham, 2006; Wang et al., 2011).  Utilisation of this promoter is dependent upon 
differentiation-specific cellular factors thereby limiting the expression of late transcripts to the 
terminally differentiating layers of the epithelium (Longworth & Laimins, 2004).  Late viral 
transcripts from the differentiation-dependent promoters of HPV16, 31 and 18 terminate at 
polyadenylation sites at the end of the L1 ORF and  encode for the capsid proteins L1 and L2 
in addition to the E1, E2, E1^E4 and E5 proteins (Graham, 2006; Wang et al., 2011).   
Late gene expression is also regulated post-transcriptionally due to the presence of cis-acting 
RNA elements within late viral transcripts (Graham, 2006).  A late regulatory element (LRE), 
overlapping with the 3’ end of the L1 gene, represses late gene expression within 
undifferentiated cells, ensuring that the viral capsid proteins are not expressed until the cells 
reach the upper layers of the epithelium (Cumming et al., 2008). 
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Figure 1.1 Genomic organisaton of HPV18.  The genome can be divivded into three 
regions. The early region, late region and the long control region (LCR). The early region 
contains the open reading frames from E6,E7,E1,E2,E4 and E5 whilst the late region contains 
the L1 and L2 ORFs. The P
105 
early promoter lies upstream of the E6 ORF whillst the 
differntiation inducuble late promoter P
811 
lies within the E7 ORF. Adapted from Doorbar 
2006. 
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1.5 Virus Life Cycle 
The life cycle of HPV is closely linked to the differentiation status of the host epithelium. 
Infection by papillomaviruses requires that virus particles gain access to the epithelial basal 
layer and enter the dividing basal cells.  HPV infects a primitive basal keratinocyte via 
microabrasion of the mucosal epithelium (Figure 1.2).  Following infection, HPV genomes 
are established as extrachromosomal elements or episomes (Moody & Laimins, 2010).  The 
receptor for entry of the virus into cells is currently unknown; however heparin sulphate has 
been shown to mediate the initial attachment of virions to cells (Shafti-Kermat et al., 2003).  
It is thought that α-6 integrin may play a secondary role in the attachment and efficient entry 
of this virus into the cell (McMillan et al., 1999).  Other candidate receptors for HPV have 
been suggested such as laminin-5 which is able to mediate binding to the extracellular matrix 
(Culp et al., 2006). 
Following attachment, the virus is internalised.  The mode of internalisation is not conserved 
among HPV types with HPV16 infecting cells through clathrin-dependent endocytosis (Day 
et al., 2003) and HPV31 by caveolae (Bousarghin et al., 2003).  Following internalisation, the 
viral capsid disassembles within the endosome compartment and N-terminal cleavage of L2 
by furin-a proprotein convertase, necessary for translocation of the capsid protein into the 
cytoplasm (Richards et al., 2006).  L2 mediates relocation of the viral genome from the 
endosomal compartment into the nucleus, where the L2-chaperoned viral genome 
accumulates at ND10 bodies (Day et al., 2004).  
Replication of HPV DNA requires the E1 and E2 replication proteins, however due to the 
limited coding capacity of the HPV genome, the virus is also dependent upon the host cellular 
replication machinery for viral replication (Chow & Broker, 2006).  During early stages of the 
virus life cycle transcription from the early promoter results in expression of the early 
proteins: E6, E7, E1 and E2 (Longworth & Laimins, 2004).  The E2 protein plays several 
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roles during productive infection and in basal cells; expression of E2 is required for the 
initiation of viral DNA replication and genome segregation.  HPVs do not encode 
polymerases or any other enzymes necessary for viral replication, therefore in addition to the 
E1 and E2 proteins, the virus must also utilise the host cell replication proteins to mediate 
viral DNA synthesis (Chow & Broker, 2006).  The viral genomes are replicated in synchrony 
with cellular DNA replication.  The E2 protein is responsible for anchoring the viral proteins 
to mitotic chromosomes through the Brd4 protein (You et al., 2004) or directly attaching to 
repetitive ribosomal sequences within the viral DNA as is in the case of HPV8 (Poddar et al., 
2009).  It is speculated that the immediate early events of virus growth involve an 
amplification of virus copy number from 1-10 copies/cell to 50-100 episomes/cell.  The next 
phase of virus growth is one of plasmid maintenance in which the virus and the cell replicate 
in tandem and there is no amplification of virus copy number. This occurs in the suprabasal 
layers of the stratified epithelium.  
The infected cell then enters the differentiating compartment of the epithelium (Figure 1.2). 
HPV replication occurs in cells which have committed to terminal differentiation and have 
exited from the cell cycle.  To overcome this, the proliferative capacity of these HPV-infected 
cells is uncoupled from differentiation and is controlled by a number of cellular factors, 
including members of the Retinoblastoma (Rb) family, consisting of p105, p107 and p130 
(Dyson et al., 1989).  The inactivation of these targets results in the release and activation of 
E2F transcription factors that drive expression of S phase genes. Different HPV types have 
been shown to display varying degrees of affinity for pRB and a correlation with oncogenic 
potential has been proposed, with high risk E7 proteins possessing a significantly greater 
affinity for pRB than E7 proteins of low risk types (Munger et al., 1989).  Whilst E7 proteins 
of low risk HPV types are able to associate with pRB, this interaction is not sufficient to 
enable activation of E2F responsive genes (Longworth & Laimins, 2004).As a result of 
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unscheduled DNA replication cellular apoptosis is triggered within these cells, which is 
counteracted by the E6 oncoprotein through degradation of the host tumour suppressor protein 
p53, preventing cell growth inhibition in undifferentiated and differentiated cells (Scheffner et 
al., 1990).  The high-risk E5 protein cooperates with E6 and E7 to promote hyperproliferation 
of infected cells and is likely to facilitate malignant progression (DiMaio & Mattoon, 2001).  
The productive phase of the virus life cycle is dependent upon cellular differentiation, 
commencing within differentiating cells of the epithelium.  For high risk HPV types including 
16 this occurs within the spinous layers of the epithelium (Peh et al., 2004; Breitburd et al., 
1987).  As previously mentioned, during the productive phase of the virus life cycle 
transcription occurs from the differentiation-dependent late promoter-P811 located within the 
E7 ORF (Wang et al., 2011).  This promoter drives the expression of E1, E2, E4 and E5 
proteins as well as the late proteins L1 and L2 (Wang et al., 2011).  Virus gene expression is 
markedly upregulated in these upper layers, especially the E4 protein, which is expressed 
abundantly in replication competent suprabasal cells.  Viral DNA amplification generates 
thousands of viral genomes (Cheng et al., 2005). Recent work from the Chow lab has 
suggested that HPV is capable of amplifying its genome in the G2M phase of the cell cycle 
since viral DNA was able to initiate amplification in G2 arrested cells (Wang et al., 2009).  
Moreover, they suggest that E7 alone is sufficient to induce this G2 arrest required for viral 
DNA amplification, following S-phase re-entry, by inducing the inhibitory phosphorylation of 
cdc2 and cdc25 (Banerjee et al., 2011), a method shared by other viruses including the vpr 
protein of HIV type 1 and the p30 protein of HTLV-1 (Datta et al., 2007; Kino et al., 2005). 
The late phase L1 and L2 proteins encapsulate newly synthesised viral genome which is then 
followed by the shedding of the virus from the uppermost layers of the epithelium via the 
natural sloughing of the skin (Figure 1.2). 
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Figure 1.2  The HPV life cycle.  Key stages of the virus life cycle are shown in relation to 
what stage of keratinocyte differentiation they occur. The virus enters through micro 
abrasions in the surface of the skin and infects the basal layer of the epithelium. Genomes are 
established in the basal cell layer with a copy number of around 50 genomes per cell. After 
cell division, one daughter cell migrates from the basal cell layer and undergoes 
differentiation. Differentiation within the spinous layers of the cell leads to the production of 
thousands of copies of the genome per cell. The virus is packages by the L1 and L2 capsid 
proteins and shed from the upper most layers of the epithelium.   
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1.6 HPV Proteins 
1.6.1 E1 and E2 proteins  
Among the first of the viral proteins to be expressed are the replication factors E1 and E2. 
Both E1 and E2 have been shown to be important for the replication of a number of HPV 
types (Ustav & Stenlund, 1991).  These proteins are thought to form a complex which binds 
to sequences at the viral origin of replication and recruits polymerases and proteins to mediate 
replication (Conger et al., 1999).  As well as binding to specific sequences at the origin of 
replication, both E1 and E2 proteins bind to each other (Frattini & Laimins, 2004a; Sun et al., 
1996). 
E1 is highly conserved amongst papillomaviruses and has been shown to play an important 
role in papillomavirus replication as an origin (ori) recognition protein initiator (Wilson et al., 
2002; Chow & Broker, 2006).  E1 has a weak affinity for a consensus motif (AACNAT) 
repeated six times within the viral origin of replication (Chen & Stenlund, 2001).  The E1 
protein contains two regions of DNA binding; a DNA binding domain (DBD) and non 
specific binding of the helicase domain (Stenlund, 2003). 
The E1 protein also exhibits helicase activity, permitting the separation of the viral DNA 
strands ahead of the replication complex (Hughes & Romanos, 1993).  In addition, it recruits 
a number of cellular replication proteins including the DNA polymerase α-primase (Park et 
al., 1994) and the replication protein A (RPA) which prevents the reassociation of dsDNA by 
binding to ssDNA (Loo & Melendy, 2004).  It is also able to associate with a number of 
cellular Hsps (heat-shock proteins) in particular Hsp40 and Hsp70 and this contributes to the 
formation of E1 di-hexamers (Lee et al., 1999). 
The E2 protein, of 40-45 kDa, is integral to the regulation of HPV replication and 
transcription (Morgan & Donaldson, 2006).  E2 is the primary ori binding HPV protein and 
consists of three main domains: an N-terminal transactivation (TA) domain of approximately 
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200 amino acids., a central flexible hinge region and a C-terminal dimerisation and DNA 
binding domain (DBD) approximately 90 amino acids (Chow & Broker, 2006).  The hinge 
region of E2 overlaps with the E4 ORF and is a highly divergent region of the protein, with 
variable sequence and length between E2 proteins of different HPV types, and is thought to 
provide a flexible linker between the two other domains.  E2 is a site specific DNA binding 
protein that helps to recruit E1 to the origin but also plays a role in regulating viral 
transcription from the early promoter.  Binding sites for E2 are located adjacent to sites for 
cellular transcription factors that activate the early promoter (Stubenrauch et al., 1998). 
Within dividing basal cells, E2 protein acts to ensure equal segregation of the viral genomes 
by tethering the viral genomes to the mitotic spindle during cell division (Sekhar et al., 2010).  
At the basal layer of the epithelium, cell division results in one daughter cell remaining in the 
basal layer and one daughter cell migrating up to the suprabasal layers to begin the 
differentiating process.  E2 ensures that viral episomes are distributed into both new daughter 
cells and therefore maintains a source of HPV DNA for persistent infection.  To achieve this, 
E2 either interacts directly with the chromatin or indirectly through cellular factors that tether 
the viral genome to the cellular chromatin (Skiadopoulos & McBride, 1998; Zheng et al., 
2005). 
During a natural infection, E1 is expressed at low levels and as mentioned previously, 
requires the presence of E2 in order to be efficiently targeted to its binding sites.  E2 
associates with E1 primarily through its N-terminus and binds to DNA as a dimer through its 
C terminus (Moscufo et al., 1999).  The initial E1:E2 origin complex is thought to be inactive 
for replication initiation and is proposed to serve as a template for formation of an active 
replication complex.  Whilst E1 and E2 proteins are required for HPV replication, only the E1 
protein is required for elongation (Chow & Broker, 2006). 
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The episomal replication of HPV in keratinocytes has been shown to be controlled by the 
levels of E1 and E2 proteins, since increasing the expression of either results in an increase in 
the copy number of HPV genome per cell (Frattini & Laimins, 1994b).  The link between 
replication and transcription provides a mechanism by which the virus can limit the timing 
and duration of genome amplification.  This suggests that HPV transcription is therefore 
regulated by a negative feedback loop whereby levels of transcription are regulated by the 
abundance of E2 within the cell (Steger & Corbach, 1997).  The E2 protein has also been 
shown to regulate the viral early promoter- p97 in HPV16,  p105 in HPV18 and p99 in 
HPV31, with high levels of E2 acting to downregulate the expression of E6 and E7 in 
experimental systems (Hines et al., 1998).  E2 binds to the papillomavirus oncoproteins E6 
and E7, leading to the modulation of their functions (Gammoh et al., 2006; Grm et al., 2005) 
In BPV, E1 negatively regulates the activation of the major early promoter by E2 (Le Moal et 
al., 1994) and this mechanism may be responsible for the suppression of transformation by E1 
(Schiller et al., 1989).  High-risk, but not low-risk HPV E2 proteins can induce themselves 
growth arrest and apoptotic cell death in several HPV-negative carcinoma cell lines.  
Apoptosis can occur via a p53-dependent as well as independent pathways (Demeret et al., 
2003; Parish et al., 2006).  E2 binds to the cellular protein p53. Expression of p53 can inhibit 
papillomavirus DNA replication and alter the transcriptional activity of E2 (Frattini et al., 
1997; Lepik et al., 1998) 
Cells expressing E1 in the absence of other viral gene products exhibit perturbations of the 
cell cycle, resulting in decreased duration of the G1 phase and increased S and G2 phase 
durations (Belyavskyi et al., 1996).  These cell cycle effects are coincident with changes in 
histone H1 kinase activity and the abundance and timing of appearance of cyclin D1 
(Belyavskyi et al., 1996).  Thus, in addition to the viral oncoproteins, E1 may also participate 
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directly in altering the host cell growth program which is an essential component of the 
papillomavirus life cycle. 
The fidelity of cellular replication is controlled by a number of pathways which block the 
propagation of damaged DNA (Sancer et al., 2004; Harper & Elledge, 2007). These are 
controlled by the ATM (ataxia-telangiectasia mutated) and the ATR (ATM and Rad3-related) 
kinases (Harper & Elledge, 2007).  ATM mediates the cellular response to double strand 
breaks (Lee & Paull, 2007) whilst ATR controls the response to UV damage as well as stalled 
replication forks (Cimprich & Cortez, 2008).  Both kinases control the G1, S and G2 cell cycle 
checkpoints necessary for viral replication upon differentiation.  Recent work from the 
McBride lab has shown that E1 and E2 are able to activate the DNA damage response 
pathways by phosphorylating a number of proteins of the pathway including Chk2 and H2AX 
(Sakakibara et al., 2011).  This work substantiates an earlier study by Moody and colleagues 
who showed that HPV31 genomes were able to activate the ATM DNA damage response 
pathways by phosphoryltaing CHK2, BRCA1 and NBS1.  Furthermore, activation of CHK2 
was required to induce caspase 3 and caspase 7 activation, required for viral genome 
amplification (Moody & Laimins, 2009).  More recent studies by Fradet-Turcotte and 
colleagues have shown that nuclear export of E1 prevents S phase arrest and activation of a 
DNA damage response.  Moreover, complex formation of HPV E1 with E2 was associated 
with the prevention of undifferentiated cells from undergoing a DNA damage response 
(Fradet-Turcotte et al., 2011).  
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1.6.2 L1 and L2 Proteins 
The HPV genome is surrounded by an icosahedral capsid-55nm in diameter and composed of 
two structural proteins, the major (L1) and minor (L2) capsid proteins respectively.  L1 
proteins are highly conserved to form 72 five fold capsomers with each composed of five L1 
major proteins, with a hole in the centre, where L2 is thought to associate (Holmgreen et al., 
2005).  It is believed that L2 localises with L1 through a hydrophobic region near the C-
terminus of the protein (Finnen et al., 2003). 
Although L1 can spontaneously self-assemble to form an icosahedral VLP, L2 plays an 
integral role in assembly of virions and is required for efficient encapsidation of viral DNA 
(Holmgreen et al., 2005).   The assembly of infectious virions in the upper epithelial layers is 
thought to require the E2 protein in addition to the capsid proteins L1 and L2 (Day et al., 
1998) and it has been suggested that E2 may improve the efficiency of viral encapsidation. 
Activation of the differentiation dependent late promoter results in production of viral 
transcripts from which late proteins L1 and L2 are transcribed.  Capsid proteins accumulate 
after the onset of genome amplification with L2 expression preceding the expression of L1 
(Florin et al., 2002). 
Capsids have evolved to fulfill a number of roles, critical to the establishment of infection.  
For non enveloped viruses such as HPV, the capsid proteins act to coat the nucleic acid and 
also provide the initial interaction site of the viral particle with the host cell (Horvath et al., 
2010).  The capsid proteins relocate from the cytoplasm to the nucleus and assemble into 
icosahedral capsids in which the viral genomes are packaged (Conway & Myers, 2009). 
Further studies have identified roles for the capsid proteins in the endosomal escape of virions 
(Campos & Ozbun, 2009) and the nuclear transport of the HPV genome (Campos & Ozbun, 
2009; Florin et al., 2006).  
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The L1 and L2 capsid proteins are also implicated in the process of cellular entry, uncoating 
and delivery of viral genomes to the nucleus.  Although cell surface interactions 
predominantly depend on the major capsid protein L1, it seems likely that the secondary cell 
surface receptor is L1-specific, although it is possible that L2 may contribute to surface 
interactions (Sapp & Bienkowska-Hoba, 2009). 
L2 localises to the nucleus via a nuclear localisation signal, situated at its N and C termini, 
and once there it associates with promyelocytic leukaemia (PML)  bodies (Florin et al., 2004).  
The PML is the structural component of ND10 bodies.  ND10 bodies are distinct subnuclear 
structures which have been proposed as transient deposition sites for nuclear proteins as well 
as having implications in the control of transcription (Doucas, 2000), cell growth and 
apoptosis (Gottifredi & Prives, 2001).  Moreover, ND10 bodies have been proposed as sites 
of papillomavirus replication (Swindle et al., 1999).  Studies have shown that the HPV E1 and 
E2 proteins associate and accumulate in these ND10 bodies (Swindle et al., 1999) as well as 
the L2 protein (Day et al., 1998).  The L2 association is thought to result in ND10 body 
reorganisation, followed by the recruitment of preformed L1 capsomeres and the assembly of 
L1 and L2 protein into an icosahedral virion (Florin et al., 2004).  L2 is also required for 
efficient packaging of the genome (Stauffer et al., 1998) and enhancing virus infectivity 
(Roden et al., 2001) as loss of L2 in the context of HPV31 resulted in a 100-fold reduction in 
the packaging efficiency and virus infectivity compared with wild type virus (Holmgreen et 
al., 2005).  
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1.6.3 E5 Protein 
E5 is a hydrophobic membrane-bound protein, approximately 83 amino acids in length, which 
associates with the Golgi apparatus, endoplasmic reticulum and perinuclear membrane. 
Although the definitive functions of this protein remain unresolved, accumulating evidences 
have suggested that E5 oncoprotein may also contribute to cervical carcinogenesis through 
modulating cellular signalling pathways in addition to augmenting the immortalization 
potential of E6 and E7. 
The HPV E5 proteins have little homology to the BPV counterparts; however their mode of 
action is similar.  In BPVs, E5 encodes the primary transforming activity and acts by 
associating with the platelet derived growth factor (PDGF) receptor (Schneider-Gaadickle & 
Schwarz, 1986).  In addition, overexpression of the HPV E5 protein increases the 
phosphorylation of the epidermal growth factor, EGF receptor as well as inhibiting its 
degradation, suggesting that HPV E5 action involves binding to the epidermal growth factor 
(EGF) and that this binding is similar to that seen by BPV and the PDGF (Conrad et al., 1993; 
Rodriguez et al., 2000).  In addition, E5 expression results in increased EGFR signalling and 
activation of the MAP kinase (MAPK) pathway, which augments the activities of E6 and E7, 
resulting in uncontrolled proliferation (Crusis et al., 1997).   E5 also contributes to the actions 
of E6 and E7 by modulating the transit of signalling proteins through the endoplasmic 
reticulum (ER) as well as interacting with factors such as the B cell receptor-associated 
protein 31 (BAP31) and the vacuolar H
+ 
-ATPase in endosomes (Rodriguez et al., 2000; 
Regan & Laimins 2008).  
Knock out studies revealed that loss of E5 within the context of the complete HPV31 genome 
resulted in impaired activation of the late viral protein functions in differentiating cells, 
suggesting that its primary activity is in differentiating cells (Fehrmann et al., 2003).  A 
similar E5 knock out study in HPV16 NIKS cells suggested that E5 may have a subtle role in 
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the productive stages of the virus life (Genther et al., 2003).  Further evidence to support E5 
as a potential oncogene comes from transgenic mouse studies.  Data from these studies 
indicate that high level expression of HPV16 E5 in the skin induces epithelial 
hyperproliferation that results in tumour formation (Maufort et al., 2007).  Furthermore, in 
oestrogen-treated mice, expression of E5 alone can induce cervical cancers (Maufort et al., 
2010).   
Moreover, it has been suggested that E5 may play a role in viral immune evasion by down 
regulating the major histocompatibility complex (MHC) and preventing the transport of HLA 
class 1 molecules to the cell surface, by retaining the complex in the Golgi apparatus, 
preventing clearance of the infected cells by the immune response (Ashrafi et al., 2006). 
Multiple mechanisms, including activation of EGFR or inflammatory cell signaling pathways 
and immune regulation have been implicated in malignant transformation of HPV by E5.  
Therefore, targeting E5 may be a rational approach for chemoprevention and treatment of 
cervical cancer, and understanding its oncogenic processes may help the design of novel 
therapeutic strategies.  
1.6.4 E4 Protein  
E4 is the most highly expressed of all the HPV proteins.  The E4 open reading frame (ORF) is 
translated from spliced transcripts as a fusion with the first 5 amino acids of E1 to generate 
E1^E4 fusion proteins (Chow et al., 1987).  Even though the E4 ORF lies in the early region 
of the genome, E4 is known to accumulate in the cell at the time of viral genome 
amplification and its loss has been shown to disrupt late events in a number of experimental 
systems (Wilson et al., 2005; Nakahara et al., 2005; Wilson et al., 2007; Peh et al., 2004). 
E1^E4 is first expressed within the upper layers of the epithelium, with expression coincident 
with the onset of vegetative viral genome amplification, suggesting a role for this protein in 
initiation of the productive phase of the HPV life cycle (Peh et al., 2002).  The continued 
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presence of E1^E4 in cells within the uppermost layers of the epithelium in which virion 
assembly occurs, also implies a function for this protein during the later stages of virus 
production and egress (Peh et al., 2002).  Although the exact function E1^E4 is still to be 
elucidated, there is growing evidence to suggest that this protein may have multiple roles at 
different stages of the virus life cycle; with E4 function being regulated through a 
combination of proteolytic cleavage and phosphorylation.  This protein is thought to be 
involved in a number of cellular processes including ND10 reorganisation, G2 arrest and 
chromosomal re-replication, keratin association and late gene expression. 
A sequence alignment of E1^E4 proteins reveals little sequence homology between HPV 
types, and variation in the size of E1^E4 proteins.  The E4 ORF lies within the hinge region 
of the E2 ORF, which has been shown to link the two major functional domains of the E2 
protein and is an extremely divergent region of this protein (Zhu, 1999).  Whilst there are 
considerable differences between E1^E4 proteins of different HPV types, particularly within 
the central region of the protein, certain domains show a greater degree of conservation. 
Sequences within the amino and carboxy termini of E1^E4 are important in mediating 
biological and biophysical characteristics of this protein.  The N terminus of E1^E4 proteins 
contain a (LLXLL) sequence motif, which has been shown to be required for the association 
between E4 and the keratin cytoskeleton (Roberts et al., 1994) and also binding to 
mitochondria (Raj et al., 2004) (Figure 1.3).  E1^E4 proteins from a number of different 
subtypes have been shown to associate with these keratin filaments. The function of the 
keratin filaments is to maintain cell structure and protect the epithelial tissues from stress. 
Whilst E1^E4 proteins from high risk, low-risk and benign viruses are able to co-localise with 
these filaments, not all induce their collapse in transient transfection assays (Doorbar et al., 
1991).  The association perhaps permits the egress and escape of virus particles during the 
later stages of the virus life cycle (Doorbar et al., 1991).  More recent studies have shown that 
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the cellular cysteine protease calpain is capable of cleaving the 16E1^E4 protein to generate 
species that lack the N terminus (Khan et al., 2011).  These C-terminal fragments are able to 
multimerize and form amyloid-like fibers.  This can lead to accumulation of 16E1^E4 and 
disruption of the normal dynamics of the keratin networks (Khan et al., 2011).  
The E1^E4 protein also contains a number of other biologically functional regions such as the 
proline rich region near the C terminus which has been linked to the ability of E1^E4 to 
interfere with G2-M progression of the cell cycle (Davy et al., 2002; Knight et al., 2004) 
(Figure 1.3).  Moreover, sequences at the C terminus of E1^E4 also mediate interactions 
between itself (Wang et al., 2004; Roberts et al., 1997) and a cellular RNA helicase (Doorbar 
et al., 2000) (Figure 1.3). 
1.6.4.1 E4 and the cell cycle 
Several studies have now found that E1^E4 expression in cultured cells can influence the cell 
cycle.  The G2/M checkpoint of the cell cycle ensures that the DNA is replicated correctly, 
prior to entry into mitosis.  This prevents the proliferation of damaged cells.  The ability of 
E1^E4 to cause cell cycle arrest in G2 and to antagonise E7-mediated cell proliferation is a 
common feature of E1^E4 proteins from a number of HPV types including HPV1, 11, 16 and 
18 (Knight et al., 2004; Davy et al., 2002; Nakahara et al., 2002).  
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Figure 1.3  The E4 protein.  A schematic representation of the E1^E4 protein in which 
the known biological functional regions are highlighted as well its interaction with cellular 
targets. Adapted from Roberts, 2006.   
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Several studies have identified that different E1^E4 proteins are able to target different 
mechanisms of the G2/M transition to cause cell cycle arrest (Knight et al., 2006; Davy et al., 
2006).  Interestingly, the G2 arrest function of HPV1 E1^E4 is mediated by a truncated 16 
kDa E1^E4 polypeptide species, lacking the extreme N terminus of the E1^E4 protein and not 
by the full length E1^E4 protein (Knight et al., 2004).  Moreover, coexpression of the full 
length and truncated E1^E4 isoforms have a far greater deleterious effect on keratinocyte cell 
growth than the individual polypeptides themselves (Knight et al., 2004). 
In addition to the ability of E1^E4 to induce a G2 arrest, the viral protein has also been shown 
to inhibit entry into S phase.  Co-expression of both the full length HPV1 E1^E4 protein and 
an N-terminally truncated E1^E4 species within keratinocytes prevented entry of these cells 
into S phase (Knight et al., 2004).  It is not clear what role E1^E4 induced cell cycle arrest 
plays in the productive life cycle, however it is believed to counteract the effects of E7 which 
acts to push these cells into S phase (Flores et al., 2000).  Furthermore, the HPV1 E1^E4 
protein has been shown to inhibit cellular DNA replication by blocking the recruitment of 
cellular licensing factors onto chromatin (Roberts et al., 2008).  It is believed that this is a 
mechanism by which the virus produces an environment which is suitable for viral DNA 
replication without competition from the host.   
1.6.4.2 E4 and Late Gene Expression 
A number of studies have identified E1^E4 actions that might indicate a role for E1^E4 in 
regulating gene expression during the later stages of the virus life cycle.  Full length HPV16 
E1^E4 has been shown to bind via its C-terminus to a RNA helicase, E4-DEAD-box protein 
(E4-DBP) (Doorbar et al, 2000) (Figure 1.3).  This interaction between E4-DBP and E1^E4 
has been shown to inhibit the RNA-independent ATPase activity of E4-DBP activity.  
Moreover, the E1^E4 protein of both high risk and low risk types (HPV16, HPV18 and 
HPV1) have been shown to associate with the serine-argenine (SR)-specific protein kinase 
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(SRPK1) (Bell et al., 2007) (Figure 1.3).   In the context of HPV1, this interaction results in a 
sequestration of E1^E4 to inclusion bodies with subsequent phosphorylation of the E1^E4 
protein.  To date, phosphorylation of the E1^E4 protein of high risk types has not yet been 
observed.  SRPK1 is known to phosphorylate SR proteins, many of which have an intimate 
role in regulating RNA splicing and it is speculated that association of SRPK1 with E1^E4 
may represent a mechanism of regulating viral late gene expression (Bell et al., 2007).  
1.6.4.3 E4 and the virus life cycle 
Whilst E1^E4 proteins are not detected within undifferentiated cells, there is evidence to 
suggest that the E1^E4 protein contributes to the early stages of the virus life cycle.  A study 
by Wilson and colleagues showed that HFK cell lines containing HPV18 genomes exhibited 
slower growth rates than an E1^E4 deletion mutant, suggesting that E1^E4 may have a 
negative effect on cellular proliferation (Wilson et al., 2007).  E1^E4 has also been shown to 
be important for the replication of viral genomes during the early stages of the virus life cycle.  
In an HPV16 background, the ability of viral genomes to replicate following transfection into 
immortalised keratinocyte NIKS cells was investigated.  An E1^E4 mutant, expressing only 
the first 9 aa of the protein affected the ability of the virus to replicate extrachromosomally, 
suggesting that the E1^E4 protein may play an important role during viral genome replication 
(Nakahara et al., 2005).  Moreover, a leucine rich motif within HPV16 E1^E4 was shown to 
be important for this replication (Nakahara et al., 2005).  This function of E1^E4 appears to 
be subtype specific, as the same effect was not seen in E1^E4 proteins of other HPV subtypes 
including HPV11, HPV18 and HPV31 (Wilson et al., 2005; Fang et al., 2006; Wilson et al., 
2007; Nakahara et al., 2005).  
The E1^E4 protein of HPV16, HPV18 and HPV31 have also been shown to be involved in 
the late stages of the virus life cycle, including in the differentiation dependent amplification 
of viral genomes.  E1^E4 proteins of HPV18 and HPV31 in which the E4 ORF had been 
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severely truncated had a reduced ability to undergo viral genome amplification upon 
differentiation (Wilson et al., 2005; Wilson et al., 2007).  Whilst suprabasal DNA synthesis 
was reduced within HPV31 E1^E4 mutant organotypic raft cultures (Wilson et al., 2005), 
consistent with observations seen in HPV16 (Nakahara et al., 2005) this function was not 
shown in HPV18, indicating that this functions may differ between different HPV types 
(Wilson et al., 2007).  As previously discussed, the G2 arrest function of HPV E1^E4 is a 
conserved feature among different HPV types (Knight et al., 2006; Davy et al., 2006).  A 
recent analysis of the contribution of this function to viral DNA amplification showed that it 
is not required for viral genome amplification or capsid protein induction (Kinght et al., 
2011). 
1.7 E6 and E7 Proteins 
1.7.1 Transforming abilities of E6 and E7  
Similar to the oncoproteins of other DNA viruses, the E6 and E7 proteins of HPV govern the 
rate of cell division as well as cell cycle and differentiation patterns.  As previously 
mentioned, during epithelial differentiation the P97 of HPV16 and the P105
 
of HPV18 directs 
the expression of E6 and E7 genes necessary for S phase entry (Francis et al., 2000; Wang et 
al., 2011).  Further expression of E6 is achieved through splice donor sites in some HPV 
types, which give rise to truncated forms of E6, named E6* (Shirasawa et al., 1994).  While 
some papillomavirus types, such as HPV16, seem to have splicing patterns that allow the 
expression of up to four E6* species, dependent upon the position of the downstream splice 
acceptors, HPV18 appears to transcribe only one mRNA species that is capable of expressing 
E6* (Pim et al., 2009).  The polypeptide product of this transcript shares the first 44 amino 
acids with full-length E6 before the first splice donor site; thereafter, it has 13 unique amino 
acids that are derived from E6 intronic sequences (Pim et al., 2009).   
Introduction 
31 
The primary transforming activity of high risk HPVs is provided by the E6 and E7 
oncoproteins.  The HPV E7 gene encodes for the major transforming function of high risk 
HPV types and expression of E7 is necessary and sufficient for immortalization of human 
keratinocytes whilst E6 contributes towards immortalization within these cells.  These two 
proteins act together in the development of HPV-induced cancers, with the action of one 
protein complementing that of the other. 
The expression of high risk E7 proteins by themselves can immortalise human keratinocytes 
at a low frequency, but E6 has no such activity (Tommasino & Crawford, 1995).  The 
combination of both E6 and E7 proteins are highly efficient at immortalising most types of 
primary cells (Hawley-Nelson et al., 1989; Munger et al., 1989).  Immortalised keratinocytes 
are not fully transformed and conversion to malignancy is dependent upon factors in addition 
to HPV.  Co-transfection assays of primary baby rat kidney epithelial cells with HPV DNA 
with the activated ras oncogene demonstrated that high risk HPV types but not low risk types 
are able to cooperate with ras to transform primary cells (Storey et al., 1988).  In addition, 
transgenic mice that express high risk E6 and E7 in epithelial cells develop squamous 
carcinomas when treated with low doses of oestrogen (Arbeit et al., 1996).  In this mouse 
model, E7 alone is sufficient to induce high grade cervical dysplasia and invasive cervical 
malignancies.  The addition of E6 results in larger and more extensive cervical cancers, 
indicating the cooperative activity of the E6 and E7 proteins in promoting tumourigenesis 
(Riley et al., 2003).  Furthermore, the growth of keratinocytes expressing both E6 and E7 in 
organotypic raft cultures results in changes similar to those seen in high-grade squamous 
intraepithelial lesion in vivo (McCance et al., 1988) which further supports this argument.  
In the productive phase of the HPV life cycle, E6 and E7 promote the proliferation of 
undifferentiated and differentiated suprabasal cells as well as protect the cells from apoptosis. 
This leads to the accumulation of DNA damage and mutations that can result in 
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transformation and the development of cancers.  To understand how the cooperative actions 
of these proteins lead to cancer, it is useful to examine the multiple pathways targeted by 
these proteins.  
1.7.2 E7 Protein 
E7 is an 18 kDa nuclear phosphoprotein of approximately 100 aa in length, with functional 
similarities to the E1A adenovirus protein and the SV40 large T antigen (TAg) (Howley & 
Lowry, 2009).  The E7 gene product from the high risk HPV types functions to deregulate 
normal cell cycle controls and increase DNA synthesis without affecting the differentiation 
programme of the host keratinocyte. It achieves this by interacting with a variety of cell 
regulatory proteins. 
1.7.2.1 E7 and Rb 
E7 proteins do not possess any intrinsic enzymatic or DNA-binding activities but function by 
binding to several cellular factors.  The best characterised of these interactions is with the Rb 
tumour suppressor and also with the related family members p107 and p130.  E7 interacts 
with Rb family members through a conserved LXCXE motif that is present in its amino-
terminus of high risk E7 proteins (Munger et al., 1989).  As previously mentioned, the Rb 
family of “pocket” proteins includes the prototypical Rb as well as p107 and p130, and these 
proteins are differentially expressed throughout the cell cycle (Berezutskaya et al., 1997; 
Classon & Dyson, 2001).  Whilst Rb is constitutively expressed throughout the cell cycle, 
p107 is expressed predominantly during S phase, and p130 predominates at G0 (Classon & 
Dyson, 2001).  The Rb family of proteins controls the G1-S transition by regulating the 
activity of the E2F family of transcription factors (Dyson, 1998).  The E2F family is a group 
of transcription factors of which there are at least 8 family members.  Some of the family 
members act as transcriptional activators, whilst others act as transcriptional repressors.  E2F-
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E2F #1-5 has binding domains for pocket proteins whilst E2F #6-8 lack these residues and 
therefore regulate gene expression independently of Rb family members (Lammens et al., 
2009).  Binding of Rb occurs through one of three conserved regions contained on the E7 
protein (termed CR1-CR3) (Lammens et al., 2009).   
Regulation of the G1/S checkpoint ensures that environmental conditions are favourable and 
that the cellular DNA is undamaged prior to commitment of the cell to DNA replication.  
Stimulation of cells to divide by extracellular signals induces transcription of cyclin D which 
forms a complex with the cyclin dependent kinases (CDK) -4 or -6 catalytic subunits which 
then phosphorylate downstream target proteins of the retinoblastoma pathway (Sherr & 
McCromick, 2002).  During G1-S progression, these cyclin kinase complexes hypo-
phosphorylate Rb, resulting in the release of pRb from E2F transcription complexes and the 
transcription of genes involved in DNA synthesis such as cyclin A and cyclin E, promoting 
early S phase entry and DNA synthesis (Zerfass et al.. 1995) (Figure 1.4).  In addition, high 
risk E7 is able to bind to another E2F family group member-E2F1 and induce E2F1 driven 
transcription (Hwang et al., 2002).  Thus E7 is able to activate the host cells DNA replication 
machinery for the purposes of viral DNA replication.  Different HPV types have been shown 
to display varying affinities for pRb.  High risk E7 proteins possess significantly greater 
affinity for pRb than low risk types.  Whilst E7 proteins of low risk HPV types are able to 
associate with pRB, this interaction is not sufficient to enable activation of E2F responsive 
genes (Longworth & Laimins, 2004).  These differences correlate with the oncogenic 
potential of these different HPV E7 subtypes (Munger et al., 1989). 
In addition to binding pRb, E7 mediates its degradation through the ubiquitin proteasome 
pathway, which is dependent upon the presence of calpain (Boyer et al., 1996; Jones et al., 
1997).  E7 is thought to associate with a cullin-2 ubiquitin ligase complex, which contributes 
to the degradation of the Rb protein (Huh et al., 2007).    
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Figure 1.4  The human papillomavirus E7 Rb pathway.  High risk human 
papillomaviruses E7 proteins induce proliferation in the cell through inhibition of Rb as well 
as constitutive activation of E2-F responsive genes. E7 also affects cellular gene expression 
through an interaction with histone deacetylase (HDAC’s). The inactivation of these targets 
results in the release and activation of E2F transcription factors that drive expression of S 
phase genes such as cyclin A and cyclin E. Adapted from Moody and Laimins 2010. 
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1.7.2.2 E7 and cyclins 
Besides targeting the pocket proteins, E7 can alter the cell cycle via additional mechanisms. 
The cyclin dependent kinase (CDK) inhibitors p21 and p27 are important regulators of growth 
arrest during epithelial differentiation and p21 is thought to act as a tumour suppressor in 
cervical carcinogenesis (Shin et al., 2009).  The main target of p21 and p27 in human 
keratinocytes is CDK2, which is important for G1-S phase entry and progression through its 
association with cyclin E and cyclin A (Desphande et al., 2005).  E7 proteins have many 
strategies to maintain high CDK2 activity.  The carboxy-termini of high risk E7 proteins bind 
p21 and p27, neutralising the inhibitory effects of cyclin E and cyclin A activities (Jones et 
al., 1997; Funk et al., 1997; Zerfass-Thome et al., 1996) allowing CDK2 activity to remain 
high.    
The ability of high risk E7 to inactivate p21 has been shown to contribute towards 
carcinogenesis (Shin et al., 2009).  Expression of mutants of E7 which are unable to inactivate 
p21, results in a marked reduction of E7 within mice, compared with control mice (Shin et al., 
2009).  Low risk E7 proteins are also able to bind to p21, however with a reduced affinity and 
decreased ability to abrogate the negative effects of p21 (Demers et al., 1994). High risk E7 
has been shown to increase the levels of the CDC25 phosphatase, which promotes the 
induction of tyrosine dephosphorylation of CDK2, promoting its activation which is another 
method by which E7 maintain high CDK2 activity (Nguyen et al., 2002; Bloomberg & 
Hoffman, 1999).    
1.7.2.3 E7 and HDACs 
In normal cells, Rb represses the transcription of E2F dependent promoters by directly 
binding to the E2F transactivation domain and recruiting various chromatin modifiers such as 
histone deacetylases (HDACs) (Harbour & Dean, 2000).  High risk E7 proteins can bind to 
HDACs through sequences distinct from those with which they bind Rb, and they can target 
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HDACs to repress transcription (Longworth & Laimins, 2004).  This E7-Rb-HDAC 
interaction is essential for viral episome maintenance as well as maintaining an S phase 
environment (Longworth & Laimins, 2004; Longworth et al., 2005).  Moreover, HDACs can 
directly deacetylate E2F factors, resulting in loss of their function (Marks et al., 2001).  E7 
also affects the expression of S phase genes by directly interacting with E2F factors (Hwang 
et al., 2002).  E7 binds to E2F6 which acts as transcriptional repressor by recruiting polycomb 
group (PcG) complexes.  This E7/E2F6 interaction is thought to prevent repression by 
E2F6/PcG complexes, creating an S phase environment which is condusive to virus 
replication (Hwang et al., 2002).  
1.7.2.4 Further functions of E7 
The E7 protein has also been shown to have a number of other diverse functions.  HPV16 E7 
can act as a transcription factor by binding to the TATA box binding protein (TBP) and 
inhibit the binding of this protein to DNA (Massimi et al., 1996).  Phosphorylation of E7 by 
Caesin Kinase II (CKII) modulates this E7 inhibitory function.  Interestingly, phosphorylation 
of the CKII motif of E7 has shown to enhance the ability of E7 protein to promote 
degradation of the pocket protein p130 in differentiated keratinocytes; pushing cells into S 
phase (Genovese et al., 2008). 
Most HPV associated malignancies have numerous chromosomal imbalances, including gains 
or losses of whole chromosomes (zur Hausen, 1999).  High risk HPV E7 protein has been 
shown to induce centrosome amplification, which correlates with cell division errors and 
occurs before the detection of genomic instability (Duensing et al., 2001).  E7 mediated 
centrosome amplification is dependent on high levels of CDK2 activity (Duensing et al., 
2006), linking this function to the degradation of Rb family members. E7 can also induce 
genomic instability through induction of DNA damage and activation of the ataxia ATM 
pathway.  High risk E7 proteins have been shown to activate the ATM pathway in 
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undifferentiated and differentiated keratinocytes (Moody & Laimins, 2009).  An important 
aspect of the ATM pathway is the induction of cell cycle checkpoints. E7 can abrogate these 
checkpoints to promote mitotic entry (Moody & Laimins, 2009).  It can also degrade claspin 
(Spardy et al., 2009) a regulator of the DNA damage signalling pathway.  Activation of DNA 
damage pathways by E7 is necessary for virus replication and malignant progression (Moody 
& Laimins, 2009).  HPV has also been linked to the Fanconi anaemia (FA) pathway (Kutler et 
al., 2003) which promotes DNA repair in response to replication stress.  HPV16 E7 normally 
activates the FA pathway, however for cells deficient for a normal FA pathway, the presence 
of E7 leads to increased chromosomal instability (Spardy et al., 2007).  
1.7.3 E6 Protein 
The E6 proteins of both low and high risk types are approximately 150 aa in length and share 
functional similarity with the adenovirus E1B and SV40 Tag viral oncoproteins (Thomas et 
al., 2006).  The major structural characteristic of E6 is the presence of two zinc fingers.  At 
the base of each of these fingers are two motifs containing zinc binding Cys-X-X-Cys 
domains which are conserved in all E6 HPV types (Howie et al., 2009)(Figure 1.5).  E6 has 
been shown to interact with a number of different proteins which mediate a number of cellular 
processes including the apoptotic pathway, chromosomal stability, epithelial organisation, 
differentiation, cell-cell adhesion, polarity and proliferation (Table 1.1). Some of these 
interactions will be discussed below. 
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Figure 1.5  E6 Protein.  Schematic representation of the E6 protein. The E6 proteins 
contain two zinc finger regions as medicated. E6 also contains at the C-terminus a consensus 
PDZ binding motif (E-T-Q-V/L). The E6AP binding region is also shown.  
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Table 1.1  Protein partners of HPV E6 protein.  Table of known functions of E6 as 
well as the cellular proteins which is known to bind. Mediators of cell polarity has been 
highlighted* as this group is expanded later in this study.  
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1.7.3.1 E6 and p53 
A major consequence of the targeting of the Rb-E2F and other cell cycle regulators by E7 is 
an increase in the levels of the tumour suppressor protein p53, which impairs growth and 
increases the susceptibility of E7 expressing cells to apoptosis (Eichten et al., 2004).  The role 
of p53 is to ensure the integrity of the cellular genome, preventing cell division after DNA 
damage or delaying it until the damage has been repaired.  Alternatively if the replication of 
damaged DNA has occurred or is too large, p53 can trigger apoptosis of the cell (Steele et al., 
1998; Lane, 1984).  
High risk E6 proteins use several mechanisms to interfere with p53 function. The E6 proteins 
of high risk HPV types, recruit the cellular E3 ubiquitin ligase E6-associated protein (E6AP) 
to a trimeric complex with p53 (Huibregtse et al., 1991), which leads to the subsequent 
ubiquitylation and degradation of p53 (Scheffner et al., 1990) (Figure 1.6).  E6 proteins of 
high risk and low risk types are also able to bind directly to p53 and block transcription by 
interfering with its DNA-binding activity (Lechner & Laimins, 1994) (Figure 1.5).  
Interestingly, low risk E6 proteins are also able to form complexes with E6AP (Brimer et al., 
2007); however this union does not result in the degradation of p53 (Li & Coffion, 1996) 
suggesting that other cellular factors may be targets for the low risk E6-E6AP complex.  
Another mechanism by which E6 proteins are able to interfere with p53 binding is through the 
binding of two related histone acetyltransferases p300 and CREB binding protein (CBP). The 
binding of these transcriptional co-activators, inhibits the ability of these proteins to acetylate 
p53 and therefore increase the stability of the E6 protein (Patel et al., 1999; Zimmermann et 
al., 1999).  E6 proteins have also been shown to bind to the histone acetyltransferase ADA3; 
however in contrast to p300 and CBP, E6 inactivates ADA3 by targeting it for degradation 
(Kumar et al., 2002).   
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Figure 1.6 E6 and the p53 pathway. E6 targets p53 for degradation via the ubiquitin 
proteasome pathway. The E6 protein associates with the ubiquitin ligase E6-AP. This 
complex then binds p53 leading to its subsequent ubiquitination. Adapted from Gittoni, 2009. 
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The ability of E6 to degrade p53 has consequences for tumour development as the abrogation 
of p53 function allows genetic mutations to accumulate that would normally have otherwise 
been repaired.  Interestingly, the E6 protein does not bind or degrade the p53 homologues- 
p63 and p73, suggesting that these proteins are not required for HPV-mediated transformation 
(Marin et al., 1998; Roth & Dobbelstein, 1999). 
1.7.3.2 p53 independent inhibition of apoptosis 
The E6 proteins of high risk and low risk types have been shown to interfere with the 
apoptotic pathway independently of p53, through its association with Bak, a pro-apoptotic 
protein, and member of the Bcl-2 family of proteins (Thomas & Banks 1998; Thomas & 
Banks 1999). Bak is an important regulator of apoptosis.  In response to cellular stress, Bak 
forms pores in the mitochondrial membrane, where it resides, resulting in the release of 
cytochrome c from mitochondria and activation of the apoptotic cascade, ultimately leading to 
death of the cell (Howie et al., 2009).  Analogously to its effect on p53, the E6 proteins are 
able to degrade Bak, via the ubiquitin mediated pathway, thereby blocking the induction of 
apoptosis (Thomas & Banks 1998; Thomas & Banks 1999).  In normal epithelia, Bak protein 
is highly expressed in the upper layers during differentiation.  It is possible that the 
degradation of this protein by the HPV E6 protein may be necessary for the progression of the 
virus life cycle.    
1.7.3.3 Resistance to cytokines 
Papillomaviruses have also evolved mechanisms to evade apoptosis mediated by the immune 
system (Howie et al., 2009).  In response to virus entry, a cell produces a number of 
inflammatory mediators such as tumour necrosis factor (TNF) – which is a potent inhibitor of 
keratinocyte proliferation (Basile et al., 2001).  Inflammatory cytokines can activate the 
extrinsic pathway through the TNF receptor TNFR1, FAS and the TNF-related apoptosis-
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inducing ligand (TRAIL) receptors (Howie et al., 2009).  High risk E6 proteins block 
apoptosis induced by TNF by directly binding to TNFR1, which inhibits the formation of a 
death inducing signalling complex and induction of apoptotic signals (Filippova et al., 2002). 
In addition to its interaction with TNFR1, E6 is also able to interact with the FAS-associated 
protein with death domain (FADD) and caspase 8 to block cell death in response to FAS and 
TRAIL (Garnett et al., 2006; Fillippova et al., 2004). 
1.7.3.4 E6 and Inhibition of Anoikis 
Another major apoptotic pathway targeted by the HPV E6 protein is anoikis, which is 
associated with anchorage independent growth (Chiarugi & Giannoni, 2008).  Integrins 
interact with the extracellular matrix (ECM) and regulate signal transduction through the focal 
adhesion kinase (FAK).  This interaction results in the activation of FAK and its downstream 
target paxillin which leads to cytoskeletal reorganisation and formation of focal adhesions.  
The bovine papillomavirus (BPV) E6 protein has been shown to bind to paxillin and this 
interaction correlates with its transforming function (Tong & Howley, 1997; Vande Pol et al., 
1998).  Moreover, HPV16 E6 has also been shown to bind to paxillin; however it is still 
unclear how this interaction contributes to pathogenesis (Tong & Howley, 1997; Vande Pol et 
al., 1998).  Fibulin 1 is another target of HPV16 E6 (Du et al., 2002) which is involved in 
transformation and tumour invasion.  Taken together, the ability of HPV E6 proteins to 
interact with these proteins, coupled with FAK activation, promote the resistance to anoikis 
and allow HPV transformed cells to proliferate in the absence of the ECM. 
1.7.3.5 Activation of Telomerase 
Another major function of the high risk E6 proteins that is important for immortalisation is 
their ability to activate the expression of the catalytic subunit of telomerase, hTERT 
(Klingelhutz et al., 1996).  p53 independent mechanisms have been described for the 
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observed TERT induction by E6 – direct transcriptional activation of the hTERT promoter by 
an E6/c-Myc complex (Veldman et al., 2002) and indirect induction through the E6AP 
dependent degradation of a natural repressor of the hTERT promoter, NFX1-91 (Gewin & 
Galloway, 2001; Gewin et al., 2004).   
1.7.4  E6 and PDZ proteins 
The targeting of p53 by E6 is the most extensively studied function of E6; however recent 
studies have identified p53 independent interactions which are important for the 
immortalisation of human cells.  E6 mutants deficient for degradation of p53 can still 
immortalise human mammary epithelial cells (Kiyono et al., 1998), suggesting that 
interactions with other cellular factors are necessary for immortalisation.  Among the 
important p53-independent targets are those which contain a PDZ (PSD-95/Dlg/ZO-1) 
domain-so called as these were the first three proteins in which this domain was identified. 
These PDZ proteins have been shown to associate with high risk E6 proteins (Thomas et al., 
2008).  
The C-terminal domain of high risk E6 proteins is highly conserved and contains a PDZ-
binding motif (PBM) (E-T-Q-V/L) (Figure 1.5) which resembles a class 1 PBM which 
mediates specific interactions with a number of PDZ substrates (Table 1.2).  PDZ containing 
proteins are primarily associated with the establishment and maintenance of cell polarity in 
epithelial cells; however they also provide scaffolding for protein folding and have cell 
signalling and tumour suppressor activity (Craven & Bredt, 1998; Gomperts, 1996).  The 
main PDZ targets are shown in Table 1.2, along with their putative and known functions 
(Table 1.2).  Through interactions with these proteins, E6 is capable of affecting the formation 
of the three major complexes required for establishing cell polarity, attachment and signal 
transduction in cells – the Scribble, PAR and CRUMBS complexes- which are discussed in 
Chapter 5.  
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Table 1.2  E6 PDZ binding partners.   The binding partners of the E6 PDZ binding 
motif along with their known functions. Those displayed with an (*) are thought to be 
putative functions of the protein. 
 
Introduction 
46 
PDZ proteins can be classified into further sub-families based on the domain structure of their 
proteins. PDZ proteins such as hDlg, MAGI-1, MAGI-2 and MAGI-3 belong to the 
membrane-associated guanylate kinase homologue (MAGUK) family of proteins.  Members 
of this PDZ family are characterised by a core arrangement of three distinct protein-protein 
interaction domains.  Each protein contains a guanylate kinase homologous (GUK) domain, a 
Src homology domain (SH3) and repetitive PDZ domains (Frese et al., 2006) (Figure 1.7). 
MUPP1 and PATJ are members of a multi-PDZ domain family containing 13 and 10 PDZ 
domain respectively as well as an amino-terminal L27 domain (Javier, 2008).  The leucine 
rich and PDZ domain (LAP) family of PDZ proteins such as Scribble are characterised by 
four PDZ domains and a leucine rich domain (Javier, 2008) (Figure 1.7).  The final major 
family group belongs to members of the tyrosine phosphatase family.  Members of this family 
include PTPN13-characrtersied by a PTP domain, FERM domain and varying PDZ domains 
(Javier, 2008) (Figure 1.7). 
PDZ domains consist of a stretch of 80-90 amino acids which are contacted by four amino 
acids at the extreme carboxy terminus of high risk HPV E6 proteins (Ponting & Phillips, 
1995).  The sequence (E-T-Q-V/L) permits the binding of E6 with PDZ proteins.  The E6 
proteins of high risk types have a T and the -3 position and V/L at the -1 position which is 
characteristic for binding PDZ proteins (Flores et al., 2006).  The E6 proteins from different 
HPV types have different affinities for different PDZ domains.  Whilst HPV16 E6 binds to 
hDlg by PDZ domain 2 (Kiyono et al., 1997), the E6 protein from HPV18 binds to hDlg via 
all three of its PDZ domains (Gardiol et al., 1999).  Structural studies have revealed that the 
interaction between E6 and its substrates occurs within the substrate groove of PDZ 
molecules between βB strand and the αβ helix (Zhang et al., 2007) with the main chain 
carboxyl group of the E6 peptide anchored within the motif of the PDZ protein (Zhang et al., 
2007). 
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Figure 1.7 PDZ proteins and their structural subunits.   Domain structures of the 
MAGUK, LAP, Multi-PDZ and Tyrosine phosphatase family of PDZ proteins.  Adapted from 
Javier and Rice, 2011. 
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The importance of an E6-PDZ interaction has been confirmed by Kiyono and colleagues who 
showed that E6 proteins which lack the PBM retain the ability to degrade p53 and 
immortalise human mammary epithelial cells (Kiyono et al., 1998) but are unable to 
transform rodent fibroblast cell lines (Kiyono et al., 1997).  In additional mice studies by 
Nguyen and others, the ability of E6 to increase tumour size and frequency in the cervix was 
dependent upon the ability of E6 to bind to its PDZ domain containing substrates (Nguyen et 
al., 2003; Shai et al., 2007; Shai et al., 2008).  In a tissue culture background the role of the 
PDZ binding motif is less clear.  In the context of the complete HPV31 genome, the E6 PBM 
was not required for the immortalisation of human keratinocytes; however it was required for 
cell proliferation (Lee & Laimins, 2004).  Furthermore, in cooperation with the ras 
oncoprotein, the E6 PBM was shown to be required for anchorage independent growth of 
human tonsillar keratinocytes (Spanos et al., 2008a; Spanos et al., 2008b).  Induction of 
epithelial to mesenchymal transition (EMT) is a hallmark of cancer development.  Several 
studies have shown that both HPV16 and HPV18 can induce EMT-like changes in human 
keratinocytes (Watson et al., 2003; Spanos et al., 2008a).  Interestingly, loss of the PBM 
correlated with a partial reversal of the EMT phenotype (Watson et al., 2003). 
Similar to their human counterparts, the papillomaviruses from Rhesus monkeys (RhPV) as 
well as the cottontail rabbit (CRPV) also cause anogenital malignancy.  The E6 proteins from 
CRPV (LE6/SE6) have PDZ binding activity and have been shown to interact with but not 
lead to the degradation of hDlg, a PDZ substrate (Du et al., 2005).  Moreover, a CRPV SE6 
mutant which was unable to form papilloma’s was also deficient for binding to hDlg, 
suggesting that an interaction with hDlg was an important biological function of CRPV E6 
(Du et al., 2005).  Interestingly, the RhPV E6 protein does not contain a functional PDZ 
binding motif; instead it confers its PDZ binding activity via the E7 protein (Tomaic et al., 
2009) (Figure 1.8). 
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A conserved PBM is also a feature of a number of other viral proteins including the 
adenovirus type 9 E4-ORF1 protein and the HTLV-1 Tax protein, which in both cases, is 
required for binding PDZ substrates and transforming activity (Lee et al., 1997) (Figure 1.8), 
suggesting that the conservation of this domain is a requirement for a number of transforming 
proteins.   
1.7.4.1 E6 and PKA 
As well as the structure of the E6 PBM regulating targeting of PDZ substrates, 
phosphorylation of E6 by protein kinase A (PKA) has been shown to negatively regulate 
HPV18 E6-PDZ interactions.  The PKA pathway has been shown to selectively regulate the 
function of high risk but not low risk E6 proteins (Kuhne et al., 2000).  In vitro binding 
experiments show that E6 phosphorylation by PKA reduces binding to hDlg and the E6 
dependent degradation of hDlg in cells with high PKA levels is inhibited suggesting that this 
inhibition is dependent upon the phosphorylation of the PDZ binding site (Kuhne et al., 
2000).  Moreover, a study by Watson and colleagues show that loss of negative regulation 
was associated with an increase in EMT and actin cytoskeleton organisation in SV40-
immotliased keratinocytes (Watson et al., 2003).  
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Figure 1.8  PDZ substrates are targets for multiple viral proteins.  The polarised 
epithelial cell can be divided into the apical and lateral regions.  The cellular PDZ proteins 
and their epithelial localisation are shown.  The HTLV-1 Tax, HPV E6 and Ad E4-ORF1 
specifically target a number of these PDZ substrates.  RhPV confers PDZ binding through E7 
to the PAR3 protein.  Adapted from Javier and Rice, 2011. 
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1.7.4.2 hDlg 
The first PDZ protein to be identified as a target of the high risk E6 proteins was hDlg; the 
human homologue of the Drosophila lethal (1) discs large-1 tumour suppressor protein (Dlg) 
(Kiyono et al., 1997; Lee et al., 1997).  As previously discussed, hDlg contains three PDZ 
domains and is a member of the MAGUK family of proteins.  The MAGUK protein family 
act as molecular scaffolds to form protein complexes and are detected on the cell membrane 
and at sites of cell-cell contact (Ide et al., 1999).  In Drosophila, Dlg localises to the 
cytoplasmic face of septate junctions between epithelial cells and the imaginal discs.  
Recessive mutations in the Drosophila Dlg locus result in loss of cell polarity and 
differentiation, neoplastic progression and ultimately larval death (Woods & Bryant, 1989).  
Further studies have revealed that mutations in the SH3 and GUK domains of this protein 
cause a loss of normal cell proliferation (Woods et al., 1996).  Based on these data it was 
suggested that Dlg functions to organise signalling complexes at cell junctions and thereby 
negatively regulates the growth of epithelial cells. Interestingly mammalian forms of the hDlg 
protein can rescue the phenotype of Drosophila Dlg mutants, implying that the human 
homologue of this protein is also involved in controlling epithelial cell growth (Thomas et al., 
1997).  A seminal study by Gardiol and colleagues identified hDlg as a target for high risk 
HPV18 in vitro and in vivo (Gardiol et al., 1999).  Moreover, subsequent studies by Kuhne 
and colleagues showed that high risk E6 proteins are phosphorylated at their PBM by a PKA 
like activity (Kuhne et al., 2000). 
First identified from human B lymphocyte cDNA, hDlg encodes a 100kDa protein which 
shares 60% homology with Drosophila Dlg and 70% similarity with rat SAP90.  Consistent 
with the cellular localisation of Dlg to septate junctions hDlg localises to regions of cell-cell 
contact in cells where it modulates cell polarity and proliferation (Lue et al., 1994).  hDlg 
exists as a number of alternatively spliced isoforms.  A number of insertions have been 
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identified including a 33 amino acid insertion termed I1 which is found in the N-terminal 
domain upstream of the first PDZ repeat (I1a and I1b), a 12 amino acid I2 insertion and a 34 
amino acid I3 insertion (McLaughlin et al., 2002; Roberts et al., 2007).  Both the I2 and I3 
isoforms are located between the SH3 and GUK domains in the C-terminal region.  In 
response to differentiation, the I2 isoforms relocalise from the nucleus and the I3 isoforms are 
selectively upregulated (Roberts et al., 2007).  While membrane localisation of hDlg is 
evident in differentiating keratinocytes, it is believed that nuclear forms are important for the 
cell cycle, mediated by the I2 isoform (Roberts et al. 2007).   
Another homologue of Drosophila Dlg is the hDlg-4 protein, also known as PSD95, which 
bares a PDZ domain and is targeted for degradation by the high risk HPV18 E6 protein 
(Hanada et al., 2007).  Although its function is not yet known, Hanada and colleagues found 
that overexpression of PSD95 in HPV cervical cancer was able to inhibit tumourigenicity, 
suggesting a role for this protein in tumour suppression – particularly, during HPV infection 
(Hanada et al., 2007).  
It is hypothesised that hDlg-1 tumour suppressor activity is not directly related to its 
membrane localization, and is instead carried out by binding to two classic tumour 
suppressors PTEN (a negative regulator of the PI3K pathway) and APC (adenomatous 
polyposis coli), another tumour suppressor protein which is a negative regulator of the Wnt 
differentiation signalling pathway (Ishidate et al., 2000).  When hDlg-1 complexes with APC, 
it prevents the cell from progressing into the first stage of cell cycle progression, DNA 
synthesis or S-phase (Ishidate et al., 2000).  hDlg-1 phosphorylation helps to determine its 
localization within the cell, and following the observation that this was affected by cell cycle 
progression (Massimi et al., 2003), Narayan and colleagues determined that hDlg-1 is also a 
substrate for cyclin-dependent kinases 1 and 2 (Narayan et al., 2009).  This places hDlg- 1 
phosphorylation under the same regulation system as the cell cycle itself, suggesting that 
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hDlg-1 is only capable of complexing with APC in particular phosphorylation states to inhibit 
cell cycle progression.  
The PDZ binding motif of E6 has been shown to contribute to the reduced localisation of 
hDlg to sites of cell adhesion and disruption of intracellular junction formation.  This domain 
has also been shown to contribute towards the E6-dependent morphological transformation of 
keratinocytes (Watson et al., 2003).  The presence of hDlg at sites of cell: cell contact 
diminishes whilst intracellular cytoplasmic levels increase significantly in high grade but not 
low grade cervical neoplasias (Watson et al., 2002).  This indicates that a loss of hDlg from 
cell: cell periphery could be an initial risk factor for disease progression (Watson et al., 2002; 
Cavatorta et al., 2004; Lin et al., 2004).   Interestingly, E6 mutants which are unable to bind 
E6AP are still able to target hDlg for degradation, suggesting that hDlg degradation although 
still proteasome mediated is independent of an E6AP interaction, and suggests a novel 
ubiquitin ligase in this process (Pim et al., 2000).  
A role for hDlg in the regulation of cell growth is further supported by studies showing that 
hDlg is a target for viral transforming proteins, including HPV E6, adenovirus 9ORF1 and 
HTLV-1 Tax.  In each case the viral protein abolishes the normal function of hDlg albeit via 
different mechanisms (Lee et al., 2000; Gardiol et al., 1999).  It is thought that 9ORF1 and 
HTLV-1 Tax form complexes with hDlg.  These complexes prevent the formation of hDlg: 
APC complexes (which negatively regulate cell cycle progression) and thereby contribute to 
the promotion of unregulated cellular proliferation (Lee et al., 1997). 
It is not only other viral transforming proteins which are able to target hDlg for degradation. 
Spliced isoforms of the E6 protein are also able to direct degradation of hDlg. Overexpression 
analysis of E6*I protein from high risk mucosal papillomavirus types showed that E6*I is 
able to direct the degradation of cellular PDZ proteins including MAGI-1 and hDlg (Pim et 
al., 2009).   Interestingly, expression of an E6 mutant of the E6 PBM in the same study, 
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which is unable to bind to hDlg, but still expresses the E6* spliced product, is also able to 
target hDlg for degradation (Pim et al., 2009).  Moreover, mutation of the splice donor site in 
the same lines was negative for hDlg degradation (Pim et al., 2004).  These data suggest that a 
significant proportion of the ability to degrade hDlg is due to E6* rather than full-length E6 
and propose that E6* expression can lead to hDlg degradation independently of full length E6 
(Pim et al., 2009).  
The sequence of the E6 PDZ binding domain is not identical between all high-risk HPV types.  
The E6 proteins of HPV type 18 and 31 contain an E-T-Q-V whilst HPV16 E6 has a leucine 
as a final amino acid (E-T-Q-L) (Figure 3.1).  A study by Thomas and colleagues have shown 
that HPV18 E6 and HPV16 E6 exhibit different preferences for PDZ substrates and this is 
dependent on the last amino acid of the PDZ binding motif (Thomas et al., 2003 ). HPV18 is 
able to bind and degrade hDlg more efficiently than HPV16 whilst binding to another PDZ 
protein hScrib( Scribble) is weak and degradation, poor.  The converse is true for HPV16 E6.  
A replacement of the valine with leucine switches HPV18 E6 preference for PDZ substrates 
from hDlg to hScrib (Thomas et al., 2003; Zhang et al., 2007).  This reinforces the results 
from a study by Watson and colleagues which showed that hDlg is predominantly targeted by 
HPV18 E6, while HPV16 E6 predominantly targets hScrib (Watson et al., 2005).  It has been 
hypothesised that these interactions represent a fundamental difference in the biological 
activities of the E6 proteins with respect to their PDZ substrates and the differential targeting 
may relate to differences in the pathogenicity between high risk HPV types.  
1.7.4.3 hScrib 
hScrib, the mammalian homologue of the Drosophila Scribble protein is a member of the 
LAP family.  The protein contains four PDZ domains and a leucine rich domain, required for 
its basolateral localisation in epithelial cells (Kim, 1997; Bilder & Perrimon, 2000) (Figure 
1.7).   hScrib was isolated in a screen for proteins targeted for ubiquination by HPV E6 
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proteins in an E6AP-dependent manner, and over expression of Scribble has been shown to 
inhibit transformation of rodent epithelial cells by HPV E6 (Nakagawa & Huibregtse, 2000; 
Nguyen et al., 2003).  hScrib is considered to have tumour suppressor activity, as significantly 
reduced expression of this protein is observed in a large number of carcinomas including 
breast and endometrial cancers  (Zhan et al., 2008; Ouyang et al., 2010).  hScrib has also been 
shown to inhibit cell cycle progression to DNA synthesis (Nagasaka et al., 2006).  As with 
hDlg-1, hScrib is known to interact with APC; interruption of this interaction prevents hScrib 
from localizing to adherens junctions, thus retarding adherens junction formation (Takizama 
et al., 2006). 
1.7.4.4 MAGI-1, 2, 3 
MAGI-1,-2, and -3 are all PDZ-containing proteins that are targeted by high-risk E6 proteins 
for degradation (Glaunsinger et al., 2000; Thomas et al., 2002).  Unlike other PDZ proteins, 
members of the MAGI family have an inverted domain structure with guanylate kinase 
homology at the amino terminus.  MAGI proteins contain at least five PDZ domains (Wu et 
al, 2000a; Wu et al., 2000b).  MAGI-1 is found in a complex with β-catenin (Dobrosotskaya 
et al., 1997), a protein which is downregulated in a number of human cancers.  MAGI-2 and 
MAGI-3 are involved in the regulation and activation of the PTEN tumour suppressor protein 
to prevent its degradation (Marte & Downward, 1997).  Degradation of MAGI-1 leads to 
mislocalisation of the PTEN tumour suppressor, which releases inhibition of the PI3K/AKT 
pathway and loss of control of cell proliferation (Liu et al., 2008).  The pathway used by high 
risk E6 protein is distinct from those used for the degradation of p53 and hDlg (Thomas et al., 
2001).  Similar to hDlg, HPV18 demonstrates a higher affinity of MAGI binding compared 
with HPV16 (Thomas et al., 2001).  MAGI-1 has been shown to inhibit cell transformation in 
a HPVE7/ras or Adenovirus E1A/ras oncogene cooperation assay in primary rodent cells 
(Massimi et al., 2004).  
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1.7.4.5 MUPP1 
MUPP1 is another of the PDZ-containing proteins targeted by high-risk E6 proteins for 
degradation (Lee et al., 2000).  This protein contains thirteen PDZ domains (Ullmer et al., 
1998) and is thought to be involved in signal transduction (Adachi et al., 2009).  MUPP1 
shares similar binding partners with another PDZ protein- PATJ such as ZO-1 and Par6, 
although it has a higher affinity for Claudin-1 and JAM (junctional adhesion molecule) 
(Adachi et al., 2009).  Despite the similarities in localization and binding partners, MUPP1 is 
not deemed essential for tight junction establishment or epithelial cell polarity, as abolition of 
MUPP1 expression alone does not severely affect cell polarity (Adachi et al., 2009).  
1.7.4.6 TIP-1 
TIP-1 (Tax-interacting protein 1) was first identified in its interaction with the HTLV-1 Tax 
oncoprotein via the PDZ domain (Reynaud et al., 2000).  Unlike other PDZ proteins, TIP-1 is 
found in the cytoplasm and has thus far not been found to be membrane-bound (Hampson et 
al., 2004; Reynaud et al., 2000).  The exact role for TIP-1 is unclear however it appears to 
complex with rhotekin and RhoA to activate serum response element (SRE) transcription 
(Reynaud et al., 2000).  This interaction subsequently leads to the transcription of elements 
responsible for cell cycle progression, apoptosis, and differentiation (Thomas et al., 2008). 
Recent studies have suggested that TIP-1 may also act as a PDZ domain inhibitor (Thomas et 
al., 2008).  High-risk E6 interacts with TIP-1 via its PDZ domain, but does not induce its 
degradation; instead, the cellular protein appears to aid E6 in inducing cell mobility, as 
knockdown of TIP-1 expression inhibits the mobility of cervical carcinoma cells in tissue 
culture (Hampson et al., 2004). 
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1.7.4.7 TIP-2/GIPC 
GIPC (GAIP-interacting protein, C-terminus) is another PDZ-containing binding partner of 
high-risk HPV18 E6 (Favre-Bonvin et al., 2005).  It is also known as TIP-2 due to its 
discovery as a Tax-interacting protein (Rousset et al., 1998).  GIPC has a variety of roles in 
cell signalling.  GIPC is also known to interact with the transforming growth factor-β (TGF-β) 
receptor type III (TβRIII) (Blobe et al., 2001).  TGF-β is a cytostatic cytokine whose function 
is to inhibit cell proliferation (Blobe et al., 2001).  By inducing degradation of GIPC, E6 
interrupts this signalling pathway leading to the loss of control of cell proliferation (Favre-
Bonvin et al., 2005). 
1.7.4.8 CAL 
CAL (cystic fibrosis transmembrane regulator-associated ligand) is another binding partner of 
high-risk E6 that is not found associated with the cell membrane, but is instead localized to 
the Golgi apparatus (Jeong et al., 2007).  Similar to hScrib, CAL shows preferential targeting 
by HPV16 E6 as opposed to HPV18 E6 (Jeong et al., 2007).  The role of CAL in the cell is 
believed to involve vesicle trafficking of cell membrane proteins as they pass through the 
Golgi, and ensuring that they are targeted to the cell membrane (Jeong et al., 2007).  This 
trafficking is probably important for the establishment of cell polarity in cells.  
1.7.4.9 NHERF-1 
NHERF-1 (N+/H+ exchange regulatory factor 1) is a multidomain scaffolding protein which 
regualtes the trafficking and signalling of several G protein coupled receptors (GPCRs).  The 
protein has a PDZ binding motif and a 14 amino acid motif which regulates the interaction 
with the actin-binding protein ezrin, contributing to several signalling events (Mahon et al., 
2002).  Furthermore, the NHERF protein is also able to regulate cell shape and migration and 
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has been shoen to interact with a number of proteins involved in transformation (Georgescu et 
al., 2008).  
1.7.4.10 PTPN3 and PTPN13 
The final proteins which contain a PDZ domains belong to a family of protein tyrosine 
phosphatases, nonreceptor type (PTPNs) as discussed earlier.  Members of this family include 
PTPN3 and PTPN13.  PTPN13 has a cell membrane localization sequence along with its PDZ 
domain, and has been implicated as a tumour suppressor due to its loss of function in many 
colon cancers (Wang et al., 2004).  PTPN13 appears to be involved in suppressing proto-
oncogenes such as c- src by dephosphorylating nuclear factors associated with their induction 
(Erdmann, 2003).  Recent studies have shown that inhibition of PTPN13 by E6 results in 
anchorage-independent growth, leading to invasive growth in mouse and human epithelial 
cells in vivo. Moreover complementation of PTPN13 in this system restored normal cell 
growth (Spanos et al., 2008).  
PTPN3, also known as PTPH1, is another member of this PDZ family which has been 
implicated in  colon cancers (Wang et al., 2004), and has been shown to be targeted by E6 for 
E6AP-mediated degradation (Jing et al., 2007).  One of its few identified substrates is a cell 
cycle protein VCP (valosin-containing protein). Overexpression of PTPN3 leads to growth 
inhibition in cell culture (Zhang et al., 1999). 
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1.8 Hypothesis and Aims 
Conservation of an E6 PBM between high risk HPV types but not low risk HPV types makes 
it a marker of oncogenicity. Many of the targets are relevant functionally to cell polarity and 
maintenance of intercellular tight junctions, whilst others also show tumour suppressor 
activity. A number of studies have highlighted the importance of the PBM in transformation 
of rodent cells as well as E6-induced anchorage independent cell growth and induction of 
EMT – hallmarks of cancer and metastatic progression. In mouse skin and cervical 
carcinogenesis an E6 PBM required for efficient tumour formation, whilst in the context of 
the virus life cycle, the E6 PBM was involved in maintenance of viral copy number as well as 
growth rate of immortalised cells.  The indication that this domain can be regulated by 
phosphorylation suggests that changes in kinase signalling pathways such as the cAMP 
dependent kinase during the life cycle can be expected to regulate this E6 function. It is not 
clear which signalling pathways are impacted by E6 binding to PDZ proteins or which PDZ 
proteins are most important for the phenotypes which have been observed. The understanding 
of these pathways will in turn, help our understanding of the HPV pathogenesis.  
The aims of this thesis are: 
1. Establish a role for the E6 PBM in the HPV18 replication cycle by construction of an 
HPV18 genome which lacks an E6 PDZ binding motif and introduce into a primary 
human keratinocyte system which supports virus replication. (Chapter 3 and Chapter 4) 
 
2. To establish whether PKA phosphorylation of the HPV18 E6 PDZ binding domain motif 
has a physiological role in the infection cycle of the virus, using a mutant HPV18 
genomes which is unresponsive to PKA recognition. (Chapter 3 and Chapter 4) 
 
3.  To determine the effect of changes in the activity of the PBM on potential cellular PDZ 
substrates. (Chapter 5) 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Molecular biology techniques 
2.1.1 Bacterial hosts, growth and storage 
The DH5α strain of Escherichia coli (E. coli) was used as a bacterial host for the growth of 
the pcDNA 3.1 and pGEMII plasmid vectors for preparation of plasmid DNA.  Bacteria were 
streaked out and stored on agar plates for short periods of time, or for longer periods of time, 
stored as a glycerol stock.  
Agar plates were made by dilution of 1.5% (wt/vol) agar in Luria-Bertani (LB) medium (1% 
(wt/vol) bacto-tryptone, 0.5% (wt/vol) bacto-yeast extract, 1% (wt/vol) NaCl).  Following 
autoclaving, the agar was boiled then cooled to approximately 50°C before the appropriate 
antibiotic was added to a final concentration of 50 µg/ml and 25 ml of agar dispensed into 
each petri dish.  Bacteria were streaked out from glycerol stocks by streaking of the bacteria 
across the surface of the agar with a fine loop, and then incubated at 37°C overnight to allow 
the growth of bacterial colonies.  
Glycerol stocks were made following the growth of bacteria in LB media supplemented with 
50 µg/ml antibiotic.  Bacteria were grown in LB media overnight at 37°C with shaking before 
a 400 µl aliquot of bacteria was taken and added to 600 µl of sterile 80% (vol/vol) glycerol 
solution. Glycerol stocks were stored in 1 ml aliquots at -80°C. 
2.1.2 Growth of E. coli 
A starter culture of host cells was prepared by inoculating 6 ml of L-broth with a single 
bacterial colony, followed by the overnight incubation of this culture in a shaker at 37°C.  The 
overnight preparation was used to inoculate 200 mls of L-broth, which was grown overnight.  
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2.1.3 Long-term storage of bacterial cultures 
A 500 µl aliquot of an overnight bacterial culture was mixed with 500 µl of sterilized 50% 
(w/v) glycerol and stored at -80°C.  To recover frozen bacteria, a small amount of the frozen 
glycerol stock was streaked out onto the appropriate agar plate and incubated at 37°C.  
2.1.4 Transformation of competent E.coli with plasmid DNA.  
Chemically competent E.coli were first thawed on ice, prior to addition of 30-50 µl of cells in 
a pre-cooled Falcon tube.  One to two micrograms of plasmid DNA were typically added 
directly into the thawed cells.  Following incubation on ice for 30 min the E.coli were heat 
shocked at 42°C for 45 sec, followed by a 2 min incubation on ice. 500 µl LB media was 
subsequently added, followed by incubation at 37°C with shaking at 200 rpm for 1 h. 250 µl 
were then plated onto ampicillin selection agar plates and incubated overnight at 37 C.  
2.2 Preparation of plasmid DNA 
2.2.1 Small preparation of plasmid DNA 
A single bacterial colony was grown in 6 ml LB media with selection antibiotic at 37°C for 16 
h with shaking at 200 rpm.  The following day, 3 ml of the overnight culture, was 
subsequently pelleted by centrifugation at 16100 xg at 4°C for 5 min, followed by DNA 
extraction using the QIAprep® Spin Miniprep Kit (Qiagen), following manufacturer’s 
instructions.  DNA was eluted into 50 µl of 1X Tris-EDTA (TE) buffer and stored at -20°C.    
2.2.2 Large-scale preparation of plasmid DNA 
Qiagen Maxiprep 
A 6ml starter culture of LB media with antibiotics was inoculated with a single colony and 
grown at 37 C with shaking at 200 rpm.  After 6-8 h 200 ml of selective L-broth was 
inoculated with the starter culture and grown overnight at 37°C in an orbital shaker.  Cells 
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were pelleted by centrifugation at 13,000 rpm in a Sorvall GS3 rotor for 10 min and re-
suspended in 4 ml, 50 mM glucose, 10 mM EDTA, 25 mM Tris pH 8.0.  Between 10 and 15 
mg of lysozyme were added and the mixtures incubated at 37°C for 20 min.  8 ml of a freshly 
prepared solution of 0.2 M NaOH, 1% (w/v) SDS was added and the samples left on ice for 5 
min before the addition of 6 ml ice-cold 3 M sodium acetate.  
Following 5 min incubation on ice, samples were centrifuged at 13,000 rpm in a Sorvall SS-
34 rotor for 15 min and the aqueous phase transferred to an equilibrated Qiagen-tip 500 
(Qiagen).  The tip was washed twice with 30 ml washing buffer (1 M NaCl, 50 mM MOPS, 
pH 7.0, 15% (v/v) isopropanol) and the plasmid DNA was eluted with 15 ml elution buffer 
(1.25 M NaCl, 50 mM Tris-HCl, pH 8.5, 15% (v/v) isopropanol).  DNA was precipitated by 
addition of 0.7 volumes of isopropanol (Fisher) and the sample was then centrifuged at 9,000 
rpm in a Sorvall SS-34 rotor for 40 min at 9°C.  The pellet was then washed with 5 ml 70% 
(v/v) ethanol and centrifuged for a further 15 min at 4°C in a microcentrifuge.  Plasmids were 
air-dried are re-suspended in 0.5-1 ml of TE buffer or sterile distilled water and stored at 4 C 
short term or - 0 C long term.  The concentration of DNA was determined by 
spectrophotometry (Nano-Drop).  
2.3 Molecular cloning 
2.3.1 Plasmid DNA vectors 
The pGEMII-HPV18 plasmid (a gift from Frank Stubenrauch, University of Tubingen and 
used in the previous study (Wilson et al., 2007) contains the total HPV18 genome (accession 
number: NC 001357) cloned into the pGEMII vector at the Eco RI restriction site at residue 
2440.  The pCDNA 3.1 expression plasmid was generated by cloning the E6 protein of 
HPV18 into the pCDNA3.1 expression vector.  The p53 untagged construct was a kind gift 
from Professor Lawrence Banks (Trieste, Italy).  
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2.3.2 Polymerase chain reaction (PCR) 
 PCR reactions were typically performed with 1 µg of plasmid DNA using the Expand High 
Fidelity PCR system (Roche), following manufacturer’s instructions.  PCR reactions were 
carried out in a total volume of 100 µl in expand high fidelity buffer supplemented with 15 
mM MgCl2, 2 mM dNTPs, 25 pmol forward and reverse primers (generated by 
AltaBiosciences), 1% (vol/vol) DMSO with 3.5 U of Taq DNA polymerase.  Amplification of 
the DNA was performed on a thermal cycler ( 7 0, Applied Biosciences) using a   min  4 C 
hot start followed by  5 repeats of  4 C for 1 min, 55 C for 30 s and 7  C for 3 min, followed 
by 8 min at 7  C before cooling to 4 C.  The PCR products were often cleaned with High Pure 
PCR product Purification Kit (Roche) according to the manufacturer’s instructions.  DNA 
was eluted in 50 µl dH20 and stored - 0 C.  
2.3.3 Agarose gel electrophoresis 
Agarose (Sigma) was melted into a 1x solution of Tris/Boric EDTA (TBE) (45 mM Tris HCl, 
45 mM orthoboric acid and 1 mM EDTA, pH 8.0) to a final concentration of 0.8-2.0% (w/v) 
depending on the size of fragment to be separated.  Ethidium bromide was added to a final 
concentration of 0.5 µg/ml prior to pouring into a Mini Sub Gel GT Electrophoresis Tank 
(BioRad).  DNA samples were mixed with loading buffer (30% (v/v) glycerol, 0.3% (w/v) 
bromophenol blue, 0.1% xylene cyanol FF 10x TBE) prior to loading.  For size comparison a 
1 kb Plus DNA marker (Gibco) was run alongside the samples.  Gels were routinely run at 80 
V for 1 hr in TBE running buffer and DNA bands were visualised with a Gene Flash UV light 
box (Syngene Bio Imaging).  For resolution of genomic DNA isolated from HFK prior to 
southern blot analysis 0.8% (wt/vol) agarose gels were prepared as described and cast in 
Fisherband horitzaontal gel electrophoresis tanks (Fisher Scientific), with gels run at 50 V 
overnight.   
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2.3.4 Purification of DNA fragments 
DNA fragments were purified using the QIAquick Gel Extraction Kit (Qiagen), according to 
the manufactures instructions.  This involved the required band to be excised from the agarose 
gel using a clean scalpel and heated in a solubilisation buffer for 10 min at 50°C to dissolve 
the agarose.  The sample was then applied to a QIAquick column and then centrifuged at 
13,000rpm for 60 sec in a microcentrifuge to allow the binding of the DNA. The bound DNA 
was washed by applying 750 µl of wash buffer to the column and then centrifuged at 13,000 
rpm for a further 60 sec.  DNA was then eluted into an eppendorf by applying between 15-30 
µl of TE and centrifugation at 13,000 rpm for 60 sec and stored at - 0 C.    
2.3.5 Restriction enzyme digestion 
Restriction enzyme digestions were typically performed using 2-10 µg of plasmid DNA 
incubated with restriction enzymes in the appropriate buffer provided with the enzyme in a 
total volume of 20-50 µl.  Restriction enzymes used in this study include EcoRI (20 units), 
BglII (10 units), BamHI (20 units) (New England Biolabs) and DpnI (10 units) (Roche). 
Following addition of the restriction enzyme, reactions were vortexed and centrifuged briefly, 
before incubation at 37°C for 1-2 hr or overnight.  To ensure complete digestion, 200 ng of 
the digested product was analysed on an agarose gel.  For digestion with multiple restriction 
enzymes these were carried out simultaneously by selecting an appropriate buffer in which 
both restriction enzymes were active.     
2.3.6 Purification of DNA fragments 
DNA fragments were purified using the QIAquick Gel Extraction Kit (Qiagen), according to 
the manufactures instructions.  In brief, the excised band is excised form the agarose gel and 
heated in a solubilisation buffer at 50°C for 10 min to dissolve the agarose.  The sample is 
applied to a QIAquick column and then centrifuged at 13,000 rpm for 60 sec in a 
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microcentrifuge to allow binding of the DNA.  The captured DNA is then washed by applying 
750 µl of wash buffer to the column and centrifugation at 13,000 rpm for a further 60 sec.  
DNA was eluted into an eppendorf by applying 30 µl TE and centrifugation at 13,000 rpm for 
a further 60 sec and then stored at -20°C until use.  
2.3.7 DNA ligation reactions 
Following restriction digests, enzymes were heat-inactivated prior to a ligation reaction by 
incubation of reactions at 65°C for 10 min, then cooling on ice for 2 min.  Ligations were 
performed by incubation of vector and insert DNA at rations typically of 1:3, 1:5 or 1:10 with 
between 4-8 units of T4 DNA ligase (New England Biolabs) and ligase buffer (660 mM Tris-
HCL pH 7.5, 50 mM MgCl2, 10 mM dithioerythritol, 10mM ATP) and incubated overnight at 
16°C.  Ligated DNA was then transformed into bacteria and sequenced following mini-
preparation of plasmid DNA.  
2.3.8 PCR sequencing 
One µg of plasmid DNA was mixed with 2.5 pmol primer, 1 µl BigDye® terminator ready 
reaction mix (Applied Biosystems) and relevant buffer in a total volume of 20 µl.  The 
reaction was carried out with 25 cycles of 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min 
on a thermal cycler.  Oligonucleotide primers utilised for the sequencing of plasmid DNA are 
listed in Table 2.1, and were generated by Altabiosciences, University of Birmingham.  The 
DNA was precipitated with 5 μl 1 5 mM EDTA and 60 μl 100% ethanol at room temperature 
for 15 min, and the sample centrifuged at 16100 x g for 45 min at 4°C.  The supernatant was 
removed and the pellet washed in 70 μl 70% ethanol, the sample was then centrifuged at 
16100 x g for 15 min at 4°C.  The supernatant was removed and the pellet air dried and re-
suspended in 10 μl HiDi Formamide (Applied Biosystems).  The reaction was heated at 95°C 
for 5 min before loading into a  6 well plate in a 3100 ABI Prism™ DNA capillary sequencer 
Materials and methods 
66 
(Applied Biosystems).  The sequencer capillary array was filled with 3100 Performance 
Optimised Polymer 6™ Performance Optimized Polymer (Applied Biosystems).  Sequencing 
data was collected using the 3100 data collection software version 3.1 and was analysed using 
ABI sequencer version 3.6.1 or FinchTV Version 1.4.0 (Geospiza).  
Table 2.1 Sequencing primers 
Primer Direction Primer Sequence 
E6 SEQ F 5’ GAC AGT ATA CCG CAT GCT GCA TGC C 3’ 
E6ΔPDZ 
F 5’ GAA CGA CTC CAA CGA CGC AGA TAA 
TGA CAA GTA TAA TAT TAA GTA TG 3’ 
R 5’ CAT ACT TAA TAT TAT ACT TGT GTT TCT 
CTG CGT CGT TGG AGT CGT TC 3’ 
 
2.3.9 Generation of mutations within the HPV18 E6 pCDNA 3.1 
expression vector 
Site-directed mutagenesis was performed using the Quick-Change Kit (Stratagene) following 
manufacturer’s instructions. The pCDNA3.1 HPV18 E6 expression vector was used as 
template DNA using the primers listed in Table 2.1, with the number of PCR cycles used 
between 18 and 25.  All of the oligodeoxyribonucleotide site-directed primers used in this 
study were generated by Altabiosciences, University of Birmingham.  PCR products were 
digested with Dpn 1 and transformed into XL-1 blue E-coli.  Colonies were grown in LB 
media and mini-preparation performed (according to manufacturer’s instructions).  Extracted 
DNA was sequence using the sequencing primer listed in Table 2.1 to confirm correct 
introduction of mutants.  
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2.4 Protein biochemistry 
2.4.1 Bradford assay 
Protein concentration was determined using the Bradford method using a Bio Photometer 
(Eppendorf).  Readings were taken at 0, 4, 8, 16 and 20 µg of 1mg/nl BSA in 1 ml of diluted 
protein assay reagent (Bio-Rad). A known amount (1-5µl) of the protein samples were then 
added to the reagent and the concentration determined.  
2.4.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were typically resolved on 12.5% polyacrylamide separating gels (350 mM 
Tris-HCL, 12.5% [wt/vol] polyacrylamide (acrylamide : bis-acrylamide 37.5 : 1), 1% [wt/vol) 
SDS, polymerised with 0.4% [wt/vol] ammonium persulphate (APS) and 0.08% [vol/vol] 
TEMED).  To ensure a level surface of all polyacrylamide gels, a layer of isopropanol was 
added to the surface immediately following pouring.  Once the separating gels had set, 
isopropanol was removed and a stacking gel (125 mM Tris pH 6.8, 4.5% [wt/vol] acrylamide, 
1% [wt/vol] SDS, polymerised with 0.5% [wt/vol] APS and 0.125% [vol/vol] TEMED) was 
poured on top of the resolving gel and the gel combs inserted.  Once set, the wells were filled 
with running buffer (25 mM Tris, 192 mM Glycine, 0.1% [wt/vol] SDS, pH 8.3).  Protein 
samples were prepared for SDS-PAGE by addition of Laemelli sample loading buffer 
supplemented with 5% [vol/vol] β-Mercaptoethanol, and boiled at 100°C for 5 min.  Samples 
were loaded into wells of the gel with gel-loading pipette tips (Biorad). Electrophoresis was 
performed in running buffer using vertical gel slab units.  The Mini Protean® 3 Cell (Bio-
Rad) was run at 25 mA for 1-2 h for smaller gels whilst for larger gels, the Sturdier system 
(Amersham Biosciences) was used and run overnight at 55 V or until the correct separation 
had been achieved. 
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2.4.3 Western blot analysis 
2.4.3.1 Electrophoretic transfer of proteins 
Following separation by SDS-PAGE, proteins were transferred to BioTrace® NT 
nitrocellulose blotting membrane (Pall Life Sciences) using a Trans-Blot® Cell transfer tank 
(BioRad), in transfer buffer (25 mM tris, 192 mM glycine, 20% (vol/vol) methanol, pH 8.3), 
at 350 mA for 3.5 h, or overnight at 15 V.  To ensure transfer of proteins was successful, 
membranes were stained in Ponceau stain (1% (wt/vol) Ponceau Red, 3% (wt/vol) 
trichloroacetic acid) to visualise proteins, before de-staining by washing in PBS containing 
0.1% (vol/vol) Tween-20 (PBS-T).  Nitrocellulose membranes were incubated in blocking 
buffer consisting of  % (wt vol) dried skimmed milk in PBS-T at room temperature for 30 
min or overnight at 4 C. Primary antibodies were diluted in 5% milk in PBS and incubated 
with membranes for between 2 h to overnight depending on the antibody.  For a full list of the 
antibodies used in this study, see Table 2.2.  To control for equal loading, GAPDH levels 
were determined using a mouse anti-GAPDH MAb.  Following incubation with primary 
antibodies, membranes were subjected to two 15 min washed with 0.2% Tween (v/v) in PBS. 
Typical secondary antibodies used in this study were a horseradish peroxidise-conjugated 
anti-mouse (Sigma-Aldrich) or anti-rabbit immunoglobulins (DAKO) (Table 2.2) visualised 
by chemiluminesence, and detected using autoradiography (GE Heathcare). 
 
 
 
 
 
 
 
Materials and methods 
69 
Table 2.2 Antibody dilutions used in Western blotting 
Antibody Name Manufacturer Species Dilution 
Cyclin A Santa Cruz Mouse 1:1000 
Cyclin E Santa Cruz Mouse  1:1000 
Chk1 Santa Cruz Mouse 1:1000 
Rb Santa Cruz Mouse  1:1000 
pH3 (ser10) Cell Signalling Mouse 1:100 
CDC20 Santa Cruz Mouse 1:1000 
Cyclin B1 Santa Cruz Mouse 1:1000 
E6 Arbor Vita Mouse 1:1000 
E7 Abcam Mouse 1:1000 
DO-1 (p53) *Gift from Prof David Lane Mouse 1:5 
E-cadherin BD Transduction Labs Mouse 1:500 
Tip-2 Favre-Bonvin et al., 2005 Goat 1:1000 
MUPPP-1 Upstate Biotechnology Sheep 1:5000 
GAPDH Santa Cruz Mouse  1:1000 
Dlg (2D11) Santa Cruz Mouse 1:1000 
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Dlg (NAG) Roberts et al., 2003 Rabbit 1:200 
MAGI-1 Sigma Rabbit 1:500 
hScrib Sigma Goat 1:500 
PTPN13 *Gift from WijianHendricks Rabbit 1:5000 
Anti-mouse IgG (whole 
molecule)-Peroxidase 
Sigma Goat 1:3000 
Polyclonal Swine Anti-
Rabbit 
Immunoglobulins/HRP 
DAKO Swine 1:3000 
Anti-goat IgG (whole 
molecule)-Peroxidase 
Sigma Rabbit 1:3000 
 
2.4.3.2 Densitometry 
Protein levels from western blot films were examined using a Scanning Densitometer GS-800 
(BioRad) and images were analysed using the Quality One 4.6.7 software (BioRad).    
2.5 Tissue culture techniques 
2.5.1 General information 
Tissue culture media and solutions were prepared as described below, or purchased from 
indicated suppliers as detailed.   
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2.5.2 Tissue culture solutions 
Dulbecco A solution  (DulbaA-Phosphate buffered saline-PBS) 
Dulbecco A solution (0.8 g/L NaCl, 0.02 g/L KCl. 0.115 g/L Na2HPO4, 0.02 g/L KH2PO4 
pH7.3) was made up in deionised water and was sterilised by autoclaving.  
EDTA (Ethylene diamintetra-acetic acid) 
Dulbecco A was prepared as described above, and EDTA added to a final concentration of 
0.02% (w/v). The solution was adjusted to pH 7.4, filter sterilised and stored at 4°C until use.  
Saline Solution 
A 0.85% NaCl solution was prepared by dissolving one saline tablet in 500 ml of deionised 
water. Saline solution was subsequently sterilised by autoclaving and stored at 4°C. 
2.5.3 Tissue culture media supplements 
Antibiotics 
A 1/100 volume of a stock solution of penicillin (10,000 units) and streptomycin (10 mg/ml) 
(Sigma) was added to all media to prevent bacterial growth.  
 
Bovine serum 
Newborn calf serum was purchased from Gibco BRL and dispensed into 50ml aliquots under 
sterile conditions and stored at -20°C. 
Foetal calf serum (FCS) 
Sterile serum was purchased from Gibco BRL and dispensed into 50 ml aliquots and stored at 
-20°C until use.  
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Geneticin G418 sulphate (G418) 
Geneticin G18 sulphate powder was purchased from Gibco BRL and dissolved in saline 
solution to a final concentration of 50 mg/ml.  G418 stock solutions were passed through a 
0.2µm filter (Pall), aliquoted and stored at -20°C.  
Glutamine 
A solution of 0.2 M L-glutamine was prepared, filtered through a 0.2 µm filter (Pall) and 
dispensed into 10 ml aliquots under sterile conditions and stored at -20°C.  A single aliquot 
was added to 500 ml media, giving a final concentration of 4 mM.  
Hydrocortisone 
A sterile ampoule of 100 mg hydrocortisone (Upjohn Ltd.) was added to 20 ml of a 1:1 
ethanol: water solution.  This 5 mg/ml stock solution was subsequently filter sterilised and 
stored at -20°C.  40 µl of the stock solution was added to 500 ml of media as required.  
Non-essential amino acids 
A 1/100 volume of non-essential amino acids (Gibco BRL) was added to media when 
required.  
 
2.5.4 Maintenance of cell cultures 
All cell cultures were maintained on plastic tissue culture dishes (Iwaki) in the appropriate 
growth medium.  Cells were incubated in a cell culture incubator at 37°C, with a humidified 
atmosphere containing 5% CO2 in air.  
2.5.5 Epithelial cell sub-culturing 
Cells were harvested at around 80% confluency the media was removed from the dishes and 
the cell monolayer was washed with pre-warmed DulbA.  1 ml of 0.05% Trypsin was added 
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to each dish and then dishes were incubated at 37°C until the cells had detached (typically 1-5 
min).  To inactivate the trypsin, the cells were re-suspended in 9 ml appropriate growth 
medium and counted using a haemocytometer.  Cells were either pelleted by centrifugation at 
1400 rpm for 5 min in a bench-top centrifuge or plated out at the required density.  
Table 2.3 Mammalian cell lines used in this study 
Cell line Cell type 
HeLa 
Cervical adenocarcinoma derived cell line, contains integrated 
HPV18 genomes  
NIH-3T3 J2 Mouse embryonic fibroblast cell line 
SAOS-2 Osteosarcoma derived cell line 
HEK 293 Human embryonic kidney cell line that contains adenovirus E1A 
HaCat Transformed keratinocytes from normal skin. HPV negative. 
 
The cell lines , HeLa, HEK 293 and SAOS-  were all cultured in Dulbecco’s modified Eagle 
medium (DMEM) HEPES modification (Sigma-Aldrich) supplemented with 4 mM glutamine 
and 10% (v/v) foetal calf serum.  NIH 3T3 J2 cells were grown in (DMEM) HEPES 
modification (Sigma-Aldrich) supplemented with 10% (V/V) bovine serum and 4 mM 
glutamine.  HaCat cells were grown in (DMEM) HEPES modification (Sigma-Aldrich) 
supplemented with 4 mM glutamine, 0.4 µg/ml hydrocortisone and non essential amino acids 
(Gibco BRL). Cells were kept at 37°C, 5.0% CO2 in an incubator and were routinely grown in 
75 cm
3
 flasks (Iwaki) or 10 cm tissue culture dishes (Iwaki).   
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2.5.6 Cryopreservation of mammalian cells 
For long-term preservation, cells were stored in liquid nitrogen.  Cells were harvested by 
trypsinization when approximately 80% confluent and pelleted by centrifugation at 538 x g 
for 10 min.  The pellets were then re-suspended in 1 ml growth medium containing 10% (v/v) 
DMSO and transferred to labelled NUNC cryotubes at a concentration of 2 x 10
6
 cell/viol 
(Nalgene-Nunc).  Tubes were stored in a Cryo Freezing container (Nalgene®MrFrosty) and 
stored at -80°C overnight to allow slow cooling.  When frozen, cells were transferred to the 
vapour phase of liquid nitrogen for permanent storage.  
2.5.7 Retrieval of frozen cells 
To retrieve frozen stocks of cells, cryotubes were placed into a water bath at 37°C and left 
until completely thawed, typically 1-2 min.  The contents were then transferred drop-wise into 
10 mls pre-warmed fresh culture medium. Cells were pelleted by centrifugation at 538 x g for 
5 min, resuspended in fresh culture medium and seeded onto tissue culture dishes at the 
required density. 
2.5.8 Transfection in 5 cm dishes 
Cells were seeded out at 5 x 10
5
 cell per dish and grown to 50-60% confluence in 5 cm dishes. 
Cells were transfected with 20 µg DNA and Lipofectamine™  000 (10µl/µg DNA 
transfected) (Invitrogen) reagent or Lipofectamine™ LTX (10µl/µg DNA)(Invitrogen) with 
PLUS reagent (1 µl/µg DNA) in 500 µl Opti-mem® (Invitrogen) according to the 
manufacturers instructions.  After 4 hours, the transfection reaction was stopped by the 
addition of growth media.  At 48 h cells transfections were harvested using the appropriate 
method. 
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2.5.9 Harvesting of cells and protein extraction 
Cells were harvested from dishes using 0.05% trypsin EDTA as previously described (2.5.5). 
Following neutralisation of the trypsin, the cells were pelleted by centrifugation at 538 x g for 
5 min before being washed in PBS and re-pelleted twice.  The pellet was then re-suspended in 
UTB (8 M Urea, 25 mM Tris-HCL pH 8.0, 0.15 M β-Mercaptoethanol) and incubated on ice 
for 20 min.  The lysate was sonicated for 20 s at 2 watts using microson ultrasonic cell 
disrupter (Misonix) and the insoluble material removed by high speed centrifugation at 16100 
x g for 10 min.  The proteins were then analysed using a Bradford assay (2.4.1) before 
resolution by SDS PAGE (2.4.2). 
2.6 Immunocytochemical techniques 
2.6.1 Preparation of samples for indirect immunofluoresence 
Cells were harvested as described in section (2.5.5), counted on a haemocytometer and re-
suspended in normal growth medium at the required cell density, normally 3-5 x 10
4
 cells per 
spot.  Aliquots were pipetted onto the spots of sterile microdot multispot glass slides (Hendley 
Essex) or coverslips (VWR international).  These were left for several hours to allow the cells 
to adhere to the glass and slides and then the slides were covered with the appropriate culture 
medium.  Cells were grown until they reached the required level of confluency, typically 60-
70%. 
2.6.2 Fixation and permeabilization  
A number of different methods were used to fix and permeabilize cells and tissues prior to 
direct immunofluorescence (IF) staining.  To fix in acetone and or methanol, samples were 
washed twice in ice-cold saline and then immediately immersed in cold (-20°C) acetone, 
methanol or a 1:1 mixture of both, and left for 10 min.  Slides were air dried before storage at 
-20°C.  Alternatively, samples were fixed in 4% (w/v) paraformaldehyde, freshly prepared in 
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PBS, for a desired length of time prior to permeabilization.  Paraformaldehyde-fixed slides 
were washed twice in PBS and either immersed in cold (-20°C) acetone for 10 min, or 
incubated in 0.1% (v/v) Triton X-100 (Sigma) in PBS for 5 min at room temperature. 
Following Triton X-100 treatment, slides were washed in agitated PBS to remove excess 
detergent, and stored in PBS until use.  
2.6.3 Indirect immunofluorescence microscopy 
During the staining procedure, slides were kept in a humidified box to prevent evaporation of 
anti-body solutions.  Fixed cells or tissue sections were blocked against non-specific antibody 
binding by the addition of blocking buffer (20% heat inactivated normal goat serum (HINGS), 
0.1% (w/v) Bovine Serum Albumin (BSA) and 0.1% (w/v) sodium azide in PBS) and 
incubated at room temperature for 1 h.  The blocking buffer was then replaced with the 
required dilution of primary antibody, diluted in blocking buffer, and slides incubated at 37°C 
overnight.  A list of antibodies used for immunofluorescence can be seen in table 5.  Excess 
antibodies were removed by washing the slides for 30 min in two changes of agitated PBS. 
The appropriate dilution of Alexa labelled anti-species specific antibody conjugates, 
(Molecular Probes) diluted in blocking buffer, were added to cells and sections.  Slides were 
incubated at 37°C for a further 60 min.  Finally, slides were washed for a further 30 min in 
two changes of PBS and nuclei counterstained with DAPI (4’6-Diamidino-2-phenylindole) 
(Sigma).  Cells and sections were mounted in 80% (v/v) glycerol in PBS containing 2% (w/v) 
DABCO (1, 4 diazobicyclo-[2, 2, and 2] octane).  Alternatively, sections were mounted in 
Pro-Long anti-fade mountant (Molecular Probes).  Immunofluorescence was observed using a 
Nikon Eclipse E600 microscope and images captured using a Leica DC200 camera and 
software.  The dilutions of the antibodies used in immunofluorescence microscopy are listed 
in Table 2.4. 
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Table 2.4 Dilutions for antibodies used in immunofluorescence 
Antibody Name Manufacturer Species Dilution 
E-cadherin 
BD Transduction 
Laboratories 
Mouse 1:200 
Filaggrin Biogenesis Mouse 1:200 
hDlg 2D11 Santa Cruz Mouse  1:30 
BRDU Becton-Dickinson Mouse 1:3 
Connexin-43 
*Gift from  Dr Sheila 
Graham 
Mouse 1:200 
hScrib Sigma Goat 1:500 
860 Sigma Mouse 1:20-40 
K5 
*Gift from Prof Birgette-
lane 
Rabbit 1:150 
AlexaFluor® 488 Goat anti-
mouse IgG 
Molecular Probes 
(Invitrogen) 
 1:500 
AlexaFluor® 488 Goat anti-
mouse 
Molecular Probes 
(Invitrogen) 
 1:500 
*AlexaFluor® 594 Rabbit anti-
goat IgG2a 
Molecular Probes 
(Invitrogen) 
 1:500 
AlexaFluor® 594 Goat anti-rabbit 
IgG 
Molecular Probes 
(Invitrogen) 
 1:500 
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2.6.4 Microscopy 
Epifluorescence microscopy was performed on a Nikon Eclipse E600 microscope and images 
were captured using Nikon DXM1200F digital camera.   
2.6.5 Immunoprecipitation 
Cells were washed with ice cold PBS and then lysed in NP-40 buffer or RIPA buffer and 
harvested using a cell scraper.  Following incubation on ice for 10 min aliquots, the lysates 
were cleared by centrifugation at 16100 x g for 10 min and an aliquot taken as a control 
sample.  The lysate was mixed with the relevant antibody for 1 h and a 4 C and then (500 µl) 
of a 50% slurry of protein A G sepharose was added and rotated at 4 C for 1 h.  The beads 
were washed 5 times with lysis buffer and re-suspended in 30 µl Laemmli buffer.  
2.7 Generation and maintenance of HFK cell lines containing HPV 18 
genomes 
Generation of HFK cell lines was undertaken according to the methods described by Wilson 
and Laimins (Wilson & Laimins, 2005) unless otherwise stated.  
2.7.1 Maintenance of HFKs prior to transfection 
Normal primary human foreskin keratinocytes (HFK), derived from neonate foreskins were 
kindly provided by Dr Joseph Spitzer and arranged under the REC notification RG_06-095 
(Roberts).  All the primary human foreskin keratinocytes used in this study were isolated by 
the foreskin tissue by Dr Sally Roberts following the protocol described by Meyers and 
Laimins (Meyers & Laimins, 1994) or purchased commercially (Clonetics 
Lonza,Walkersville USA).  HFKs were cultivated in serum-free keratinocyte growth medium 
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(SFM, Invitrogen) replaced every 2 days and cells were grown to 80% confluency.  All cells 
were maintained in an incubator with 5% CO2 at 37°C.  Cells were passaged by removal of 
media followed by washing twice in PBS before addition of 1 ml of 0.05% trypsin/EDTA and 
incubation at 37°C.  After 5-10 min, the trypsin was inactivated by addition of 1 ml trypsin 
neutralising solution (TNS, Invitrogen 0. 5 mg ml soyabean trypsin inhibitor in Dulbecco’s 
PBS without calcium or magnesium, pH 7.2) before transfer of cells to a 15 ml conical tube. 
Cells were pelleted by centrifugation at 538 x g for 5 min at room temperature.  The 
supernatant was subsequently removed and the pellet re-suspended in 10 ml SFM and 
transferred to a 10 cm tissue culture dish or, prior to transfection into a 5 cm dish at the 
required density.  
2.7.2 Freezing of HFKs 
Cells were frozen as described in section (2.5.6), with resuspension of HFKs at a density of 
between 1 and 2 x10
6
 cells per vial.  Freezing media for these cells was made up of SFM 
supplemented with 10% (vol/vol) FBS and 10% (vol/vol) DMSO or following transfection 
with HPV18 genomes, in E-medium supplemented with 10% (vol/vol) FBS and 20% 
(vol/vol) glycerol.  
2.7.3 Preparation of E-medium 
Following transfection of HFKs with HPV18 genomes, cells were grown in E-medium. To 
make 2 litres of E-medium the following components were mixed: 1200 ml DMEM HEPES 
modification; 640 ml Ham’s F-12, 20ml of 100 X cocktail (described below); 40 ml of 100 X 
Penicillin Streptomycin (PAA Laboratories); 100 ml FBS (5% (vol/vol)); 2ml 1000 X Cholera 
toxin (ICN Biomedical) and 2 ml 1000 X Hydrocortisone (Sigma).  
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100 X Cocktail 
To make 200 ml of 100 X cocktail the following components were mixed: 20 ml 0.18 M 
Adenine (Sigma, 0.486 g in 15 ml H20 with addition of 10 m HCL until dissolved, then 
addition of 5ml H20); 20 ml 5 mg/ml Insulin (Sigma, 0.1g added to 20 ml 0.1 M HCL); 20 ml 
5 mg/ml transferring (Sigma, 0.1g added to 20 ml PBS); 20 ml 2 x 10
-8
 M 3,3’,5-Triiodo-L-
thyronine (T3) in PBS (Sigma, 13.6 g added to 100 ml 0.02 M NaOH to make 2 x 10
-4 
M T3 
further diluted in PBS to make 2 x 10
-8
 M).  The 100 X cocktail mix was filter sterilised and 
frozen prior to use.  
Following mixing, E-medium was then filter sterilised and kept at 4°C.  Prior to use, the E-
medium was supplemented with 2 mM L-glutamine and 5 ng/ml epidermal growth factor 
(EGF, BD Biosciences).  
2.7.4 Maintenance and irradiation of J2-3T3 mouse fibroblasts 
Following transfection of HFK with HPV 18 genomes, cells were cultivated with a feeder 
layer of irradiated NIH 3T3 J2 mouse fibroblasts.  J2 3T3 cells were routinely grown in 
Dulbecco’s Modified Eagle Medium (DMEM) HEPES modification (Sigma-Aldrich) 
supplemented with 10% [vol/vol] new born bovine serum, in 10 cm tissue culture dishes 
(Iwaki) and were grown to a confluency of no greater than 80% before passaging.  J2-3T3 
cells were grown to no more than passage 25 and then replaced with earlier J2-3T3 cells.  J2-
3T3 cells were passaged as described previously (2.5.5) and were frozen in DMEM 
supplemented with 20% [vol/vol] bovine serum, and 10% [vol/vol] DMSO.  When J2-3T3 
cells were required as feeder cells, they were harvested and re-suspended in E-medium at 2 x 
10
6
 cells/ml in a 50 ml tube (Corning).  Cells were irradiated using 50 Gray of a Caesium-137 
source.  Irradiated J2-3T3s were plated out at 2 x 10
6
 cells per 10cm dish in E-medium and 
allowed to settle for at least 2 h before the addition of HFKs.  J2-3T3 that had been irradiated 
and were not required straight away were stored in E-medium at 4 C for up to 3 days. 
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2.8 Generation of HFK HPV18 genome containing cell lines 
2.8.1 Construction of mutant genomes 
To generate mutations within the HPV18 genome a number of different primer pairs were 
used in site-directed mutagenesis (See table 2.5) using the QuikChange Kit (Stratagene) 
following manufacturer’s instructions.  The pGEMII-HPV18 plasmid was used as the 
template DNA and the number of PCR cycles used was between 18 and 25.  
 
Table 2.5 Mutants generated in pGEMII-HPV18 genome expression vector and 
their sequencing primers 
Primer Direction Primer Sequence 
E6ΔPDZ 
F 5’ CGA CTC CAA CGA CGC AGA TAA 
TGA CAA GTA TAA TAT TAA GTA TG 3’ 
R 5’ CAT ACT TAA TAT TAT ACT TGT CAT 
TAT CTG CGT CGT TGG AGT CG 3’ 
E6ΔPKA 
F 
 
5’ CTC CAA  CGA CTC AGA GAA ACA 
CAA GTA TAA 3’ 
R 5’ TTA TAC TTG TGT TTC TCT GAG TCG 
TTG GAG 3’ 
 
The complete HPV18 wild type and mutant genomes were sequenced using the primers used 
in table 2.6, which cover the entire HPV18 genome, to ensure that only the mutations 
generated by site-directed mutagenesis were changed within the genome.  
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Table 2.6 Sequencing primers for the total HPV 18 genome 
Primer Direction Primer Sequence 
E6 Forward (5’) 5’ CC GAA AAC GGT CGG GAC CG 3’ 
E7  Forward (5’) 5’ CAC AAC ATA CGT GGG CAC TAT AG 3’ 
E1 (1) Forward (5’) 5’ CCA GAA GGT ACA GAC GGG GAG 3’ 
E1 (2) Forward (5’) 5’ GA CGG GGG CAC AGA GGG C 3’ 
E1 (3) Forward (5’) 5’ GCC CTG TTG CGT TAC AAA TG 3’ 
E1 (4) Forward (5’) 5’ G CAA ACA TTA TAG GCG AGC CC 3’ 
E1 (3) Reverse (3’) 5’ G CAG ACA CCG AAG GAA ACC C 3’ 
2F Forward (5’) 5’ CCA GCA AAG GAT AAT AGA TGG CC 3’ 
3F  Forward (5’) 5’ GGC CCT ACA AGG CCT TGC AC 3’ 
E2F Forward (5’) 5’ GGA GAT TGT ATT ATG TAA AGC 3’ 
4F Forward (5’) 5’ GGA ATA CTG ACT GTA ACA TAC C 3’ 
5F Forward (5’) 5’ CCC CTG CCA CAG CAT TCA CAG 3’ 
L2 (1)  Forward (5’) 5’ CAC GTC CCC CAG TGG TTA TTG 3’ 
L2 (2) Forward (5’) 5’ CCT GAG TTT CTT ACA CGT CCA TCC 3’ 
L1 (1)  Forward (5’) 5’ GCC TGT ATA CAC GGG TCC TG 3’ 
L1 (2) Forward (5’) 5’ CA CAA CGT TTA GTG TGG GCC 3’ 
L1 (3) Forward (5’) 5’ GCA GAT CCT TAT GGG GAT TCC ATG 3’ 
L1 (4) Forward (5’) 5’ G CAG TAT AGC AGA CAT GTT GAG G 3’ 
End (1) Forward (5’) 5’ GCG TGT GCG TGT ACG TGC CAG 3’ 
End (2) Forward (5’) 5’ CAA TTG GCG CGC CTC TTT GG 3’ 
   
2.8.2 Preparation of HPV18 genomes for transfection into HFK 
To extract the HPV18 genome from the bacterial vector, 10 µg of pGEMII-HPV18 wild type 
or mutant genomes were digested with EcoRI in a total volume of 50 µl.  Complete digestion 
of the bacterial product was verified by running 200 ng of the product on an agarose gel. 
Following verification, the reaction was heat inactivated at 65°C for 20 min.  HPV18 
genomes were then re-circularised in a 900 µl total volume ligation reaction mix (with T4 
DNA ligase containing 400 U/ml, New England Biolabs,) to encourage self-ligation of the 
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HPV genomes, and incubated overnight at 16°C.  The DNA was then precipitated by the 
addition of 2 volumes of isopropyl alcohol and 1/5 volumes of 5 M NaCl followed by 
vortexing before incubation at -20°C overnight.  Following centrifugation at 16,100 g for 30 
min at 4°C, the supernatant was removed and the pellet washed with 70% ethanol (pre cooled 
to -20°C), prior to centrifugation at 16,100 g for a further 15 min.  The supernatant was 
subsequently removed and the DNA pellet re-suspended in 12 µl of 1 X TE buffer.  The DNA 
concentrations were then estimated by running a 200ng aliquot on an agarose gel.  
2.8.3 Transfection of HFKs with HPV18 genomes 
HPV18 genomes were co-transfected into HFKs with pcDNA3.1 (Invitrogen), a plasmid 
which carries the neomycin resistance gene.  Control transfections were also carried out in 
parallel, including pcDNA3.1 (Neo) alone with a green fluorescent protein (GFP, Clontech) 
reporter expression vector and no plasmid vector DNA.  For each transfection, 94 µl of SFM 
was dispensed into a polypropylene falcon tube, followed by the addition of 6 µl FuGene 6 
Transfection Reagent (Roche).  In a separate falcon tube, 100 µl of SFM, 1 µg of HPV 
genomic plasmid DNA or control plasmid together with 1 µg of Neomycin resistance plasmid 
were mixed, prior to the addition of the SFM/FuGene 6 mixture.  This was incubated at room 
temperature for 30 min.  HFKs at 50-60% confluency were selected, and the media replaced 
with SFM media (Invitrogen-Gibco), prior to the addition of the transfection mixture.  The 
dish was rocked gently to mix.  
The transfection efficiency of the GFP transfection was established the following day using a 
Zeiss Axiovert 100 microscope, with GFP-expressing cells typically representing 5% of the 
total population.  Tranfected keratinocytes were then trypsinised and re-plated onto 100 mm 
tissue culture dishes with 2 x 10
6
 irradiated J2-3T3 fibroblasts in the presence of E-medium. 
Over the next 8 days the HFKs underwent a process of selection in which, on alternate days, 
the cells were treated with either G418 or fresh irradiated J2-3T3 fibroblasts.  The selection 
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period began with the replacement of E-medium with E-medium supplemented with 100 
µg/ml G418 (PAA Laboratories).  On the days following selection, 1 x 10
6 
irradiated J2-3T3 
cells were added.  The concentration of G418 was increased to 200 µg/ml for the latter two of 
the four selection days and the following the last day of G418 treatment the media was 
replaced with E-medium without selection and 2 x 10
6 
irradiated J2-3T3 cells.  In the event 
that cells reached 80% confluency during the selection process, the dish was split equally onto 
two dishes of irradiated J2-3T3 fibroblasts in the presence of E-medium and the selection 
process was resumed the following day. 
Once colonies reached approximately 2 cm in diameter, routinely observed after 1- weeks 
post selection, the plates were pooled and transferred onto a single plate with irradiated J2-
3T3 cells.  Upon reaching 80% confluency, the HFKs were passaged into five, 100 mm tissue 
culture dishes and once 70-80% confluency was reached, cells from four of the five dishes 
were taken for stocks and frozen in liquid nitrogen. 
2.8.4 Maintenance of HFKs following transfection of HPV18 genomes 
HFKs were routinely grown on a feeder layer of 2 x 10
6
 irradiated J2-3T3 fibroblasts, in E-
medium supplemented with EGF and L-Glutamine prior to use.  The media was replaced 
every two days and the cells grown to a confluency of no greater than 80% prior to passaging. 
Irradiated J2-3T3 cells were plated out in E-medium at least 2 h, or on the previous day, prior 
to addition of the HFK.  HFKs were passaged by first removing the J2-3T3 feeder layer, using 
0.5 mM EDTA in PBS.  Once the feeder cells were detached, a transfer pipette was used to 
aspirate the EDTA and the dish was then washed twice in warmed PBS.  HFKs were then 
removed with 2 ml trypsin/EDTA (0.25% [wt/vol] trypsin/ 1 mm EDTA) and incubation at 
37°C for 5-10 min with regular checks.  The cells were harvested in 10 ml media and transfer 
to a 15 ml conical tube.  A further 3 ml of media was then used to wash the dish and the 
HFKs spun by centrifugation at 538 g for 5 min at room temperature. The supernatant was 
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removed and the cells washed in 10 ml PBS, prior to a further 5 min centrifugation and re-
suspension in E-medium.  HFKs were routinely seeded out at 2 x 10
5
 cells/dish on irradiated 
J2-3T3 cells.  The plates were rocked several times to ensure thorough mixing and the cells 
incubated at 37°C.  The media was replaced every 2 days, with cells taking typically 7 days to 
reach a confluency of 80%.  
2.8.5 Analysis of HFK cell lines harbouring HPV18 genomes 
2.8.5.1 HFK cellular proliferation assays 
HFKs were plated out at 2 x 10
4
 cells/well in a 6 well plate (Iwaki) containing 2 x 10
5
 
irradiated J2-3T3 cells/well.  Cells were harvested at various times, with each time point 
performed in duplicate. Viable HFKs were counted following removal of the feeder 
fibroblasts.  
2.8.6 Differentiation of HFKs in semi-solid media 
2.8.6.1 Preparation of semi-solid medium 
Semi-solid medium (1.5% [wt/vol] methylcellulose (Sigma) in E-medium supplemented with 
5% [vol/vol] FBS, was prepared by dispensing 6 g of methylcellulose (Sigma) into a Pyrex 
bottle with a stir bar and autoclaving. 200 ml of E-medium containing no EGF, was 
subsequently added, and the solution gently swirled before placing in a water bath at 60°C. At 
regular intervals of approximately 5 min, the solution was gently swirled and after 30 min the 
bottle was cooled on ice for 2 min.  A further 180 ml of E-medium (-EGF) was added to the 
bottle, before being left to stir overnight at 4°C. The following day, 20 ml of FBS was added 
and a further 2 h of stirring at 4°C was performed prior to storage of the semi-solid media at 
4°C for up to 2 weeks.  
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2.8.6.2 Suspension of HFK in semi-solid medium 
HFKs at a confluency of approximately 80% were harvested following removal of J2-3T3 
fibroblasts as described previously (2.8.4).  Cells were pooled and re-suspended in E-medium 
(-EGF) to form a single cell suspension.  The cell suspension was then added to a Petri dish 
containing 25 ml semi-solid media, pre warmed to 37°C, by dispensing the cells, in a volume 
of 1 ml, to each dish in a drop-wise manner.  To ensure an even distribution of the cells, the 
semi-solid media was mixed extensively before incubation at 37°C.      
2.8.6.3 Harvesting of HFKs from semi-solid medium 
HFKs were harvested at 24 h or 48 h following suspension in methylcellulose. Using a cell 
scraper, the semi-solid medium was transferred equally into 4 x 50 ml tubes and the dish 
washed three times in ice-cold PBS to remove the remaining cells.  The 50 ml tubes were 
filled with PBS and mixed, prior to centrifugation at 537 g for 10 min at 4°C.  Following 
centrifugation, the supernatant was removed to leave 10 ml remaining in each tube and the 
cells re-suspended in this volume and pooled into 2 tubes.  PBS was added to 50 ml and 
centrifugation step was repeated.  Finally the cells were pooled into 1 tube and after 
centrifugation, were re-suspended in 10 ml PBS, transferred to a 15 ml conical tube, pelleted, 
then divided into aliquots for DNA and protein analysis.  
2.8.7 Organotypic raft cultures 
Organotypic raft cultures were prepared as described in (Wilson and Laimins, 2005). 
Typically, 1.5- 2 x 10
6
 HFKs were grown on a collagen plug in a 2 cm tissue containing 2 x 
10
6
 J2-3T3 fibroblasts.  The plugs were allowed to expand until the collage turned yellow 
(typically after 24-48 h) after which, the collagen plug was carefully lifted and placed on a 
wire mesh platform in E-medium (-EGF) to create an air/liquid interface (Figure 2.1). The 
rafts were allowed to grow for 13 days with the media changed with fresh E-medium every 2 
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days. 5-Bromo- ’-deoxyuridine (BrdU) was added 12-15 h before fixing.  The rafts were 
fixed by flooding the rafts with 4% (w/v) paraformaldehyde in DMEM.   Rafts were paraffin-
embedded and sections (4 microns) prepared for staining by Propath Ltd.  
2.8.7.1 Protein extraction from Raft Cultures 
Protein was extracted from raft cultures by peeling of HFKs from the collagen layer followed 
by homogenisation in 1 ml raft lysis buffer (50 mM Tris pH7.4, 150 mM NaCl, 1 mM EDTA, 
1% [vol/vol] NP40 supplemented with protease inhibitors), performed on ice in a glass 
Dounce homogeniser. Following a 30 min incubation, lysate was transferred with a transfer 
pipette into a pre-cooled eppendorf tube and underwent centrifugation at 16,100 g for 15 min 
at 4˚C.  The supernatant was subsequently removed and the pellet was solubilised in 250 µl of 
Laemelli buffer supplemented with 5% [vol vol] β-Mercaptoethanol, before centrifugation at 
16,100 g for 10 min at 4˚C.   The supernatant was then heated at 100˚C for 5 min prior to 
SDS-PAGE and Western blot analysis (as described in sections 2.4.2 and 2.4.3 respectively).   
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Figure 2.1 Organoytpic Raft Culture Model.  Representation of the organotypic raft 
culture system. HFKs containing HPV genomes were seeded onto collagen plugs containing 
fibroblasts. When HFKs reached confluence, the collagen plugs were lifted onto stainless 
steel support grids. HFKs are stimulated to differentiate by the air liquid interface formed and 
lead to the production of a stratified epithelium as shown above.  
 
 
  
Materials and methods 
89 
2.9 Southern blot analysis 
2.9.1 Isolation of genomic DNA 
HFKs were harvested following removal of J2 3T3 fibroblasts (2.8.4) or harvested from 
methylcellulose (2.8.6.3) and pelleted cells were washed once in PBS and resuspended in 3 
ml lysis buffer (400 mM NaCl. 10 mM Tris-HCl, 10 mM EDTA, pH 7.4).  RNase A was 
added to a final concentration of 50 µg/ml, cell lysates vortexed, and then incubated for 15 
min at room temperature.  Proteinase K (Roche) was subsequently added to a final 
concentration of 50 µg/ml and SDS to 0.2% [wt/vol], prior to vortexing and incubation at 
37°C overnight.  DNA was sheared by passing the lysate through an 18-gauge needle, up to 
10 times.  Phenol-chloroform extraction was performed by addition of 6 ml 
phenol/chloroform/isoamylethanol (25:24:1) (Sigma-Aldrich) prior to centrifugation at room 
temperature for 5 min at 4838 g.  The upper aqueous phase was retained and the extraction 
repeated a further two times, before extraction of the aqueous phase with 
chloroform/isoamylethanol (24:1) (Sigma-Aldrich).  DNA was then precipitated by the 
addition of two volumes of 100% ethanol and 1/10
th
 volume of 3 M sodium acetate, and left 
either at -80°C for 1 h or at -20°C overnight.  Following centrifugation at 4°C for 30 min at 
4838 g, the supernatant was removed and the DNA pellet washed twice, first in 100% ethanol, 
then in 70% ethanol before re-suspension in 50-100 µl 1 x TE buffer and incubation at 37°C 
for 30 min.  The DNA yield was determined using a spectrophotometer (Nanodrop™) and 
samples were stored at 4°C until required.  
2.9.2 Preparation of genomic DNA for Southern blot analysis 
For analysis of viral episomes, genomic DNA extracted from HFKs was subjected to 
restriction enzyme digest with BglII, which has no restriction sites within the HPV18 genome.  
For analysis of linear genomes, DNA was digested with EcoRI which has one site within the 
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HPV18 genome.  DpnI digests of all DNA samples was carried out to remove any residual 
DNA input.  The 5 µg of digested genomic DNA was analysed by electrophoresis in an 0.8% 
[wt/vol] agarose gel.  To enable quantification of genome copy umbers, copy number 
standards were generated by digestion of pGEMII-HPV18 with EcoRI to release the HPV18 
genome from the vector and the equivalent 5 and 50 genome copies/cell were run as standards 
alongside the DNA on the agarose gel.  
2.9.3 Capillary transfer of DNA from agarose gel to nylon membrane 
Prior to blotting, the agarose gel was washed twice in 250 mM HCL for 20 min at room 
temperature with shaking, and twice in 0.4M NaOH for 30 min at room temperature with 
shaking.  To set up the transfer of DNA from the agarose gel to the nylon membrane, a tray 
was filled with 1 L of 400 mM NaOH and a glass plate rested in top of the tray.  A 24 x 33 
sheet of Whatman™ 3MM paper was soaked in 0.4M NaOH and laid across the glass plate 
with both ends submerged in the NaOH, thus forming a wick.  All the bubbles were removed, 
followed by three more layers of  4 x 33 Whatman™ paper on top, in the same manner as 
before.  The agarose gel was then placed on top of the paper wick, with the loading wells 
facing downwards.  Bubbles were subsequently removed with a pipette prior to placing a 20 x 
22.5 cm sheet of Gene Screen Plus nylon membrane (Perkin Elmer) pre-soaked in NaOH on 
top, followed by four layers of  1 x  3.5 Whatman™ paper, placed one at a time, with care 
taken to remove all bubbles.  Two stacks of absorbent paper towels, approximately 10 cm in 
height were placed on top, covering the Whatman™ paper, ensuring that there were no gaps 
between the stacks.  A second, smaller glass plate was placed in top of the towels, and a 
weight centred on top.  SaranWrap was placed between the top and bottom filter paper layers 
to ensure that they were not in contact, and the gel was left to transfer overnight.  Following 
transfer, the position of the loading wells was marked with a pencil, transfer stack was 
disassembled, and the DNA auto-cross linked to the membrane using a UV crosslinker 
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(Stratalinker, Stratagene) on auto-crosslink mode.  The membrane was then frozen at - 20°C 
in SaranWrap, following soaking in 2 x SSC.     
2.9.4 Preparation of radiolabelled DNA probe  
In preparation for generation of a DNA probe, the pGEMII-HPV18 vector was linearised by 
EcoRI digestion (2.3.5). 50 ng of digested vector was subsequently diluted into 45 µl of 1 x 
TE buffer and the DNA denatured by heating at 95°C for 5 min followed by incubation on ice 
for 2 min.  The denatured DNA was then used as a template for radiolabelled probe 
generation using the Ready To Go DNA labelling beads- dCTP kit (Amersham), following 
manufacturer’s instructions.  Following re-suspension of the labelling beads with the 
denatured linear DNA, 50 µCi of [
32
P] dCTP (Perkin Elmer) was added and the mixture left to 
incubate at 37°C for 30 min.  To purify the labelled probe DNA, the Illustra Probe Quant G-
50 microcolumn (Amersham), a radiolabelled probe purification kit, was used following 
manufacturer’s instructions. 
2.9.5 Hybridisation of radiolabelled probe to immobilised DNA 
To prepare the hybridisation buffer: a 2 x hybridisation solution (5 x SSC (1.5 M sodium 
citrate, 750 mM NaCl, pH 7.0), 10 x Denharts (0.2% [wt/vol] Ficoll 400, 0.2%[wt/vol] 
Polyvinylpyrolilone, 0.2% [wt/vol] BSA fraction V (Sigma-Aldrich)) and 20% [wt/vol] 
Dextran Sulphate, was diluted prior to use 1:1 with formamide (Sigma-Aldrich) and addition 
of SDS to a final concentration of 0.1% [wt/vol]. 200 µl of (10 mg/ml) salmon sperm DNA 
(Invitrogen) as denatured by heating at 95°C for 5 min, followed by cooling on ice for 2 min 
and was subsequently diluted into 10 ml hybridisation buffer.  The nylon membrane on which 
the DNA was immobilised was then rolled and carefully placed into a glass hybridisation 
canister.  The hybridisation buffer containing salmon sperm DNA was then added and the 
canister placed into a hybridisation oven with rotation at 42°C for 1 h.  Following the pre-
Materials and methods 
92 
hybridisation step, hybridisation buffer containing the radiolabelled DNA probe was prepared 
by addition of 200 µl of (10 mg/ml) salmon sperm DNA to the probe, followed by boiling for 
5 min, cooling and addition to the 10 ml hybridisation buffer as described above.  The pre-
hybridisation buffer was removed and the hybridisation buffer containing the probe was 
added and left to rotate overnight at 42°C.  
2.9.6 Stringency washes 
Following the removal of the membrane from the hybridisation cassette, the membrane was 
rinsed in buffer 1 (600 mM sodium acetate, 300 mM NaCl pH 7.0, 0.1% (w/v) SDS, using a 
sponge to wipe the surface of the membrane to clear any excess unbound probe.  Two further 
washes in the same buffer followed, with gentle agitation. The membranes were then washed 
for two 15 min washes with buffer 2 (150 mM sodium citrate, 75 mM NaCl pH7.0, 0.1 % 
(w/v) SDS and then 2 x 15 min washes with buffer 3 (30 mM sodium citrate, 15 mM NaCl pH 
7.0, 0.1% (w/v) SDS).  Following this, the membrane was then washed once for 30 min at 
65 C with buffer 4 (30 mM sodium citrate, 15 mM NaCl pH 7.0, 1% (w/v) SDS).  The 
membrane was then wrapped in SaranWrap and exposed to autoradiography film.   
2.10 Flow cytometric analysis 
For DNA and cell cycle analysis, cell pellets were resuspended in 70% ethanol and fixed at -
 0 C for 1 h.  Cells were then pelleted by centrifugation at 16 100 x g for 10 min and washed 
twice with phosphate buffered saline (PBS).  After the second PBS wash, 1 ml of PBS 
containing 10 µg/ml of RNase (Sigma Chemicals) was added and the samples were incubated 
at 37 C for 1 h.  The cells were pelleted by centrifugation and resuspended in 500 µl of PBS 
containing 20 µg/ml of propidium iodide (PI).  The relative cellular DNA content of stained 
cells was measured using an EPICS XL flow cytometer (Coulter Electronics).  PI 
fluorescence was collected by using a 488-nm long-pass filter, followed by a 635-nm-band-
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pass filter.  Single cells were selected for analysis by using the distribution of PI fluorescence 
signal integral against PI fluorescence signal peak to discriminate doublets and debris.  The 
relative size of PI fluorescence signal integral (DNA content) in single cells was plotted as a 
frequency histogram.  Equal numbers of cells (20,000) were analysed by fluorescence-
activated cell sorting.  The proportions of cells in phases G0/G1, S and G2/M were sorted using 
the Multicycle dedicated cell cycle analysis software (Phoenix Flow Systems).   
2.11 G2/M assay 
For G2/M checkpoint analysis, cell pellets were resuspended in 70% ethanol and fixed at - 0 C 
for 1 h. Cells were then pelleted by centrifugation at 16 100 x g for 10 min and washed twice 
with 20 ml phosphate buffered saline (PBS). After the second PBS wash, the cells were 
resuspended in 10 ml ice cold 0.25% Triton x 100 in PBS and left to permeabilise on ice for 
15 min. Following permeabilisation, cells were pelleted by centrifugation at 16 100 x g for 5 
min and the supernatant removed.  Cells were resuspended in 100 µl of 1% BSA in PBS 
followed by centrifugation of the cells at 16 100 x g for 5 min and removal of the supernatant.  
Cell pellets were resuspended in 100 µl of 1% BSA containing anti-phospho histone H3 (ser 
10) antibody (Cell Signalling) (used as a marker for cells in mitosis) and transferred to a 1.5 
ml eppendorf and left to incubate 1-3 hours.  Following a primary incubation, cells were 
washed twice in 1ml 1% BSA/PBS at 16 100 x g for 5 min.  After the removal of the 
supernatant, cells were resuspended in 100 µl 1% BSA/PBS and 1:50 dilution of FITC-anti 
rabbit antibody and left to incubate for 30 min in the dart at room temperature.  Following the 
secondary incubation, cells were washed once with 1%BSA/PBS and a further wash with 1 x 
PBS.  Cells were stained with PI (25 µg/ml) and 0.1 mg/ml RNAse at room temperature for 
30 min prior to analysis on the EPICS XL flow cytometer (Coulter Electronics). 
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2.12 Effect of PKA inhibitors/activators on keratinocyte cell growth 
HFKs containing either wild type or mutant HPV18 genomes were seeded into a 6-well plate 
containing an irradiated J2-3T3 fibroblast feeder layer at a concentration of 5x10
4
 cells/well. 
Each cell line was set up in duplicate at each time point for scientific accuracy.  Cells were 
allowed to stratify in these wells for 48 h before the addition of specific activating/inhibiting 
PKA analogues.  Forskolin (FK) and 3-isobutyl-1-methylxanthine (IBMX) were used in 
combination at concentrations of 50 µM and 1 mM respectively.  Dibutryl cAMP (Bt2cAMP, 
Calbiochem) was dissolved in Hanks balanced salt solution and diluted in culture medium to a 
final concentration of 1 mM.   The general PKA inhibitor, H89 (Calbiochem) was dissolved 
in DMSO and added to the culture medium at a final concentration of 10 µM.  Cells were 
harvested at various time points up to 96 h, with each activator/inhibitor performed in 
duplicate.  Viable HFKs were counted following removal of feeder fibroblasts. 
2.13 Cell invasion assays 
For cell invasion assays, 8 µm polycarbonate transwell membrane inserts were pre prepared 
by coating the underside of the insert with 100 µl of 2-20 µg/ml collagen and left to set 
overnight at 4 C.  The next day, HFKs were harvested as detailed in section (2.8.4) and 400 µl 
of HFKs containing wild type or mutant genomes (0.5 x 10
6
/ml) cells in serum free media 
were inserted into the top of each transwell insert in quadruplicate for each condition (Two 
total cell number samples and two migration samples).  The outside of the transwell was filled 
with 400 µl serum free media and transwells were incubated at 37 C. After 30 min, “total” 
control samples were removed and fixed.  After 5-8 hours incubation at 37 C, the “migrated” 
samples were fixed.  During the fixing procedure, both sides of the transwell membrane were 
washed carefully with PBS.  For migrated samples only, the cells on the upper surface of the 
membrane were scraped with a cotton swab to remove any non migrated cells from the inside 
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surface of the membrane.  Both control and migrated transwells were fixed in 4% 
paraformaldehyde for 10 min and then washed again with PBS.  To permeabilise the cells, 
transwells were subjected to a 0.1% triton x-100 wash for 90 s followed by a DAPI wash for 5 
min to stain nuclei.  Membranes were cut carefully from the transwells and mounted in 80% 
(v/v) glycerol in PBS containing 2% (w/v) DABCO (1, 4 diazobicyclo-[2, 2, and 2] octane). 
4-5 fields for each transwell were observed using a Nikon Eclipse E600 microscope and 
images captured using a Leica DC200 camera and software.  The percentage of invasion was 
calculated by normalising the migrated counts to the counts from the control transwells. 
2.14 Assessment of HPV E2 gene integrity assay  
The integrity of the E2 gene was assessed using sets of specific primers which were designed 
to amplify the full length of the HPV18 E2 protein.  Primer pairs were designed by Dr 
Constandinou-Williams for another HPV study (Collins et al., 2009).  Primers were designed 
to the full length E7 protein as a control in this experiment (Table 2.7). 100 ng of plasmid 
DNA was mixed with 5 µL of 2.5 pmol primer mix (containing forward and reverse primers), 
12.5 µl of 2X GoTaq® reaction mix (Promega) and water to a total volume of 25 µl.  The 
reaction was amplified using a thermal cycler with 1 cycle of  5 C for 5 min followed by 40 
cycles of  5 C for 45 sec, 1 min at the annealing temp (55 C for E7 and 53.8 C for E ), 7  C for 
  min followed by 7  C for 10 min.  For resolution of DNA fragments, PCR samples were run 
on a 2% (wt/vol) agarose gel as described at 25mA for 1 hour.   
Table 2.7 Primer sequences used in E2 integration assay 
Primer Direction Primer Sequence 
HPV18 E7 
F 5’ GTT GAC CTT CTA TGT CAC GA 3’ 
R 5’ CAA TTC TGG CTT CAC ACT TA 3’ 
 
HPV18 E2 
 
F 5’ TTA GAT GAT GCA ACG ACC AC 3’ 
R 5’ CGG TGG GAT ACC ATA CTT TT 3’ 
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CHAPTER 3 THE FUNCTION OF THE E6 PDZ BINDING 
MOTIF IN THE EARLY STAGES OF THE HPV18 LIFE 
CYCLE 
3.1 Introduction 
3.1.1 The development of expression systems for studying the 
papillomavirus life cycle 
Whilst ectopic over-expression studies have enabled assignment of numerous functions to 
papillomavirus proteins, they may be inadequate for identification of the complete and 
genuine functional repertoire of these proteins.  The fact that the papillomavirus life cycle 
strictly requires keratinocyte differentiation has posed a substantial barrier to the study of 
papillomaviruses in the laboratory.  To understand the significance of viral proteins in the 
context of the HPV life cycle it is therefore desirable to utilise an expression system which 
permits completion of the viral replication cycle, in which viral proteins are expressed in a 
timely manner and at physiological levels which most closely resemble events of a true 
infection. 
A number of cell lines have been established which allow HPV genomes to be stably 
maintained, including the HPV16 W12 cell line (Stanley et al., 1989) and the HPV31 
CIN612-9E cell line (Bedell et al., 1991).  Differentiation of these cell lines permitted the 
study of the viral life cycle within a tissue culture setting, however genetic analysis could not 
be performed and the functional contribution of the viral proteins could not be elucidated. 
Other systems were required, in which viral genes could be manipulated, and their effects of 
the HPV life cycle examined.  One of the most reliable systems for studying the replication 
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cycle of the virus and one that allows the genetic analysis of virus gene function is based on 
normal primary human foreskin keratinocytes (HFKs) derived from neonatal foreskin as a 
host cell.  These cells can be co-transfected with HPV genomes derived from high risk types 
together with a drug resistance marker (Frattini et al., 1996).  Following drug selection, the 
population of cells harbouring viral genomes is expanded, generating a cell line which stably 
maintains HPV genomes as extrachromosomal elements.  These cell cultures can 
subsequently be grown as organotypic raft cultures or induced to differentiate following 
suspension in a semi-solid media composed of methylcellulose, or in the presence of high 
concentrations of calcium ions.  The cells grown in a 'raft' culture are held at the liquid 
medium-air interface until they stratify, differentiate, and reach the thickness of normal 
epithelia, forming sheets of tissue virtually indistinguishable from real skin.  If the viral DNA 
is introduced into the keratinocytes before they are placed into the raft culture environment, it 
carries out its full reproductive program including controlled RNA transcription, DNA 
replication, and packaging into the capsid proteins, as it would in the human body.  Such 
progeny viruses are then capable of re-infecting fresh skin cells and repeating the entire 
infection cycle (Myers et al., 1997).  These systems have been crucial for the understanding 
of a number of the HPV viral proteins and the regulation of viral gene expression and 
replication.  
3.1.2 Conditional regulation of E6 PBM function 
Functions of HPV E6 proteins in human carcinogenesis have been extensively studied; 
however their roles in the viral life cycle are still poorly understood.  In this regard, 
transfection studies of human keratinocytes with E6 viral proteins from HPV31 and HPV16 
have demonstrated a distinct E6 requirement for the long term maintenance of viral episomes 
(Thomas et al., 1999; Park & Androphy, 2002).  Similar experiments with HPV31 genomic 
DNA containing mutations in the E6 PDZ binding domain (E6 PBM) revealed that abrogation 
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of this domain function was associated with decreased cellular proliferation and a reduction in 
viral genome copy number (Lee & Laimins, 2004), thus demonstrating that E6 binding to 
PDZ proteins is necessary for optimal support of viral DNA maintenance.  Whether these 
functions of the E6 PBM in the life cycle are shared amongst other high risk HPV types such 
as HPV18 remains to be determined and forms the basis of this initial study.  
As well as the structure of the E6 PBM facilitating binding to PDZ substrates, 
phosphorylation of HPV18 E6 by the kinase, protein kinase A (PKA) negatively regulates E6-
PDZ interactions.  The C terminal motif of HPV18 E6 contains an RXXT consensus sequence 
for the cyclic AMP-dependent PKA which overlaps with the E6 PBM.  In vitro binding 
experiments have shown that HPV18 E6 phosphorylation by PKA reduces its binding to hDlg 
(a substrate of the PDZ binding motif), and the E6-dependent degradation of this PDZ protein 
in cells with high PKA levels is inhibited and this is dependent on phosphorylation of the 
PDZ binding site in E6 (Kuhne et al. 2000).  Further studies have shown that the Thr156 of 
the PBM of HPV18 E6 is critical for the binding to PDZ substrates including hDlg, with both 
neutral and acidic charge mutations abolishing binding (Gardiol et al., 1999).  These data, 
support in vivo data, whereby induction of PKA leads to the stabilisation of the hDlg protein 
in HPV positive cervical carcinoma cells, whereas in an HPV negative cell line (HaCaT), 
hDlg levels are not altered (Kuhne et al., 2000).  Furthermore, an E6 mutant that is capable of 
binding hDlg but which is no longer phosphorylated by PKA further demonstrated the 
involvement of the conserved PKA consensus site in the regulation of the PDZ binding 
domain of HPV18 E6 (Kuhne et al., 2000).  
PDZ proteins are localised at the membrane cytoskeleton at sites of cell-cell contact where 
they have been shown to regulate cell growth, polarity and adhesion in response to cell-cell 
contact (Fanning & Anderson, 1999).  Moreover, studies from Drosophila have shown that 
mutation of the Dlg or Scrib proteins results in hyperproliferation and a loss of cell polarity 
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(Bilder et al., 2000; Woods et al., 1996; Goode & Perrimon 1997).  Our understanding of E6 
PBM-PDZ interactions has largely came from overexpression studies (Lee et al., 2000; 
Nakagawa & Huibregtse, 2000; Pim et al., 2000; Thomas et al., 2002), therefore the true 
physiological significance of a regulated, conditional function of the E6 PBM, in the context 
of an HPV18 infection remains unclear.  As such, the contribution of the E6 PBM to the early 
and late viral life cycle functions of HPV18 was investigated and the significance of this 
domain during early viral life cycle stages forms the initial basis of this study.  
3.2 Results 
3.2.1 A molecular signature for malignant potential  
As mentioned previously, of those HPV types within the alpha genus implicated as 
aetiological agents for the development of cervical cancer, all of them express an E6 protein 
with a four amino acid PBM at the extreme C-terminus.  None of the E6 proteins from low 
risk HPV types have this motif, nor is it present in E6 proteins of beta types linked to the 
development of skin cancers.  A multiple alignment of these E6 protein sequences reveals a 
strictly conserved PKA consensus recognition motif (PKA-RM) overlapping the PBM with a 
threonine, or occasionally a serine at position -3, being the putative phospho-acceptor site in 
protein of HPV types most frequently found in cancer (Group 1, Figure 3.1).  In viruses 
classified as probably, or possibly carcinogenic, a PKA-RM is often present within the 
extreme C-terminus of E6, however overlap with the PBM is infrequent (Group 2B, Figure 
3.1) (Bouvard et al., 2009).  Significantly, a C-terminal PKA-RM is absent in E6 proteins 
classified as non-carcinogens (Group 3, Figure 3.1).  Overall, this suggests that PKA 
regulated E6 degradation of PDZ domain containing substrates is only a function of high risk 
HPV types that have a strong association to carcinogenesis development.  
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Figure 3.1 Sequence alignment of high risk HPV types.  An alignment of HPV 
sequences from high risk and low risk types revealed that all of the HPV types within the 
alpha genus recognised as high risk types (Group 1 and 2A and 2B) contain a PBM at the 
extreme C-terminus. The grey area highlights how conserved this domain is between the high 
risk typesOf the types frequently found in cancer (Group 1) a PKA consensus motif (RXXT) 
overlapping the E6 PBM is a conserved feature.  
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3.2.2 Construction of HPV18 genomes containing mutations within the E6 
open reading frame that alter PDZ binding activity 
To study the function of the PBM of E6 in the HPV18 life cycle, two mutant viral genomes 
were constructed by site directed mutagenesis (Chapter 2: Materials and Methods, Section 
2.8.1).  The plasmid vector pGEMII contains the complete HPV18 genome cloned into the 
EcoRI restriction site at nucleotide position 2440 and was used as a template for site-directed 
mutagenesis.  The mutation referred to as E6ΔPDZ contains three nucleotide substitutions 
(G
567
->T, A
570
->T, C
571
->G) within the E6 open reading frame (ORF) (pGEMII18-E6ΔPDZ) 
and substitutes translation termination codons at amino acid positions 155 and 156 of the E6 
protein (Figure 3.2).  The E6 protein expressed from this genome therefore lacks the extreme 
four amino acids of the PBM.  The second mutant genome generated, E6∆PKA contains one 
nucleotide substitution (G
565
->T, pGEMII18-E6ΔPKA) within the E6 ORF and substitutes 
amino acid arginine 153 for leucine (Figure 3.2).  This mutation disrupts the integrity of the 
PKA recognition signal (
153
RRET
156
 -> 
153
LRET
156
) that overlaps with the PBM and 
abrogates recognition of E6 by PKA and thus phosphorylation of the threonine acceptor 
(Threonine 156) within the PBM (Figure 3.2) (Watson et al., 2003).   
Bidirectional DNA sequencing of the complete HPV18 genomes confirmed insertion of the 
nucleotide changes and the absence of mutations outside these nucleotide positions (Chapter 
2: Materials and Methods, Section 2.8.1). 
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Figure 3.2 Construction of mutants within the E6 ORF.  The mutation referred to as 
E6ΔPDZ (shown in blue) contains three nucleotide substitutions (G567->T, A570->T, C571->G) 
within the E6 open reading frame (ORF) and substitutes translation termination codons at 
amino acid positions 155 and 156 of the E6 protein. The second mutant genome generated, 
E6∆PKA (shown in purple) contains one nucleotide substitution (G565->T) within the E6 ORF 
and substitutes amino acid arginine 153 for leucine. Following the insertion of the E6ΔPDZ 
and E6ΔPKA genomes, total genome sequencing was carried out to check the integrity of the 
genome.  
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3.2.2.1 The mutations within the E6 coding sequence do not alter p53 degradation 
assay 
Before characterising the effects of expression of the different E6 protein upon the HPV18 
life cycle, it was first necessary to confirm that they were biologically active with regards to 
functions not mediated by the extreme C-terminal sequences.  The most well characterised 
function of E6 is inactivation of p53 through E6AP-mediated proteasomal degradation.  
Therefore to assess ability of the E6ΔPDZ and E6ΔPKA mutant proteins to target p53 for 
degradation, SAOS-2 cells were transfected at 50-60% confluency with equal amounts of 
pcDNA 3.1 based plasmids containing the E6 cDNAs, or an empty vector as a control, 
together with an equivalent amount of a construct encoding untagged p53 (gift from 
Lawrence Banks).  Cells were harvested 24 hours after transfection and p53 levels determined 
by western blotting.  As shown in figure 3.3, p53 levels in control cells were detected strongly 
after 24 hours, whereas the levels of p53 were diminished in cell transfected with the wild 
type or mutant constructs (Figure 3.3), indicating that the E6 proteins are active for p53 
degradation. 
 
 
 
 
 
 
 
Chapter 3 
108 
 
            
 
 
 
 
 
Figure 3.3 Changes made within the PBM do not affect the ability of E6 to degrade 
p53.  To assess the ability of mutants of E6 to carry out known functions of E6 protein, 
SAOS-2 cells were transfected with 10 µg of pCDNA vector containing E6 wild type, 
E6ΔPDZ or E6ΔPKA cDNA’s  together with 10 µg untagged p53. Cells were harvested after 
24 h and p53 levels were analysed by western blot analysis with an anti-p53 antibody. 
GAPDH levels were analysed to control for protein loading. 
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3.2.3 Stable transfection of primary HFKs with HPV18 genomes 
For stable transfection into HFKs, the HPV18 genomes were excised from the pGEMII 
plasmid by EcoRI restriction digestion and the viral genome recircularized in the presence of 
T4 DNA ligase (Chapter 2: Materials and Methods, Section 2.8.2).  Low passage HFKs 
(between passage (P) 0 and 2 depending on donor used) were co-transfected with each of the 
mutant viral genomes and a plasmid that expresses the drug resistance marker, neomycin 
(Chapter2: Materials and Methods, Section 2.8.3).  Following a short period of exposure to 
the drug G418-whereby only cells transfected with the neomycin resistance gene are provided 
with resistance, drug resistant colonies emerged after 10 to 14 days.  These colonies were then 
pooled and expanded on a feeder layer of γ-irradiated J2-3T3 cells in the absence of G418.  
Sequencing of extracted DNA from these cell lines with a primer covering the E6 PBM 
confirmed that the cell lines contained the correct HPV18 genomes.  
To control for HFK donor effects, the E6ΔPKA genomes were transfected into HFK isolated 
from three different donors, whilst E6∆PDZ was transfected into HFK from four different 
backgrounds.  For each donor used, stable transfections with the wild type genome were also 
carried out in parallel.  Drug-resistant colonies were obtained for each transfection. During 
the establishment of these lines it was noted that the appearance of drug resistant colonies was 
delayed in cultures carrying E6ΔPDZ genomes, compared with HPV18 wild type or E6ΔPKA 
genome containing HFK cultures.  The number of colonies also varied between the different 
mutant lines, with E6ΔPDZ genome containing lines presenting only   or 3 large colonies 
following drug selection, compared to anything between 20 and 30 colonies established with 
wild type and E6ΔPKA containing donors.  
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3.2.4 The E6 PBM is important for efficient establishment of viral 
genomes 
To confirm that the transfected HFK cell lines had established episomal copies of HPV18 
genomes, DNA was extracted and analysed by Southern blot analysis using a HPV18 
genomic probe (Figure 3.4, A/B).  Total DNA was isolated from each of the cell lines that had 
been expanded in monolayer cell culture to passages P3-P5.  To maintain these cells in an 
undifferentiated state, cells were not allowed to reach a 100% confluence and were routinely 
harvested for DNA extraction when between 70-80% confluent.  Equal amounts of DNA was 
digested with the restriction enzyme EcoRI which cuts the HPV18 genome only once and 
therefore will linearize viral genomes that are replicating as extrachromosomal plasmids.  
Digestions were also carried out in the presence of BglII; the HPV18 genome does not contain 
any restriction sites for BglII and therefore episomal genomes remain intact and migrate as 
both supercoiled (SC) and open circular (OC) plasmid DNA in both wild type and E6 mutant 
cell lines.  The restriction enzyme DpnI was added to each digestion, to digest any residual 
background input plasmid DNA.  The HPV18 genomic DNA was labelled by preparing a 
radiolabelled DNA probe (Chapter 2: Material and Methods, Section 2.9.4) and used to probe 
the Southern blots.  Ethidium bromide stained gels were used to provide an indication of 
DNA loading in all Southern blots. 
As shown in figure 3.4, the wild type genomes in HFKs established successfully with a 
similar copy number present across all donor lines at between 40- 50 copies per cell.  In 
contrast, whilst E6∆PDZ genomes established as episomes, the level of replication was 
reduced compared to wild type genomes, with HFKs carrying E6ΔPDZ genomes establishing 
at a copy number of between 8 - 19 copies per cell.  Similar results were obtained in three 
independent transfection experiments, using different HFK isolates (Figure 3.4A).  The 
E6ΔPKA genomes established at a similar copy number to wild type genomes (40 - 50 copies 
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per cell, Figure 3.4B.).  This data suggests that the function of the E6 PBM is important for 
the efficient establishment replication of HPV18 genomes and concurs with a previously 
reported study investigating the function of the E6 PBM in HPV31 replication in primary 
keratinocytes (Lee & Laimins, 2004).  Moreover, disruption of the PKA-RM had no affect 
upon establishment replication of episomes suggesting that loss of negative regulation of the 
E6 PBM function is not important in the establishment of viral episomes in HFKs.  
3.2.5 Alteration of E6 PBM function is associated with changes in growth 
and morphology of cells containing HPV18 genomes 
It was noted that during the routine handling of the cell lines there were obvious differences in 
both the growth characteristics of the cells and in their cellular morphology.  Therefore, to 
assess the contribution of the E6 PBM towards the growth of HPV18 transfected HFKs, cell 
growth assays were performed with cells containing wild type, E6ΔPDZ and E6ΔPKA 
genomes.  Cells containing wild type or mutant genomes were seeded at low density onto γ-
irradiated J2-3T3 fibroblasts in 6-well plates.  At various times (routinely 2, 4 and 6 days post 
seeding), keratinocytes were harvested after removal of feeder cells, counter stained with 
trypan blue to detect viable cells (Chapter 2: Materials and Methods, Section 2.8.5.1).   
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Figure 3.4 Abrogation of the PBM results in a reduction of viral genomes established 
in HFKs.  Total DNA was isolated from 3 donor lines transfected with wild type, E6ΔPDZ or 
E6ΔPKA genomes and digested with EcoR1, which linearizes the HPV18 genome. The 
HPV18 genome was also digested with Dpn1 to remove residual input DNA and southern blot 
analysis was performed with HPV18 genomic DNA as a probe. Copy number was calculated 
from phosphoimaging analysis of autoradiographs compared with a copy number control. 
Copy numbers are indicated. (A) Southern blot analysis of HFKs containing wild type 
genomes and HFKs containing E6ΔPDZ genomes.  (B) Southern blot analysis of HFKs 
containing wild type genomes and HFKs containing E6ΔPKA genomes.  
 
 
Chapter 3 
113 
The growth rate of HFK cells was significantly enhanced as expected, following transfection 
of HPV18 genomes, with un-transfected HFKs growing at a significantly lower rate in 
comparison with HFKs harbouring wild type HPV18 genomes (Figure 3.5A).  HFKs carrying 
the E6ΔPDZ genomes showed a significant reduction in their growth, when compared to wild 
type keratinocytes (Figure 3.5B).  This result concurs with findings from studies of HPV31, 
whereby deletion of the PDZ binding motif results in a significant retardation in cellular 
growth of HPV31 transfected HFKs (Lee & Laimins, 2004).  In contrast, cells that contained 
the E6∆PKA genomes grew at a faster rate than cells transfected with wild type HPV18 
genomes (Figure 3.5C).  Taken together, these data suggest that the E6 PBM function 
facilitates efficient growth of the HPV genome-containing keratinocytes and that the negative 
regulation of E6 mediated targeting of cellular PDZ proteins by phosphorylation of the E6 
PBM has a role to play in controlling the growth of HPV18 genome containing keratinocytes.  
The growth characteristics of the different cell lines were consistent between all HFK donors. 
A combined analysis of HFK growth rates from all three donor backgrounds verified the 
significant change in growth rates between HFKs containing wild type genomes and those 
containing E6ΔPKA genomes at 6 days post seeding (<p=0.001). Furthermore, the difference 
in growth rates between HFKs containing wild type genomes and those containing E6ΔPDZ 
genomes was also significant at the same time point (p=0.01) (Figure 3.5D).   
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Figure 3.5 Abrogation of the E6 PBM is associated with decreased cell growth, whilst 
constitutive activation of the PBM is associated with an increase in cell growth.  (A/B/C) 
Cellular proliferation profiles of normal HFKs as well as HFKs harbouring wild type, 
E6ΔPDZ or E6ΔPKA genomes. Cell growth profiles were performed in duplicate in 3 donor 
lines. Errors bars represent the standard deviation of the experiments shown. Growth profiles 
are representative of 3 sets of independent experiments. (D) Combined analyses of all data. 
HFKs containing wild type genomes grow significantly faster than HFKs which contain 
E6ΔPDZ genomes at 6 days (p=0.01) and significantly slower than HFKs which contain 
E6ΔPKA genomes at same time point (p=0.001).    
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A difference in morphology of the cell cultures was also observed.  Phase contrast images of 
the cell colonies were taken when cultures had reached a confluence of between 40 to 50% for 
further analysis.  In monolayer cultures of cells at early passage (P6-P7), cells containing the 
E6ΔPDZ genomes showed a reduced ability to form colonies consisting of tightly adhered 
cells with a uniformed cobblestone appearance, compared to the untransfected cells or cells 
transfected with the wild type or E6ΔPKA genomes (Figure 3.6).  Cell cultures of HFKs 
carrying the wild type genome are characterised by the presence of cells with multiple nuclei 
and a high frequency of large cells, an observation reported by others (Duensing et al., 2000; 
Duensing et al., 2001).  Whilst the occurrence of cells with similar appearance is a feature of 
HFKs carrying the wild type genome and mutant E6ΔPKA genome containing cell lines, 
there is a significant increase in the number and degree of cellular multinucleation in the 
presence of E6ΔPDZ genomes (Figure 3.6).  This phenotype was consistent across multiple 
donor cell lines, containing the same mutant genome.  
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Figure 3.6 Growth of HFKs containing E6ΔPDZ genomes in monolayer cultures is 
characterised by the presence of large multi-nucleate cells.  HFKs containing wild type, 
E6ΔPDZ or E6ΔPKA genomes as well as normal HFKs were grown in monolayer culture. 
When HFKs reached 50% confluency, phase contrast images were taken using a Nikon 
Eclipse E600 microscope.  Images are representative of phenotypes observed in 3 separate 
donor backgrounds.  
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3.2.6 Disruption of the E6 PDZ binding motif induces extensive nuclear 
abnormalities and changes in cell  
Nuclear atypia is an important marker for the diagnosis of cervical neoplasia as well as other 
malignancies.  Nuclear abnormalities can show different degrees of severity beginning with 
nuclear enlargement and irregular size and shape, but more advance stages frequently include 
the formation of multiple irregular nuclei.  To address whether changes to the PDZ binding 
activity affect the degree of nuclear atypia seen in monolayer cultures, HFKs containing 
HPV18 wild type, E6ΔPKA or E6ΔPDZ were grown on coverslips to 80% confluency, fixed 
in 4% paraformaldehyde (PFA) and stained with DAPI to detect cell nuclei.  Cells were then 
visualised under the microscope for the presence of atypia and any atypic nuclei were marked 
against a panel of defined nuclear abnormalities including large misshapen, bi-nucleate, 
multinucleate, aberrant chromosome and aberrant metaphase (Figure 3.7A).  Approximately 
2000 cells were assessed for nuclear abnormalities from normal HFKs and HFKs containing 
wild type, E6ΔPDZ or E6ΔPKA genomes.  The results shown are the individual counts from 
1 experimental count across 3 donor backgrounds and the average data from 2 separate counts 
across 3 donor backgrounds (Figure 3.7, B and C).  
Disturbances of polarity during mitosis including cellular multi-nucleation were observed in 
cells containing the wild type, E6ΔPDZ and E6ΔPKA genome containing lines.  There was an 
overall increase of 4.5% (p=0.01) in the number of atypic mitoses in HPV18 wild type cells 
compared to normal HFKs.  This result is consistent with previous findings from Duensing 
and others (Duensing et al., 2000; Duensing et al., 2001).  Abrogation of the E6 PBM resulted 
in a further increase of atypic nuclei (1.8 %) formation compared to wild type cells (p=0.03) 
and nomal HFK cell cultures (p=0.01), due mainly to the presence of a marked increase of bi 
and multinucleate cells in these cultures (Figure 3.7C).  Monolayer cultures containing the 
constitutively active mutant (E6ΔPKA) have less aberrant nuclei than cells containing the 
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wild type genomes and the atypia present in these cultures is mainly bi nucleate cells (Figure 
3.7B).  These data together suggests that the enhancement of nuclear atypia in the E6∆PDZ 
cells, particularly multinucleation might be the basis for the loss of viral episomes seen in 
HFKs carrying these mutant E6ΔPDZ genomes.  
3.2.7 The E6 PBM is involved in the maintenance of viral copy number 
Southern blot analysis of total DNA extracted from the cell lines has already shown that loss 
of the E6 PBM was associated with reduced establishment replication of the viral genome 
(replication).  To determine whether the PBM of HPV18 E6 had any effect in the stable 
maintenance of HPV18 episomes, DNA was extracted from HFKs upon increasing passage 
(up to P15) and Southern blot analysis was performed on the total DNA extracted from these 
monolayer cell cultures.  In HPV18 wild type cells, episomes were maintained at a 
comparable copy number (40 to 60 copies per cell) (Figure 3.8A).  In cells carrying genomes 
which are constitutively active for binding PDZ substrates (E6ΔPKA), episomes are 
maintained in a fashion similar to the HPV18 wild type genome containing cells 
(approximately 40 copies per cell) (Figure 3.8C).  However, analysis of episomal 
maintenance of the E6ΔPDZ genomes showed a reduction in the copy number of viral 
episomes upon increasing passage (from 21 copies per cell to 5 copies per cell), with 
significant loss occurring between passages P10 and P15 (Figure 3.8B).  An analysis of linear 
forms of the genome in wild type HFKs and those harbouring E6ΔPDZ genomes confirms the 
previous findings from figure 3.7A/B (Figure 3.8D).  This suggests that the loss of an intact 
PBM has a deleterious effect on the maintenance replication of viral genomes in primary 
keratinocytes.   
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Figure 3.7 Abrogation of the E6 PBM induces extensive nuclear abnormalities.  
Monolayer cultures of normal HFKs and HFKs containing wild type, E6ΔPDZ and E6ΔPKA 
genomes were assessed for the presence of atypic mitoses. HFKs containing wild type or 
mutant genomes were grown over coverslips to 80% confluency, fixed in 4% 
paraformaldehyde and stained with DAPI (blue) to detect the presence of nuclei. 2000 nuclei 
were counted from each cell line and marked against a panel of defined nuclear abnormalities. 
(A) Representative images of the panel of defined nuclear abnormalities used to score the 
nuclei. Any nuclei which could not be defined were marked as ‘unknown’. (B) Bar graphs 
represent the data collected from 1 experimental count across 3 donor backgrounds.  There is 
a marked increase in the presence of bi-nucleate and multi nucleate cells in HFKs containing 
E6ΔPDZ genomes.  (C) Bar graph represents the data from 2 separate counts across 3 donor 
backgrounds. Overall there is a significant increase in the percentage of total atypic nuclei in 
HFKs containing wild type genomes compared to normal HFKs (p=0.01). This is further 
increased in HFKs containing E6ΔPDZ genomes compared with wild type genomes (p=0.03).     
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Within the four different donor backgrounds in which this E6ΔPDZ mutant HPV18 genome 
was established, three showed a consistent reduction in maintenance of the mutant episomes, 
with much reduced levels by passage P15; however in one keratinocyte host, a reduction of 
mutant episomes occurred only upon prolonged passaging of cells. 
Interestingly, the morphological phenotype of E6ΔPDZ genome-containing cells observed at 
early passages (P6) was lost at later passages (P15) and the cells revert to a growth pattern of 
the ‘normal’ cobblestone phenotype of cultures containing the wild type and E6ΔPKA 
genome containing HFKs.  Analysis of the growth patterns of E6ΔPDZ cells at later passages 
showed that they had an increased growth rate compared to earlier passages of cells in which 
maintenance replication of the viral genomes was supported (Figure 3.8E).  However, the 
growth rate of E6ΔPDZ cells at the later passage still did not exceed that of wild type or 
E6ΔPKA genome containing cells (Figure 3.8F).  No changes were observed in the growth 
rate or phenotype of cultures containing E6ΔPKA and wild type genomes at later passages 
(Figure 3.7F).   
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Figure 3.8 HFKs containing E6ΔPDZ genomes are associated with a reduction in 
viral copy number upon increasing passage. This reduction correlates with an increase 
in growth rates of HFKs containing these E6ΔPDZ genomes.  Total DNA from HFKs 
harbouring wild type, E6ΔPDZ or E6ΔPKA genomes were extracted at various passages, 
digested with BlgII  (a non-cutter of the HPV18 genome) or EcoRI (which linearizes the 
DNA) and examined by southern blot analysis with an HPV18 genomic probe. Genomes 
migrate as linear, open-circular or supercoiled DNA. Copy number was calculated form 
phosphoimaging analysis of autoradiographs compared with a copy number control. Southern 
blots are representative of data derived from 3 different donor backgrounds. (A) HFKs 
containing wild type genomes are stably maintained as episomes upon repeated cell 
passaging. (B/D) Abrogation of the PBM results in a reduction in viral copy number upon 
repeated cell passaging. (C) Constitutive activation of the E6 PBM (E6ΔPKA) does not affect 
the stable maintenance of upon repeated cell passaging. (E) Cellular proliferation of HFKs 
containing E6ΔPDZ genomes at later passages (P15) is increased compared with HFK 
containing E6ΔPDZ genomes at early passages (P6). (F) Cellular proliferation of HFKs 
containing E6ΔPDZ genomes at late passages (P15) grows slower than equivalent passage 
HFKs containing wild type or E6ΔPKA genomes.   
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3.2.8 The inability of HPV18 E6ΔPDZ to maintain viral genomes is due to 
viral integration of episomal DNA. 
To determine the fate of the HPV18 genome in cells that are unable to maintain episomes, the 
HPV18 wild type and E6ΔPDZ genome containing HFKs were analysed in a PCR integration 
assay.  This assay uses the principles described for HPV integration into the host 
chromosomal DNA (Figure 3.8A), which commonly occurs within the E2 gene (Collins et al., 
2009).  Primers are designed to the E2 ORF, so if there is a disruption of E2 sequence due to 
integration of the viral DNA, or loss of HPV episomes, an E2 band will not be amplified.  
PCR was also carried out with primers recognising the E7 gene.  The E7 gene is not lost upon 
viral DNA integration, so amplification of an E7 PCR band will highlight the continued 
presence of the HPV DNA.  This method can be used to investigate episome loss (Collins et 
al., 2009).  In HPV18 wild type cells, there is no loss of E2 or E7 upon increasing passage 
(P8-P15) indicating that the majority of HPV DNA is in an episomal state (although it is 
important to note that integration could have occurred in a subset of cells  which isn’t visible 
against a background of high episomes) (Figure 3.8B).  In early passages of HFK cells 
harbouring E6ΔPDZ genomes (P8), E2 and E7 bands were detected by PCR (Figure 3.8B).  
By P9 however, the intensity of the E2 PCR band was beginning to diminish and by P15, the 
presence of the E2 was lost completely (Figure 3.8B).  The continued presence of an E7 PCR 
band within these later passages suggests that E6ΔPDZ DNA is still present within these 
HFKs albeit in an integrated form and that the genomes are not simply being ‘lost’ from these 
cells suggesting that the inability of HFKs containing E6ΔPDZ genomes to maintain viral 
episomes is due, in some part to viral integration of the DNA in HFKs harbouring E6ΔPDZ 
genomes.  In agreement with these results, a study of HPV31 and HPV16 epsiomes 
containing E6 mutants which do not bind PDZ substrates showed that these genomes are often 
found integrated at later passages (Lee & Laimins, 2004; Nicolaides et al., 2011).  
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Figure 3.8 Abrogation of the E6 PBM is associated with integration of episomal 
DNA.  HFKs containing wild type and E6ΔPDZ genomes were assessed in a PCR integration 
assay. (A) Graphical representation of the principles underpinning the assay. Integration of 
the virus results in a disruption of E2 sequence and so amplification of an E2 band by PCR 
would not occur. (B) HFKs containing wild type genomes do not integrate their viral genomes 
as the presence of an in-tact E2 band by PCR is amplified upon increasing passage of these 
cells. In HFKs containing E6ΔPDZ genomes, the presence of an E2 by PCR is lost upon 
passaging of these cells, suggesting that disruption of the E2 sequence due to integration has 
occurred. The presence of an in tact E7 band by PCR is a control for the sustained presence of 
viral genomes. This data is representative of 2 independent experiments carried out in 2 donor 
backgrounds.  
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3.2.9 Deletion of the PBM or loss of PKA negative regulation does not 
affect the steady-state stability of the E6 or E7 protein in 
undifferentiated monolayer cultures  
Human papillomaviruses encode the E6 and E7 proteins from a single bicistronic pre mRNA 
using a common promoter lying immediately upstream of the E6 ORF within the LCR, which 
is P97 in HPV16, P99 in HPV31 and P105 in HPV18, and a common polyadenylation site 
(Baker & Calef, 1995; Wang et al., 2011).  It is feasible that the mutations inserted into the 
coding sequence of E6 have altered the stability of the E6 protein through the loss of the four 
amino acids from the C-terminus of the proteins or the arginine to leucine change in the PKA-
RM.  Also, the mutations in the E6 ORF are close to the ATG initiation methionine of E7 
(Figure 3.2) and since E7 is expressed from the bicistronic messenger RNA these changes 
may affect translation of the E7 protein (Tang et al., 2006; Wang et al., 2011).   
Therefore to examine whether the changes made within the E6 ORF result in changes to the 
steady state levels of the E6 and E7 proteins, early passage HFKs containing wild type, or 
mutant (E6ΔPDZ, E6ΔPKA) genomes were grown to 80% confluency, lysed in a buffer 
containing 8M urea and the solubilized proteins were resolved by SDS-PAGE and subjected 
to western blot analysis with anti-E6 or anti-E7 monoclonal antibodies as described (Materials 
and Methods Chapter 2: Section 2.4.3).  It is clear from the western blot shown in figure 3.9 
that there were no differences in the steady state expression levels of E6, or the E7 protein 
between HFKs containing wild type or mutant HPV18 genomes (Figure 3.9).  These results 
together suggest that the mutations that have been made to E6 within the context of the 
HPV18 genome do not affect the steady-state expression levels of the two oncoproteins and it 
is therefore more likely that the changes observed in the behaviour of the established cell lines 
in primary keratinocytes relates to the changes in E6 PBM function.  
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Figure 3.9 Changes to the E6 PBM do not affect the steady state expression of E6 or 
E7 in monolayer cultures.  Monolayer cultures of HFKs containing wild type, E6ΔPDZ or 
E6ΔPKA genomes were grown to 80% confluency, harvested and lysed in 8 M urea buffer. 
Lysates were prepared for western blot analysis with anti-E6 and anti-E7 antibodies. No 
change was observed in the steady state levels of E6 or E7 expressed from HFKs containing 
wild type or mutant E6 genomes. GAPDH demonstrates equal loading of protein samples. 
Western blot is representative of 3 independently performed experiments.   
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3.3 Discussion 
The aim of the initial part of this study was to establish cell lines carrying HPV genomes with 
mutations that alter the activity of the E6 PBM and characterise the biological function of this 
domain in the context of cells carrying the complete genome in monolayer cell cultures that 
represent the early phase of the virus life cycle.  By inhibiting and enhancing the interaction 
of the E6 PBM though genetic changes within the HPV18 genome distinct changes in both 
the cell morphology and cell behaviour of human keratinocytes was observed.  Furthermore, 
changes in viral DNA replication such as establishment and maintenance replication were also 
observed.  Moreover, these changes appear to be independent of the ability of E6 to target p53 
for degradation.  Abrogation of the E6 PBM was associated with an increase in nuclear atypia 
and a reduction in the growth rate of cells and this correlated with a reduction in 
establishment replication of the mutant genome and in the persistence of episomal DNA.  The 
changes observed were consistent across all donor lines however episome loss occurred much 
later in one donor line. 
Abolition of the E6 PBM in the context of the complete HPV genomes, (E6ΔPDZ), results in 
a reduction of copy number in the establishment of genomes.  This reduction, concurs with 
the results from parallel studies in HPV31 (Lee & Laimins, 2004) and HPV16 (Nicolaides et 
al., 2011) in which abrogation of the E6 PBM was associated with a reduced copy number 
upon transfection with viral genomes.  Additionally, the level of episomal forms of E6ΔPDZ 
genomes were reduced and completely lost in some donors after several additional passages; a 
feature which was not observed in HFKs containing wild type or E6ΔPKA genomes.  The 
inability of E6ΔPDZ genomes to persist in keratinocytes as epsiomes was accompanied by the 
appearance of cells with integrated copies of the viral genomes suggesting that the function of 
the E6 PBM is required to maintain episomes.  In agreement with these results, similar studies 
in HPV31 and HPV16 containing E6ΔPDZ mutants showed that these genomes do not 
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maintain at wild type levels and are found integrated at later passages (Lee & Laimins, 2004; 
Nicolaides et al., 2011).  Loss of viral episomes at later passages was not observed in 
E6ΔPKA cells, indicating that constitutive activity of this domain does not have a detrimental 
affect on the establishment or maintenance of viral genomes.  In this light it is tempting to 
speculate that if the ability of the E6 PBM to target substrates in inhibited e.g. by PKA 
phosphorylation, this event might promote integration of the viral genomes and since those 
genomes that contain a PKA-RM are those that are strongly associated with cancer (e.g. 
Group 1 Figure 3.1) then changes in PKA signalling could be a risk factor for viral integration 
which is a risk factor for cervical carcinogenesis.  
The results from Nicolaides and colleagues correlate the loss of episomes seen in the 
E6ΔPDZ line with loss of HPV E6 protein stability, suggesting that PDZ targeting is 
necessary for the stabilisation of the E6 protein (Nicolaides et al., 2011).  In this present 
study, the steady state levels of E6 and E7 proteins were analysed by western blot analysis 
and no significant changes were observed in the steady state levels of E6 or E7 protein 
between wild type lines and those harbouring either E6ΔPKA or E6ΔPDZ mutant genomes 
suggesting that the changes made within the E6 ORF in the context of the complete HPV18 
genomes do not compromise the stability of the E6 or E7 proteins in monolayer cultures. 
These analyses do not consider whether changes to the PBM alter the half life of the E6 or E7 
proteins, which is something to be considered and merits further analysis.   
It has been proposed that the actions of the E6 and E7 proteins work in synchrony; in a way 
that loss of one function of one of the proteins increases the action of other functions.  HPV 
E7 initiates DNA synthesis in cells resulting in increased cell growth. By inducing cell 
survival and delayed apoptosis of cells with DNA damage, via the degradation of p53, E6 
allows E7 to sustain its pathological effect.  It is unlikely that the changes observed are a 
response to a defect in E6 mediated p53 degradation as in accordance with (Gardiol et al., 
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1999), changes to the PBM function by means of the E6ΔPDZ and E6ΔPKA mutations, have 
no effect on the ability of the E6 protein to target p53 for degradation.  One can therefore 
speculate that the binding of E6 to PDZ proteins may act to create a balance with another 
activity mediated by E6 and/or E7 and so loss of this interaction (E6ΔPDZ) between E6 and 
PDZ proteins may result in a reduction of episomes, observed in this study.  A recent study by 
Accardi and colleagues showed that E6 and E7 co-operate in targeting the PDZ protein, 
Na
+
/H
+
 exchange regulatory factor (NHERF-1) for degradation (Accardi et al., 2011) which 
shows some precedent for this hypothesis.   
In this study, HFKs containing E6ΔPDZ genomes showed a significant reduction in their 
growth, even when compared to normal HFKs.  At later passages, HFKs containing E6ΔPDZ 
genomes grew significantly faster than cells containing the same genome at earlier passages, 
but still slower than the wild type genome containing cells.  A similar finding was observed 
by Lee and colleagues in an HPV31 background (Lee & Laimins, 2004).  HFKs harbouring 
E6ΔPDZ genomes appear to integrate into host DNA at later passages.  Integration of the 
viral DNA often provides host cells with a growth advantage due to the loss of E2-mediated 
inhibition of transcription of E6 and E7, which may explain the changes in growth observed at 
later passages in these cell lines.   However, the growth of these cells was still slower than 
wild type cells suggesting that the function of the PDZ domain does contribute to the 
enhanced growth potential of genome containing cells. 
Compared with wild type and E6ΔPKA genome containing cells, HFKs containing E6ΔPDZ 
genomes had a reduced ability to form colonies consisting of tightly adhered cells with a 
uniformed cobblestone appearance in monolayer cultures.  In addition this E6ΔPDZ mutation 
had a tendency to display more nuclear aberrations (in particular bi-nucleate and multi-
nucleate cells) when compared with monolayer cultures containing wild type or E6ΔPKA 
genomes.  Centrosome abnormalities in response to HPV E6 expression have been reported 
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previously and primarily lead to the development of multiple nuclei as well as micronuclei 
and large multi-lobed nuclei which may have formed as a consequence of a persistent block 
of cytokinesis (Duensing et al., 2001).  This may be explained in part by the ability of HPV 
E6 proteins to relax G2/M checkpoint control, thereby allowing an increased proportion of 
cells to enter mitosis.  
Targets of the PBM function in a common genetic pathway to regulate apicobasal cell polarity 
and also play important roles in the control of cell proliferation, survival, differentiation and 
cell division.  The presence of one of these targets in particular, hDlg, at the midbody 
suggests that hDlg may play a functional role in the process of cytokinesis (Massimi et al., 
2003; Unno et al., 2008).  The targeting of this protein by the E6 PBM may be tightly 
regulated in a way that loss of binding by means of the E6ΔPDZ domain may have a 
dominant negative effect on cell division and lead to the differences observed in atypic nuclei 
between wild type and mutant cell lines.  These data together suggest that targets of the PBM 
may behave not only as tumour suppressors but also as oncogenes and that the ultimate 
outcome is tightly regulated.  A recent study by Frese and colleagues revealed that E4-ORF1 
acts with hDlg to specifically promote the activation of phosphphatidykinositol 3-kinase 
(PI3K) in cells, revealing an oncogenic role for this putative tumour suppressor in specific 
cellular contexts (Frese et al., 2003).  The changes in hDlg may also explain the differences 
observed in cell growth as previous studies have shown that overexpression of NE-Dlg (a 
mammalian homologue of the Drosophila Dlg protein) induced growth suppression in cells 
(Hanada et al., 2000). 
Abrogating the negative regulation of the PDZ domain by means of the PKA mutation results 
in a significantly faster growth than normal HFKs and HFKs containing wild type genomes 
and these cells maintained their episomes upon serial passage.  This data suggests that the 
constitutive targeting of PDZ domain containing proteins leads to an enhancement in cell 
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growth that cannot be explained by increased levels of E6 and/or E7 oncoprotein, or 
integration of the viral episomes.  Several of the PDZ domain targets of E6 function in some 
settings as tumour suppressors and negatively regulate cell growth.  These include hDlg and 
hScrib (Ishidate et al., 2000; Nagasaka et al., 2006).  In this respect the constitutive ability of 
the E6 PBM to bind to PDZ substrates and target them for degradation may explain the 
changes in growth observed.  
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CHAPTER 4 THE FUNCTION OF THE E6 PDZ BINDING 
MOTIF IN THE PRODUCTIVE STAGES OF THE VIRUS 
LIFE CYCLE AND THE ROLE OF NEGATIVE 
REGULATION OF THIS MOTIF IN CELL BEHAVIOUR 
4.1 Introduction 
Previous work from this study has shown that PDZ targeting has a role in the early stages of 
the virus life cycle, including cell growth control and maintenance of viral episomes and this 
is sensitive to changes in PKA signalling, suggesting that regulation of this domain by 
phosphorylation is important in the early stages of the virus life cycle.   Understanding the 
mechanisms which regulate late viral life cycle stages such as differentiation is crucial to the 
understanding of HPV biology.  Previous studies from Lee and colleagues have shown that 
the E6 PBM is required for HPV31 positive cells to stratify and differentiate (Lee & Laimins, 
2004).  Furthermore, the function of the E6 PBM has been implicated in cell invasion and 
anchorage independent growth (Spanos et al., 2008) as well as epithelial hyperplasia (Nguyen 
et al., 2003).  
As previously discussed, an important feature of E6-PDZ domain interactions is that they are 
highly defined.  E6-PDZ interactions are mediated by a four amino acid motif which can be 
disabled by point mutations (Gardiol et al., 1999; Glausinger et al., 2000) or phosphorylation 
of the threonine within the motif by PKA (Kuhne et al., 2000).  A number of other HPV 
proteins have been shown to be phosphorylated in vitro and in vivo, including E1, E4 and E7 
proteins (Ma et al., 1999; Doorbar et al., 2009; Breitbund et al., 1987; Knight et al., 2011; 
Genovese et al., 2008).  Phosphorylation allows the cell to respond to external stimuli or 
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intra-cellular control mechanisms.  Phosphorylation can lead to a conformational change in 
the structure of the protein or it may expose or enhance a protein interaction domain, thus 
allowing protein-protein interactions.  The biological activity of a protein can also increase or 
decrease as a result of phosphorylation by converting a protein into an active or inactive 
conformation.  Furthermore, the activity of protein kinases can themselves be regulated in this 
manner.    
PKA is regulated by fluctuating levels of cyclic AMP within the cell; hence it is a cyclic AMP 
dependent protein kinase.  The outcome of an increase in cAMP can result in an activation or 
inhibition of cell proliferation and cell cycle progression (Fernandez et al., 1995).  The 
catalytic subunit of PKA phosphorylates proteins as the serine and threonine residues and is 
able to phosphorylate proteins in both the cytoplasm and the nucleus.  PKA has previously 
been shown to be involved in transformation and tumour progression (Cardone et al., 2005; 
Farrow et al., 2003; Mantovani et al., 2008) as well as proliferation (Robinson et al., 2008; 
Mantovani) and apoptosis (Kim et al., 2008; Dohi et al., 2007; Paradiso et al., 2004) in a 
number of other cancers including breast and pancreatic cancer.  
HPV E6 is a phospho-protein in vivo (Kuhne et al., 2000) and activation of the PKA pathway 
leads to an increase in the level of E6 phosphorylation (Kuhne et al., 2000).  The PKA 
pathway has been shown to selectively regulate the ability to bind to targets of the PBM of 
high risk E6 proteins (Kuhne et al., 2000).  The molecular basis for the differential regulation 
of the E6 mediated degradation of PDZ substrates such as hDlg is provided by mutation 
studies which show that there is functional interplay between E6/hDlg binding and PKA 
phosphorylation due to the overlap of the PKA phosphorylation site with the E6 PBM.  What 
role this conditional regulation plays within the context of the late stages of the virus life 
cycle remains unclear.  Studies from Watson and colleagues in HPV18-E6 expressing SV40 
immortalised keratinocytes suggest that the conditional regulation of E6 by PKA contributes 
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to EMT and the degradation of PDZ proteins including hDlg (Watson et al., 2003) and as 
such work to elucidate the role of PKA regulation of E6 within the context of the HPV18 viral 
life cycle forms the basis of the second part of this study.  
4.2 Results 
4.2.1 Abrogation of the E6 PBM results in differentiation-dependent 
morphological changes in organotypic raft cultures 
To investigate the effect of changes to the E6 PBM on epithelial stratification and the 
productive virus life cycle, organotypic raft cultures were grown using primary cells 
transfected with each of the mutant genomes (E6ΔPKA and E6ΔPDZ) or the wild type 
genome.  Each HPV18 genome containing keratinocyte cell line was grown in organotypic 
raft culture by seeding the cells onto a collagen matrix embedded with J2-3T3 fibroblasts.  
The collagen-keratinocyte plug was transferred onto a gridded metal platform when cells 
reached confluency (typically 1-2 days).  Cell stratification was allowed to proceed for 13 
days and then fixed with formaldehyde (4%) and embedded in paraffin (Materials and 
Methods section 2.8.7).  For the purposes of morphological examination, representative 
sections from each donor HFK were stained with haematoxylin and eosin (H and E).  
As can be seen from Figure 4.1A, raft cultures of untransfected HFKs were typically 6-7 cell 
layers thick and exhibited a typical pattern of epidermal differentiation, with each cell layer 
identifiable; cuboidal basal cells, larger cells of the stratum spinosum, clear evidence of cells 
of the stratum granulosum with a granular appearance and finally the enucleated cells of the 
stratum corneum (Figure 4.1A).  A similar morphological differentiation pattern is apparent in 
the rafts formed from the HPV18 wild type cells with the exception that there is significant 
thickening of the spinous and parabasal cell layers and occurrence of areas where nuclei had 
been retained throughout all layers of the raft culture (Figure 4.1A).  Cross sections of raft 
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cultures of E6ΔPDZ and E6ΔPKA transfected HFKs revealed striking changes.  The overall 
thickness of raft cultures from E6ΔPDZ genomes was consistently reduced in multiple 
experiments compared with those formed from primary keratinocytes containing the wild type 
or E6ΔPKA genomes (Figure 4.1A/B).  In addition, the morphology of the raft more closely 
resembled that of the stratified structures generated from normal keratinocytes than those of 
cells carrying wild type genomes (Figure 4.1A).  Conversely, the morphology of raft cultures 
of cells containing E6ΔPKA genomes were similar to those formed from cells carrying the 
wild type genomes, but were generally of greater thickness, a property particularly relevant to 
the basal and parabasal cell layers (Figure 4.1B).  Overall, the morphology of the stratified 
structures formed from the different HPV18 genomes indicates the function of the E6 PBM is 
necessary for the hyperproliferative growth of the genome containing cells and concurs with 
findings from Lambert and co-workers who showed that this domain conferred hyperplasia on 
keratinocytes in transgenic mice (Nguyen et al., 2003).  Moreover, the greater thickness of the 
organotypic rafts formed from E6ΔPKA genome containing cells suggests that a loss of 
negative regulation of this E6 domain exaggerated the hyperproliferative phenotype.  It was 
also noted that in the E6ΔPKA derived rafts there was evidence of an increase in frequency of 
areas across the basal cell layer which appeared to be invading into the collagen below 
(Figure 4.1B).  This will be investigated further in section 4.5 of this chapter.  
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Figure 4.1 Morphology of HPV18 genome containing cells upon stratification.  A and 
B represent Haematoxylin and eosin sections of organotypic raft cultures from untransfected 
(UNT) HFKs as well as HFKs containing E6ΔPDZ, E6ΔPKA genomes and wild type 
genomes. The different epithelial layers have been highlighted.  Raft cultures were grown for 
13 days, harvested and paraformaldehyde fixed.  A and B are a representation of the 
phenotype observed from at least 3 separate donors. Note the areas of invasion seen by HFKs 
containing E6ΔPKA genomes (B) as highlighted by arrows.  
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4.2.2 Increased suprabasal cellular DNA synthesis upon constitutive 
activation of the E6 PDZ binding motif 
To examine whether changes in the activity of the E6 PDZ binding function affect the 
vegetative cycle of the virus, cells containing wild type, E6ΔPDZ or E6ΔPKA genomes were 
stratified in organotypic raft culture as previously described (Materials and Methods section 
2.8.7).  As previously shown, changes in the activity of the HPV18 E6 PBM are linked to 
marked changes in the growth of undifferentiated cells (section 3.2.5).  Since the virus 
stimulates infected cells to re-enter S-phase and replicate the host DNA once they have left 
the basal cell layer, the role of the E6 PDZ binding domain in this viral activity was examined 
in the first instance.  To identify nuclei undergoing cellular DNA synthesis, the organotypic 
raft cultures were incubated with the thymidine analogue bromodeoxyuridine (BrdU) – a 
marker for cells in S-phase - 14 hours prior to raft harvesting and paraffin-embedded sections 
were subsequently stained with an anti-BrdU monoclonal antibody (Beckton-Dickinson). 
In organotypic raft cultures generated from normal HFKs, DNA synthesis was largely 
restricted to the cells of the basal layer.  In the presence of HPV18 wild type genomes, BrdU 
positive nuclei were detected in both the basal compartments and the more differentiated 
suprabasal epithelial compartments (Figure 4.2A).  In rafts derived from the E6ΔPKA 
genome-containing cells which have a constitutively active PDZ binding domain, there is a 
significant increase in the number of BrdU positive nuclei in both the basal and suprabasal 
epithelial compartments compared to the wild type genomes (p=0.04) (Figure 4.2 A and B).  
The E6ΔPDZ genomes, which are deficient for binding to PDZ substrates, were able to 
induce suprabasal cellular DNA synthesis albeit at a slightly reduced level than the wild type 
genome, however this difference was not significant (p=0.80).  Moreover, the number of 
BrdU positive nuclei in organotypic rafts derived from E6ΔPDZ mutants was significantly 
lower than the constitutively active PKA mutant (E6ΔPKA) (p=0.008) (Figure 4.2A/B).   
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Figure 4.2 Constitutive activity of the PBM results in increased suprabasal DNA 
synthesis.  (A) Paraffin embedded sections of normal HFKs and HFKs containing wild type, 
E6ΔPDZ and E6ΔPKA genomes were stained with an anti-BrdU antibody (Green) and 
counterstained with DAPI (Blue) for detection of nuclei by immunofluorescence microscopy.  
Ten fields of view were taken along each raft section and the total number of nuclei were 
counted as well as the number of nuclei stained with BrdU to determine a percentage of BrdU 
incorporation.  (B) Bar graph of the BrdU incorporation data from 1 donor line. P values were 
calculated from a one sided T-test performed on normal HFKs and HKS containing wild type, 
E6ΔPKA and E6ΔPDZ genomes. There is a significant difference in the percentage of BrdU 
incorporation between wild type cells and E6ΔPKA genome containing cells (p=0.04) and 
between E6ΔPKA and E6ΔPDZ cells (p=0.008). This data is representative of 3 
independently performed experiments in 3 donor lines with similar observations.  
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These data indicate that although the function of the E6 PBM is not required for induction of 
suprabasal DNA synthesis, the activity of this domain actively contributes quantitatively to 
this virally-induced effect.   
4.2.3 The E6 PBM is required for the differentiation dependent 
amplification of viral genomes 
Suspension of cells containing HPV genomes in a semisolid medium (1.5% methylcellulose) 
is a well established technique to successfully study the differentiation-dependent HPV late 
functions, including amplification of the viral genomes.  Cells containing wild type, E6ΔPDZ 
or E6ΔPKA HPV18 genomes were resuspended in 1.5 % methylcellulose for  4 h and 48 h 
and total DNA extracted from the cells.  Equal amounts of the DNA samples were digested 
with DpnI to digest any residual cellular input DNA and BglII, a non-cutter of the HPV18 
genome, and analysed by Southern blotting with an HPV18 genomic probe.  As can be seen in 
Figure 4.3A, suspension of cells containing the wild type HPV18 genomes induced efficient 
amplification of the viral genomes at 24 h and 48 h.  However, loss of the E6 PBM sequence 
was associated with poor viral DNA amplification and this was observed in the two separate 
donors examined (Figure 4.3A).  Whilst the wild type genomes amplified by at least 3-3.5 
fold by 48 h, the mutant genomes only amplified 0.5 fold.  This data indicates that the E6 
PBM of HPV18 is necessary for the efficient differentiation-dependent amplification of viral 
genomes.  In addition, organotypic raft cultures of cells containing E6∆PDZ genomes were 
compromised for E4 and L1 production, as highlighted by the reduced frequency of E4 or L1 
positive cells in raft cultures containing E6∆PDZ genomes compared with wild type or 
E6∆PKA rafts, supporting the idea that the PDZ binding motif is also important for the 
actiation of  late HPV18 life cycle events (data not shown). HPV18 genomes containing the 
mutation in the PKA-RM were amplified following the induction of differentiation in the two 
different donor backgrounds examined (Figure 4.3B).  The level of amplification was on 
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average 1.5 and 2 fold at 24 and 48 h respectively (Figure 4.3B) indicating that a loss of 
cAMP-dependent kinase regulation of the E6 PBM does not affect viral genome amplification 
and suggests  that the role of the E6 PBM in genome amplification is independent of PKA 
phosphorylation.   
In the absence of a functional E6 PBM the level of extrachromosomal episomes decreases 
upon extended passaging of the cells (Figure. 3.7B; Chapter 3).  At these higher passages, the 
epsiomes are barely detectable following Southern blotting, even upon prolonged exposure of 
the autoradiographs.  Whether these episomes are able to amplify upon differentiation was 
also examined by suspension of the cells in 1.5% methylcellulose.  Minimal differences were 
observed between fold amplification changes in wild type and E6ΔPKA genomes at higher 
passages (p=12) with fold changes of 3.2 and 2.6 at 48 h respectively (Figure 4.3C). An 
equivalent passage of cells transfected with E6ΔPDZ genomes do not amplify the viral DNA 
even in those donors where low levels of mutant episomes are still detectable, with a fold 
change of 0.2 at 48 h (Figure 4.3C).  Taken together, these results suggest that the E6 PBM 
plays an important role in the differentiation dependent amplification of HPV18 viral 
genomes.  
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Figure 4.3 Differentiation dependent viral genome amplification of HPV18 genome 
requires an intact PDZ binding motif.  (A) Total DNA was extracted at various times 
following cellular suspension in semi solid methylcellulose (MC) media of HFKs containing 
wild type genomes or E6ΔPDZ genomes.  Equal amounts of DNA from each cell line were 
digested with Dpn1 and BlgII and subjected to Southern blot analysis with an HPV18-specific 
probe. Bar graphs show the amplification of viral genomes upon differentiation.  Data was 
derived from phosphoimaging data and normalised to monolayer cells at T=0 for each cell 
line. (B) Southern blot analysis of differentiation dependent amplification of E6ΔPKA 
genomes with bar graph showing phosphoimaging data from 3 separate experiments in 1 
donor line. (C) Analysis of wild type, E6ΔPKA and E6ΔPDZ genomes at high passage 
(p=12).  Fold amplification changes of HFKs containing wild type and mutant E6ΔPKA 
genomes were similar; however abrogation of the PDZ binding motif reduces the ability to 
amplify viral genomes in 1.5% MC. Bar graph showing the phosphoimaging data from 
experiment C.     
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4.2.4 Deletion of the E6 PBM or loss of PKA negative regulation does not 
affect the steady-state stability of the E6 or E7 protein in 
organotypic raft cultures. 
 
To verify that the phenotypes observed upon stratification of HFKs containing wild type or 
mutant genomes in organotypic raft cultures was not attributed to changes in the levels of E6 
or E7 proteins, organotypic raft cultures of normal HFKs and those containing wild type 
E6ΔPDZ or E6ΔPKA genomes were grown as previously described (Materials and Methods 
Chapter 2: Section 2.8.7).  Raft cultures were harvested in raft lysis buffer and solubilised in 
lamelli buffer, then equal amounts of the lysate were analysed by western blot analysis with 
an anti-E6 and anti-E7 antibody.  GAPDH antibody was also used to ensure equal protein 
loading.  No differences were observed in the protein expression levels of E6 or E7 in raft 
cultures from wild type genomes and those containing E6ΔPDZ or E6ΔPKA mutant genomes 
(Figure 4.4).  These results suggest that the differences in phenotypes observed upon 
stratification of wild type and mutant genome containing HFKs in organotypic raft cultures is 
not attributed to changes in the expression levels or stability of the E6 or E7 protein and is 
more likely that the changes observed in organotypic raft cultures between wild type and 
mutant containing cells relates to the changes in the E6 PBM function.  
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Figure 4.4 Changes to the E6 PBM do not affect the steady state expression of E6 or 
E7 in organotypic raft cultures.   Following differentiation of HFKs harbouring wild type, 
E6ΔPDZ or E6ΔPKA genomes in organotypic raft cultures cellular lysates were prepared for 
western blot analysis with anti-E6 and anti-E7 antibodies. No change was observed in the 
steady state levels of E6 or E7 expressed from HFKs containing wild type or mutant E6 
genomes in organotypic raft cultures. GAPDH demonstrates equal loading of protein samples. 
Western blot is representative of 3 independently performed experiments.    
Chapter 4 
147 
4.2.5 The E6 PBM function does not play a role in the expression of 
markers of differentiation in organotypic raft cultures. 
Amplification of HPV DNA to thousands of copies per cell occurs in the suprabasal cells of 
the differentiating epithelium and is essential for the production of new virions.  Since 
abrogation of the E6 PBM resulted in a reduced amplification of viral genomes in HFK 
containing E6ΔPDZ genomes, the ability of HFKs containing wild type genomes as well as 
those containing E6ΔPDZ and E6ΔPKA genomes to expresses a number of markers of 
differentiation was analysed by immunofluorescence staining of paraffin embedded sections 
from organotypic rafts (Materials and Methods section 2.6.3).  Organotypic rafts of normal 
HFKs as well as HFKs containing wild type, E6ΔPDZ and ΔE6PKA genomes were stained 
for the expression of K5, K1 and filaggrin.  K5 is an early differentiation marker and localised 
to the basal cell layers.  The keratin marker K1 represents cells in the suprabasal layers of 
cells which have left the basal cell layer and have undergone the commitment to terminally 
differentiate.  Filaggrin expression is contained to the granular layer where it is thought to be 
necessary for the cross linking of keratins that occur in cellular cornification.  Normal HFKs, 
as well as those containing wild type genomes showed a similar pattern of staining for the 
differentiation markers analysed, with each marker being expressed in the appropriate 
epidermal compartment (Figure 4.5A-C).  Moreover, expression of K5, K1 or filaggrin was 
not compromised in organotypic raft cultures of HFKs containing either E6ΔPDZ or 
E6ΔPKA genomes.  In addition, organotypic rafts containing E6ΔPKA or E6ΔPDZ genomes 
showed a staining pattern similar to that of wild type and normal HFKs.  Taken together these 
data suggest that changes to the E6 PBM do not effect the expression of markers of 
differentiation in organotypic raft cultures.    
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Figure 4.5 Changes to the PDZ binding motif do not effect the expression of 
epithelial differentiation markers.  Organotypic raft cultures of normal HFKs and HFKs 
containing wild type, E6ΔPKA or E6ΔPDZ genomes were grown to 13 days, fixed in 4% 
paraformaldehyde and paraffin embedded sections were prepared for indirect 
immunofluorescence with anti-K5, anti-K1 and anti-Filaggrin antibodies.  (A) Prepared 
sections were stained with the anti-K5 antibody (Red) and counterstained with DAPI (Blue) 
for detection of nuclei. A similar pattern of K5 staining was observed and localised to the 
basal cell layers. No changes were observed in the expression or localisation of K5 in raft 
cultures from HFKs containing wild type genomes and those containing E6ΔPKA and 
E6ΔPDZ genomes. (B) Immunostaining of raft sections with anti-K1 antibody (Green). 
Expression of K1 is strong and localised to the suprabasal cell layers. No changes were 
observed in the K1 staining pattern in normal HFKs and those which contain wild type, 
E6ΔPDZ or E6ΔPKA genomes. (C) Raft sections were also stained with anti-Filaggrin 
(Green) – a late differentiation marker and component of the cornified cell envelope. Similar 
to the finding of K5 and K1, no changes were observed in the expression or localisation of 
Filaggrin in raft cultures from normal HFKs and those containing wild type genomes. 
Changes to the PBM in E6ΔPKA and E6ΔPDZ mutant genomes do not effect the expression 
or localisation of this protein and show a similar pattern of expression to wild type and normal 
HFKs.   
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4.2.6 Loss of negative regulation of the E6 PBM results in a more invasive 
phenotype 
It was noted from the H and E staining of HFKs containing E6ΔPKA genomes that these cells 
were characterised by the presence of a number of ‘pockets’ of cells which appeared to be 
invading down into the collagen below.  Cell invasion requires a cell to migrate through an 
extracellular matrix (ECM) or basement membrane extract (BME) barrier by first 
enzymatically degrading the barrier in order to become established in a new location.  This 
invasion can be detected and calculated by means of a Transwell invasion assay.   
In principal, the upper surface of the insert membrane (8 µm pore size) is coated with a 
uniform layer of rat-tail derived collagen and a defined number of cells (0.5 x 10
6
) are added 
into SFM.  This layer serves as a barrier to discriminate invasive cells from non-invasive 
cells.  Invasive cells are able to degrade the matrix proteins in the layer and ultimately pass 
through the pores of the polycarbonate membrane to the underside.  After 5-8 hours, the cells 
are removed from the top of the membrane and the invaded cells are stained with DAPI and 
quantified and the extent to which they have invaded is calculated (Materials and Methods 
section 2.14).  The percentage of invasion can be calculated by counting the no of DAPI 
stained nuclei present at 0 h from 4-5 fields of view, compared with the number of nuclei 
which have been able to invade to the underside of the membrane (Figure 4.6A).  
Using this method, the invasive capacity of HFKs transfected with wild type and E6ΔPKA 
genomes was examined.  Normal HFKs would be expected to have a very limited capacity to 
invade and therefore served as a negative control.  Overall, cells transfected with wild type 
HPV18 genomes had an increased capacity to invade when compared to control normal HFKs 
(p=0.05).  Furthermore, cells containing the E6ΔPKA genomes, which have a conditionally 
active E6 PBM had an increased potential to invade compared with wild type containing 
HFKS (p=0.002) and normal HFKs (p=0.0002) (Figure 4.6B).   
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Figure 4.6 The loss of the negative regulation of the E6 PBM results in a more 
invasive phenotype.  (A) Normal HFKs as well as HFKs containing wild type or E6ΔPKA 
genomes were harvested and seeded in SFM at a concentration of 5x10
5
 into the upper layer 
of a Transwell® insert separated by a 0.8 µM polycarbonate membrane. Membranes were 
fixed at 0 h and then after 5 h, counterstained with DAPI to detect nuclei and the percentage 
of invasion was calculated by counting the no of DAPI stained nuclei present at 0 h from 4-5 
fields of view, compared with the number of nuclei which have been able to invade to the 
underside of the membrane. Representative images collected during the Transwell experiment 
are shown. (B) Combined Transwell® data from 6 independent experiments across 3 different 
donor lines. Overall, HFKs containing the constitutively active mutant (E6ΔPKA) has an 
increased potential to invade compared with HFKs containing wild type genomes (p=0.002) 
and normal HFKs (p=0.0002).      
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This data is consistent in six separate experiments with three experimental repeats coming 
from one donor line.  Taken together the data from the Transwell assays and from the 
morphological appearance of the organotypic raft cultures suggest that the constiuitive 
expression of an E6 PBM confers a more invasive phenotype upon the host keratinocytes. 
4.2.7 Changes in PKA signalling are associated with changes in HFKs 
containing wild type genomes 
Previous growth analysis data from this study suggests that an increase in growth of cells 
containing a genome with an E6 mutation that conferred constitutive activity upon the E6 
PBM (E6∆PKA) could be attributed to changes in PKA signalling.  To test the hypothesis that 
conditional regulation of the E6 PBM has a role in regulating cell growth, the HFKs in this 
study were treated with a number of activators and inhibitors of the cAMP-dependent kinase; 
if a correct hypothesis exists then when cells containing a genome with a responsive E6 PBM 
(i.e. HPV18 wild type genomes) are treated with an inhibitor of PKA they would behave 
similarly to the E6ΔPKA mutant cells which are not regulated by PKA and grow faster that 
the vehicle only treated cells.  In contrast, treatment with an activator of PKA would enhance 
the negative regulation of the E6 PBM and provide a growth profile similar to that of the 
E6ΔPDZ mutant which is defective in binding to PDZ proteins. 
PKA is an enzyme whose activity is dependent on the intracellular levels of cAMP.  Each 
PKA is a holoenzyme that consists of two regulatory subunits and two catalytic subunits.  
Under low levels of cAMP, the holoenzyme remains intact and is catalytically inactive.  
When the concentration of cAMP rises i.e. by the addition of an activator of PKA such as 
forskolin (FK), cAMP binds the two binding sites on the regulatory subunits, which leads to 
the release of the catalytic subunits.  The release of the catalytic subunits allows these units to 
phosphorylate proteins in the cytosol and nucleus. Down-regulation of PKA (by compounds 
such as H89) occurs by a feedback mechanism.  One of the substrates that are activated by the 
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kinase is a phosphodiesterase which quickly converts cAMP to AMP, thus reducing the 
amount of cAMP that can activate protein kinase A.  3-isobutyl-1-methylxanthine (IBMX) is 
a potent cyclic nucleotide phosphodiesterase inhibitor which increases the amount of cyclic 
AMP in a cell.  H89 is a competitive inhibitor and competes with ATP binding to the catalytic 
subunits and prevents substrate phosphorylation. 
Cells containing either wild type or the mutant E6∆PKA HPV18 genomes were seeded into a 
6-well plate containing a -irradiated J2-3T3 fibroblast feeder layer at a concentration of 
5x10
4
 cells/well.  Each cell line was set up in duplicate at each time point.  Cells were allowed 
to grow for 48 h before the addition of the PKA activator or inhibitor.  FK and IBMX (Figure 
4.7A) were dissolved in DMSO and used in combination at concentrations of 50 µM and 1 
mM respectively.  Dibutyryl cAMP (Bt2cAMP, Calbiochem) (Figure 4.7A) was dissolved in 
Hank’s balanced salt solution and diluted in culture medium to a final concentration of 1 mM.  
The general PKA competitive inhibitor, H89 (Calbiochem) (Figure 4.7B) was dissolved in 
DMSO and added to the culture medium at a final concentration of 10 µM.  All activators and 
inhibitors were used at concentrations that were non toxic to the HFKs (data not shown).  
Cells were harvested at various times after the addition of activator/inhibitor cells, by first 
removal of the J2-3T3 feeder layer using EDTA and the keratinocytes removed with trypsin-
EDTA solution (Materials and Methods section 2.8.4).  Cell numbers were derived from 5 
counts at each time point and two wells were harvested for each time point.  Cells containing 
the E6ΔPKA genomes were used as a negative control in these experiments since they have 
an intact E6 PBM, but have a mutant PKA consensus motif and are therefore unresponsive to 
changes in PKA signalling.   
Addition of the inhibitor of PKA, H89 to cultures of cells containing the E6∆PKA genome 
had no effect upon the growth profile of these cells compared to cells treated with the DMSO 
alone.  However, as predicted, H89-treated wild type cells grew significantly faster than 
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DMSO-treated cells (Figure 4.7C).  The results are representative of 3 experiments carried out 
in 2 donor lines.  The most significant difference in growth is seen at 24 h (p=0.004) and 
(p=0.0003) respectively (Figure 4.7C).  To avoid bias, the inhibitor studies were repeated in a 
blind study carried out by Dr Sally Roberts.  The results from this study correlate with the 
results from this H89 study.  In these experiments, the greatest difference in growth was also 
observed at 24 h (p=0.0002) and there was no significant difference is observed in the 
E6ΔPKA line with or without the activator (p=0.8) (data not shown).  
FK activates PKA by stimulating cAMP levels, causing the phosphorylation of substrates 
including the phosphodiesterases (PDEs), which degrade cAMP and thereby reduce PKA 
activity.  IBMX selectively inhibits phosphodiesterases.  There is no change in the growth 
profiles of cells containing E6ΔPKA genomes, with or without the addition of the general 
activators FK/IBMX (Figure 4.7D) (p=0.5 at 24 h post-addition of activator).  However, as 
predicted, wild type cells treated with FK/IBMX grew significantly slower than untreated 
wild type cells at 12, 24 and 48 h post treatment (Figure 4.7D).  Similar to the activator 
studies, the greatest effect of the inhibitor could be seen at 24 h post treatment (Figure 4.7D).  
This result was consistent in 3 experiments across the 2 donor backgrounds tested. 
Since FK is known to potentially have off target effects, a specific activator of PKA, 
dibutyryl-cAMP was used in this assay to confirm the previous findings observed.  The data 
from the dibutyryl-cAMP experiments confirms the results from the FK/IBMX experiments. 
Dibutyryl-cAMP treated wild type HPV18 genome containing cells grew slower than wild 
type cells which had been untreated (Figure 4.7E). The data for cells derived from two 
separate donors is shown.  The difference in growth between treated and untreated wild type 
cells can be seen at 12, 24 and 48 h with the greatest effect seen at 24 h in all donor lines 
(p=0.0005, p=0.02 respectively).  As expected there is no difference in growth between 
E6ΔPKA cells treated or untreated with dibutyryl-cAMP (p=0.7, p=0.6 respectively) (Figure 
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4.7E).  Untransfected HFKs were also counted with and without the addition of dibutyryl-
cAMP to confirm the changes observed were due to the presence of HPV virus, in particular, 
E6 and no significant difference was observed in the growth profiles (p=0.5) observed (data 
not shown).   Taken together the data from the activator and inhibitor studies is in agreement 
with the hypothesis supporting the notion that the activity of the E6 PBM is conditionally 
regulated by PKA in primary human keratinocytes.  Changes in PKA activity by addition of 
specific activators and inhibitors of PKA were associated with a change in the growth of the 
HPV18 genome-containing cells; an increase in cell growth correlating with loss of negative 
regulation and reduced cell growth correlating with loss of E6 PBM function. 
4.2.8 The effect of E6 PBM activity on cell cycle 
4.2.8.1 Changes to E6 PBM activity does not affect the expression of cyclins  
The basis for the effect of the E6 PBM on cell growth may reflect changes in cell cycle 
progression, therefore to address this question the expression of a number of cyclins involved 
in cell cycle progression were analysed.  The cell cycle is governed by a family of cyclins and 
CDKs which mediate activating and inactivating phosphorylation events.  Different cyclin-
CDK combinations determine the downstream proteins targeted.  CDKs are constitutively 
expressed in cells whereas cyclins are synthesised at specific stages of the cell cycle, in 
response to various molecular signals.  A change in the expression of these cyclins in HFKs 
transfected with wild type or mutant genomes may explain the changes observed in growth 
rates and extensive nuclear abnormalities observed and so attention has been focused on 
altered expression of cyclins as they have been shown to be important in the events leading to 
cell proliferation and differentiation within the cell cycle (Fehrmann et al., 2003). 
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Figure 4.7 Treatment of wild type cells with activators or inhibitors of PKA correlate 
with changes in keratinocyte cell growth.  (A) Chemical structures of the activators 
IBMX/FK and Dibyutryl cAMP used in this study. (B) Chemical structure of the general 
inhibitor H89, used in this study. (C) HFKs containing wild type or E6ΔPKA genomes were 
seeded out on γ-irradiated J2 fibroblasts at a concentration of 5x104 cells and treated with a 
variety of activators and inhibitors of PKA. Cells were treated at 48 h post seeding and cell 
counts taken at 12 h, 24 h and 48 h post drug treatment. Cell counts were carried out in 
duplicate and each time point was counted 5 times. Errors bars represent the standard 
deviation of the experiment. P values were calculated from a one sided student T-test. 
Treatment of wild type cells with the general inhibitor H89 (10 µM) results in a significant 
increase in growth compared to wild type untreated controls, with the greatest effect seen at 
 4 h post treatment (p=0.004 and p=0.0003 respectively). HFK s containing E6ΔPKA 
genomes are not affected by the treatment with the general H89 inhibitor (p=0.8). These data 
are representative of 3 independent experiments in 2 donor backgrounds. (D) FK/IBMX 
activation of PKA reduces the growth of HPV18 wild type genomes. HPV18 wild type and 
E6ΔPKA genomes were harvested and seeded as previously discussed and incubated with or 
without FK (50 µM) and IBMX (1 mM) after 48 h. Cell counts were taken at 12 h, 24 h and 
48 h post treatment with activator. Treatment of wild type cells with FK/IBMX significantly 
reduces the growth compared with untreated control wild type containing HFKs. The greatest 
effect is seen at 24 h post treatment. No significant changes were observed in E6ΔPKA 
genome containing cells with or without treatment with FK/IBMX.  Data is representative of 
3 separate experiments carried out in 2 donor lines. (E) Analysis of wild type treated with the 
specific activator Dibutryl cAMP revealed similar findings to the FK/IBMX study. HFKs 
containing wild type genomes treated with Dibutryl cAMP (1 mM) grew significantly slower 
than untreated wild type controls, with the greatest change in growth seen at 24 h post 
treatment (p=0.0005 and p=0.002) respectively. No significant changes were observed in 
E6ΔPKA cells with or without the treatment of Dibutryl cAMP (p=0.7 and 0.6 respectively). 
Data is representative of 3 independent experiments carried out on 2 donor lines.  
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From monolayer cell cultures, early passage cells (P6) containing wild type, E6ΔPKA or 
E6ΔPDZ genomes were harvested in lysis buffer containing 8M urea and equal amounts of 
the protein lysates analysed by western blotting to determine the protein expression levels of 
cyclins E, A and B1- cyclins which regulate G1 to S and G2-M cell cycle progression.  The 
results from western blot analysis showed that cells containing wild type, E6ΔPDZ or 
E6ΔPKA genomes contained detectable levels of all three cyclins (Figure 4.8) and all three 
were expressed at higher levels than in the untransfected cells.  This increase in cyclin 
expression by HFKs containing HPV genomes have been previously reported (Fehrmann et 
al., 2003).  No marked changes were observed in protein expression levels of the cyclins B1 
and A in either mutant line compared with the wild type genome containing cells (Figure 4.8).  
Western blot analysis of cyclin E showed a slight reduction in expression of cyclin E in HFKs 
carrying E6ΔPDZ genomes when quantitated against GAPDH protein loading, control 
however this change was not significant when compared with the wild type control (p=0.67).  
These experiments were repeated three times with similar results.  These studies confirm the 
induction of cyclin A, cyclin B1 and cyclin E in HFKs containing wildtype, E6ΔPDZ or 
E6ΔPKA genomes but demonstrate that the E6 PBM does not influence this process. 
 
 
 
 
 
 
 
 
Chapter 4 
160 
 
           
 
                    
 
Figure 4.8 Changes to the E6 PBM do not affect the expression levels of cell cycle 
markers.  Lysates from normal HFKs as well as those containing wild type, E6ΔPKA and 
E6ΔPDZ genomes were grown to 80% confluency, harvested and subjected to western blot 
analysis with the cell cycle markers Cyclin E , Cyclin A and Cyclin B1. No significant 
changes were observed in the Cyclin A, Cyclin E and Cyclin B1 protein expression levels 
between cell carrying wild type, E6ΔPDZ or E6ΔPKA genomes suggesting that abrogation of 
the E6 PBM or constitutive expression of this domain does not effect the levels of cell cycle 
markers. GAPDH is shown as a marker for loading control. The western blots are 
representative of 3 separate experiments from 1 donor line.  
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4.2.8.2 Changes to the E6 PBM do not affect the ability of cells to progress through the 
cell cycle 
Since no significant differences were observed in the cyclin expression between HFKs 
containing wild type or mutant genomes, the cell cycle profiles of normal HFKs or HFKs 
containing wild type or E6ΔPDZ genomes were determined at various passages post 
transfection by flow cytometry analysis.  
For DNA cell cycle analysis, cell pellets were resuspended in 70% ethanol and fixed as 
described (Materials and Methods section 2.11) and cell pellets resuspended in PBS 
containing propidium iodide (PI).  The relative cellular DNA content of stained cells was 
measured by flow cytometry and the proportions of cells in phases G0/G1, S and G2/M were 
calculated using the multicycle dedicated cell cycle analysis software (Phoenix flow systems, 
San Diego, Calif).  
Cells carrying E6ΔPDZ genomes or wild type genomes produced cell cycle profiles that were 
similar to untransfected cells at both low and high passages (P5, P15 respectively) (Figure 
4.9A) and this was consistent across multiple donors (data not shown).  A combined analysis 
of FACS profiles from a number of low and high passages cells further confirmed there was 
no significant changes in the proportions of cells in G0/G1, S and G2/M phase between HFKs 
containing wild type genomes or E6ΔPDZ genomes (p=0. , p=0.7 and p=0.3 respectively) 
(Figure 4.9B).  Moreover, no significant changes were observed in the G2 + M:G1 ratios at 
early and late passages between wild type expressing and E6ΔPDZ genome containing cells 
(Figure 4.9C).  These results taken together suggest that change observed in the growth 
profiles of cells containing E6ΔPDZ genomes may not be attributed to changes in the ability 
of cells to progress through cell cycle as similar cell populations were observed in HFKs 
containing wild type and E6ΔPDZ genomes at both low and high passages.  
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Figure 4.9 Abrogation of the E6 PBM does not affect the ability of cells to cycle. 
HFKs containing wild type or E6ΔPDZ genomes were grown to 80% confluency, harvested, 
fixed and incubated with propidium iodide (PI).  The relative cellular DNA content of stained 
cells was measured by flow cytometry and the proportions of cells in G0/G1, S and G2/M were 
calculated. (A) Cell cycle profiles of HFKs containing wild type or E6ΔPDZ genomes at low 
(P5) and high (P15) passages are shown. (B) A combined analysis of FACS profiles from 
multiple low passage (P5-9) and multiple high passage (P10-15) donors revealed no 
significant differences in the proportion of cells in G1, S or G2 between normal HFKs and 
those containing wild type or E6ΔDZ genomes. Errors bars represent the standard deviation 
of the experiment shown. (C) The relative G2/M:G1 populations were calculated.  No 
significant changes were observed in the G2/M:G1 ratios of HFKs containing wild type 
genomes or E6ΔPDZ genomes at multiple low passages or multiple high passages.  
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4.2.8.3 Abrogation of the E6 PBM is associated with an increased population of cells in 
mitosis 
Single parameter DNA histograms cannot discriminate G2 from M-phase cells so to address 
the question whether the cells may be arresting in mitosis (M), the G2/M checkpoint assay 
using  the marker for M phase cells, phospho-histone 3 (pH3) was used to determine the 
population of cells that are in M phase.  Briefly, cells are fixed and incubated with an anti-
phospho histone H3 (Ser10) antibody (Cell Signalling) and positive cells identified using a 
FITC conjugated secondary antibody and the percentage of positive cells determined using 
flow cytometry (Materials and Methods section 2.12).  
Overall, cells carrying E6ΔPKA or wild type HPV18 genomes showed, on average, similar 
populations of cells in M phase (1.7% and 5% respectively) compared with untransfected 
keratinocytes (0.18%) (Figure 4.10A).  The difference in M phase populations between wild 
type and E6ΔPKA cells is not significant (p=0. ).  Interestingly, cells containing the mutant 
E6ΔPDZ genomes had a significantly greater population of cells in M phase when compared 
with wild type (p=0.008) or E6ΔPKA cells (p=0.005).  Twenty percent of cells carrying 
E6ΔPDZ genomes were found to be in M phase compared to 5% of the cells containing the 
wild type HPV genomes (Figure 4.10A).  The data presented, represents the combined results 
of 3 separate experiments from one donor. 
An assessment of pH3 protein levels by western blot analysis confirmed the results seen by 
the G2/M assay.  Western blot analysis of cell lysates revealed a distinct pH3 band in lysates 
prepared from cells carrying the E6ΔPDZ genomes (Figure 4.10B), which may explain the 
higher population of cells we see in this mutant cell line in the G2/M assay.  No pH3 band 
was detected in lysates from untransfected, wild type or E6ΔPKA genome containing HFKs 
(Figure 4.10B), concurrent with the lower populations of M cells in the G2/M assay.   
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Figure 4.10 Abrogation of the E6 PBM results in an increase of cells in M phase.  (A) 
Normal HFKs as well as HFKs containing wild type, E6ΔPDZ or E6ΔPKA genomes were 
grown to 80% confluency, cells were harvested, fixed and incubated with an anti-pH3 (ser 10) 
antibody followed by a FITC conjugated secondary antibody. The percentage of cells in M 
phase was determined by flow cytometric analysis. Bar graph is representative of 3 
independent experiments carried out in 1 donor line.  Overall HFKs carrying the E6ΔPDZ 
genomes have a greater % of cells in M phase compared with matched HFKs containing wild 
type genomes (p=0.008) and E6ΔPKA genomes (p=0.001). P values were calculated from a 
one sided student T-test. (B) Western blot analysis of lysates from the same donor line. Cells 
were harvested and probed for immunoblotting by an anti-pH3 antibody  Western blot 
analysis shows a distinct pH3 in lysates from HFKs carrying E6ΔPDZ genomes which is 
absent in matched donors of normal HFKs as well as those containing wild type or E6ΔPKA 
genomes.  
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Taken together these data suggest that abrogation of the E6 PBM may be important during the 
final stages of cell cycle since an increased proportion of cells in M phase were observed by 
FACS analysis and confirmed by western blot analysis in HFKS containing E6ΔPDZ 
genomes. 
4.3 Discussion 
To understand if the function of the E6 PBM was necessary for late viral functions, the 
vegetative life cycle of the virus was induced within HFKs containing wild type and mutant 
(E6ΔPDZ or E6ΔPKA) genomes either by suspension of the cells in methylcellulose or by 
stratification in organotypic raft culture.  In histological cross sections of normal HFKs as 
well as HFKs containing wild type, E6ΔPDZ or E6ΔPKA genomes, abrogation of the E6 
PBM by means of the E6ΔPDZ mutation was consistently found to present a reduced 
thickness of the basal cell layer with morphology more similar to that of normal HFKs than 
those containing HPV18 wild type genomes. This finding is consistent with comparable 
analyses of E6ΔPDZ genomes in HPV31 genome containing cells and in mice, both of which 
showed similar histology (Lee & Laimins, 2004; Nguyen et al., 2003).  Conversely, 
histological cross sections of HFKs containing the E6ΔPKA genomes showed an enhanced 
hyperplasia upon constitutive activation of the E6 PBM.  Changes in basal layer thickness 
between E6ΔPDZ and E6ΔPKA genome containing cells could possibly be explained by the 
changes we see in proliferation rates between the two mutants since HFKs containing 
E6ΔPKA genomes have been shown to grow significantly faster than those containing wild 
type or E6ΔPDZ genomes (Chapter 3 Section 3.2.5) and this correlates with the increased 
hyperplasia in cells harbouring E6ΔPKA genomes compared with those containing wild type 
or E6ΔPDZ genomes.   
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The studies described above suggest that the PBM of E6 is involved in modulating 
proliferation as well as impacting on the early viral functions such as the establishment of 
episomes and maintenance of viral copy number.  Since the late phases of the viral life cycle 
are linked to differentiation of keratinocytes, the E6 PBM function was assessed following 
differentiation in methylcellulose.  HFKs containing wild type or E6ΔPKA genomes were 
able to amplify their genomes to a similar level, and this was consistent across a number of 
donors investigated.  Interestingly, HFKs carrying a mutant of E6 which is unable to bind to 
PDZ substrates (E6ΔPDZ) failed to amplify their genomes in methylcellulose suggesting that 
the E6 PBM is required for differentiation dependent amplification.  The data from these 
experiments are in variance to the studies from Lee and Laimins, who show that in an HPV31 
background, the PBM of E6 is not required for the differentiation dependent amplification of 
viral genomes (Lee & Laimins, 2004).  Interestingly, the study by Lee and colleagues do 
show a moderate decrease in genome amplification in HFK containing E6ΔPDZ genomes 
compared to wild type genomes (2.7 fold compared with 4.0 fold respectively) suggesting that 
the E6 PBM may be required for efficient amplification of viral genomes (Lee & Laimins, 
 004).  Moreover, the differences observed in amplification of E6ΔPDZ genomes between 
this study and that of Lee and colleagues could be attributed to an HPV subtype specific 
difference. 
The loss of viral genome amplification in cells harbouting E6ΔPDZ genomes could not 
attributed  to changes in the stability or expression of E6 or E7 proteins, since raft lysates of 
HFKs harbouring wild type or mutant genomes showed a similar expression pattern of both 
E6 and E7 proteins.  Loss of efficient viral genome amplification in cells harbouring E6ΔPDZ 
genomes could also not be explained by the inability of the suprabasal cells to re-enter S 
phase since the level of BrdU incorporation (a marker of S phase activity) in suprabasal 
E6ΔPDZ cells was comparable to cells carrying wild type genomes.  This may not be that 
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surprising since the expression of the E7 protein of both high risk and low risk HPV types has 
been shown to be capable of inducing S phase reactivation in suprabasal cells of differentiated 
keratinocytes (Cheng et al., 2005).  The difference in BrdU incorporation between HFKs 
carrying E6ΔPKA genomes and those carrying wither wild type or E6ΔPDZ genomes was 
significant suggesting that phosphorylation of the E6 PDZ binding motif may be an additional 
means of regulating S-phase re-entry and replication of HPV18 genomes during the 
productive stages of the HPV18 life cycle. 
As previously mentioned, loss of the conditional regulation of the E6 PBM within HPV18 
genome by means of the E6ΔPKA mutation has been shown to be associated with a 
significant increase in cell growth (Chapter 3 Section 3.2.5).  This suggests that changes in 
PKA signalling in HFKs carrying wild type genomes may lead to changes in keratinocyte cell 
growth.  Indeed, the treatment of cells harbouring wild type genomes with activators of PKA 
including FK/IBMX and dibutryl-cAMP resulted in a reduction in keratinocyte cell growth, 
whilst the treatment of wild type cells with an inhibitor of PKA, H89, resulted in a significant 
increase in keratinocyte cell growth.  Taken together these data suggest that changes in PKA 
signalling have a significant effect on keratinocyte cell growth.  It is important to note that 
H89 is known to have off target effect in other cell types and can inhibit other kinases 
(Lochner & Moolman ,2006) so future experiments would be to confirm findings of the 
inhibitor data using a specific inhibitor of PKA such as (Rp)-8-Cl-cAMPS.   
Modulation of E6 PDZ targeting was also linked to cell invasion since HFKs containing the 
E6ΔPKA genomes showed an increased invasive potential compared with wild type genomes 
that could still be regulated by PKA.  E6 PBM substrates have previously been shown to be 
implicated in cell invasion.  A study by Goode and Perrimon revealed that Drosophila Dlg 
was required to block cell invasion as loss of Dlg was associated with an increase potential of 
follicle cells to change shape and invade (Goode & Perrimon, 1997).  Moreover, a study by 
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Dow and colleagues also implicate the PDZ substrate hScrib in invasion, as loss of hScrib in 
human epithelial cells expressing oncogenic ras was associated with the promotion of cells 
through the extracellular matrix in an organotypic raft culture system (Dow et al., 2008).  In 
this light it is tempting to speculate that constitutive degradation of PDZ proteins in cells 
harbouring the E6ΔPKA mutation may explain the enriched phenotype observed.    
Data from this study has shown that abrogation of the E6 PBM results in an accumulation of 
mitotic defects in cells lacking an intact PBM including an increase in populations of bi-
nucleate and multi-nucleate cells.  Furthermore, HPV18 mutants which lack the PBM have 
been shown to grow significantly slower than matched wild type controls.  In an attempt to 
elucidate a mechanism for the phenotypes observed, FACS analysis on normal HFKs as well 
as HFKs carrying wild type or E6ΔPDZ genomes was carried out.  An analysis of multiple 
samples from both low and high passages showed no significant difference in the populations 
of G1, S or G2 cells derived from wild type or E6ΔPDZ genomes suggesting that the PBM of 
E6 does not play a significant role in the progression of cells through cell cycle.  An analysis 
of cyclin levels in cells containing wild type or E6ΔPDZ genomes revealed no significant 
changes which further supports the argument that the E6 PBM does not affect the ability of 
cells to process through cell cycle. 
Interestingly, on further scrutiny, a detailed analysis of cells specifically in mitosis revealed 
that abrogation of the E6 PBM resulted in a significant increase of cells in M phase compared 
with wild type cells.  This was verified by western blot analysis of lysates from wild type and 
E6ΔPDZ cells for the M phase marker pH3.  Constitutive activity of the E6 domain was not 
associated with an increase in M phase populations, since no significant differences were 
observed from HFKs carrying wild type genomes and those carrying the constitutively active 
mutant, E6ΔPKA.  The increase in population of cells in mitosis is consistent with the 
aberrant nuclear morphology and replication associated with cells lacking an in tact PBM, 
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suggesting that the function of the E6 PBM may be important during the final stages of 
mitosis/cytokinesis, during the separation of daughter cells.  Work from Unno and colleagues 
have shown that hDlg- a substrate of the PBM plays an important role in cytokinesis, via its 
GUK domain (Unno et al., 2008).  Moreover, overexpression of the hDlg protein in U2OS 
and Hela cells impaired cytokinesis (Unno et al., 2008). In this light, it is tempting to 
speculate that abrogation of the PBM, leads to an increase in target substrates, such as hDlg 
and may explain the aberrations in mitosis and the phenotypes observed.   
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CHAPTER 5 AN ANALYSIS OF THE EXPRESSION OF PDZ 
DOMAIN CONTAINING SUBSTRATES OF E6 IN HPV18 
GENOME CONTAINING KERATINOCYTES 
5.1 Introduction 
Nearly all cells in human tissue require polarisation to carry out their normal function. 
Polarisation of epithelial cells helps the cell to identify what ions and molecules should be 
taken up and what should be excreted and on which surface this should occur (Thomas et al., 
2008).  Three polarity modules are important in the establishment and maintenance of 
apicobasal cell polarity in epithelial cells, known as the Scribble, Par and Crumbs polarity 
modules.  These three complexes have been described as a polarity ‘super complex,’ whereby 
each complex is required to localize all of its proteins at the appropriate membrane positions 
in order to achieve and maintain epithelial cell polarity (Macara, 2004).  Cell polarity is 
thought to be involved in tissue arrangement and in cell migration (Gonzalez-Mariscal et al., 
2003).  In epithelial tissues, the apical and basolateral membrane domains are separated by a 
physical barrier called the apical junctional complex (AJC).  This is the most significant 
epithelial cell-cell adhesion structure and comprises tight junctions (TJ) and adherens 
junctions (AJ) (Hartsock & Nelson, 2008).  TJ provide a seal between the membranes of 
neighbouring cells whilst AJ use the actin cytoskeleton to keep the cellular membranes of 
neighbouring cells together (Hartsock & Nelson 2008; Perez-Moreno & Fuchs, 2006).  
The Scribble polarity complex is comprised of three proteins: Discs Large (hDlg), Scribble 
(hScrib) and Lethal giant larvae (Hug1-1).  Due to the similarity in their mutant phenotypes 
and the genetic interactions observed between them, it has been surmised that hScrib, hDlg 
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and Hug1-1 function in a common pathway to regulate the establishment and maintenance of 
apicobasal polarity in epithelial cells (Bilder et al., 2000).  An understanding of how hScrib, 
hDlg and Hug1-1 function in the establishment and maintenance of apicobasal cell polarity 
has largely come from studies in Drosophila.  hDlg is a protein observed mainly at cell-cell 
junctions and maintains cell polarity by defining AJ.  hDlg is also associated with the 
establishment of TJ and is hypothesised to act by recruiting tight junction proteins to sites of 
cell-cell contact in order to establish a non-permeable seal between epithelial cells (Stucke et 
al., 2007).  Another member of the Scribble polarity complex, hScrib, is required for the 
definition of TJ and correct localisation of apical membrane complexes.  hScrib is known to 
co-localise with hDlg at AJ (Gardiol et al., 2006; Massimi et al., 2008) (Figure 5.1).  hScrib is 
also thought to have roles in signal transduction at points of cell-cell contact (Dow et al., 
2003).  The third component of the Scribble complex, Hugl-1 has not yet been implicated in 
the E6 disruption of cell polarity; however its expression is reduced in a number of non-HPV 
associated cancers including melanomas and cancers of the endometrium (Kuphal et al., 
2006; Tsuruga et al., 2007). 
The Par complex is restricted to the apical region of the cell membrane, and co-localises with 
the PDZ proteins MAGI-1, 2 and 3 (Yamanaka et al., 2003, 2006).  It sits above the Scribble 
complex forming TJ (Figure 5.1).  Although many of the proteins which make up the Par 
complex contain PDZ domains (such as Par3 and Par6) none have yet been implicated as 
targets for the high risk E6 PBM, however the MAGI-1,-2,-3 proteins have been shown to be 
targeted by high risk E6 proteins for degradation (Glaunsinger et al., 2000,Thomas et al., 
2002).  
The Crumbs complex, like the Par complex, is also localised to the apico-lateral membrane 
boundary (Figure 5.1).  This complex is known to play a direct role in the establishment of 
cell polarity (Roh et al., 2003).  Studies have shown that a change in the expression of any 
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component of the Crumbs complex (Crb3; Pals1 (protein associated with lin-7); or PAT-J 
(Pals-1 associated tight junction protein)) results in a loss of cell polarity (Lemmers et al., 
2002, Roh et al., 2003).  Members of this complex have been shown to be specific substrates 
for the E6 PBM.  High risk HPV16 and HPV18 have been shown to target and degrade PAT-
J, ultimately leading to the destabilisation of cell polarity complexes and a change in cell 
polarity (Storrs & Silverstein, 2007).  Interestingly, the HPV18 E6* isoform is also able to 
degrade PATJ, highlighting the first evidence of a PDZ substrate which is degraded by both 
isoforms of HPV18 E6 (Storrs & Silverstein, 2007).  
As previously mentioned, a large number of PDZ domain containing proteins, with roles in 
the regulation of cell polarity have been found to be targets of the HPV E6 PBM in vitro.  
Several of these targets are proteins found at regions of cell-cell contact, including the MAGI-
1, 2, 3 proteins and MUPP1 (Glausinger et al., 2000; Thomas et al., 2002; Lee et al., 2000) 
which are found at subapical TJ (Ide et al., 1999; Hamazaki et al., 2001) and hDlg and hScrib 
proteins which are found at lateral AJ (Bilder & Perrimon, 2000; Firestein & Rongo, 2001).  
The biochemical data supporting the identification of hDlg and hScrib as targets of high risk 
E6 is very strong; however it is still unclear what the natural target, or targets of the virus are 
in vivo.  During the development of cervical cancer there is a marked progressive loss of both 
hScrib and hDlg protein expression (Watson et al., 2002; Cavatorta et al., 2004; Nakagawa et 
al., 2004; Lin et al., 2004).  An analysis of hDlg levels from low grade and high grade 
squamous intraepithelial lesions revealed an increase in membrane and cytoplasmic staining 
of hDlg in cells of the superficial layer, in intraepithelial lesions from low grade patients, 
whilst the reverse staining pattern for hDlg is a feature of high grade intraepithelial lesions 
(Lin et al., 2004).   
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Figure 5.1 The Scrib, PAR and Crumbs polarity complex.  The components of the 
Scribble complex are found at adherens junctions, just below the PAR complex which is 
localised to tight junctions. The Crumbs complex components are localised to the apical 
region of the cell membrane. Localisation of some of the E6 PDZ binding partners is shown. 
Figure adapted from Thaibault, 2011.      
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This part of the study forms part of an investigation to determine whether some of the known 
PDZ substrates such as hDlg and hScrib, are affected by the expression of E6 with altered 
PDZ activity in the context of whole HPV18 genomes.  In addition, this study looks at 
whether changes to the PDZ binding activity affect the expression or localisation of 
components of polarity defining structures such as TJ and AJ.  
5.2 Results 
5.2.1 hDlg protein levels are reduced in HFKs harbouring wild type or 
E6ΔPKA genomes 
By using heterologous over expression systems, high-risk HPV E6 proteins have been shown 
to target not only p53 but also PDZ proteins for degradation (Lee & Laimins, 2004).  To 
assess the biological activity of the different E6 molecules, the protein levels of hDlg, one of 
the cellular targets of the PBM was examined by western blotting of protein extracts.  hDlg is 
recognised as a protein triplet.  The immune-reactive bands had apparent molecular weights 
of approximately 130 kDa and 120 kDa as previously reported (Lue et al., 1994; Wu et al., 
1998).  The lower band had a weight of approximately 110 kDa.  The differences in band 
mobility and size may be due to post-translational modifications of hDlg, for example 
phosphorylation (Hanada et al., 1997; Mantovani et al., 2001).  There is mounting evidence 
that hDlg exists in a number of different cellular locations.  Predominantly it is found at sites 
of cell-cell contact, although nuclear and cytoplasmic forms have also been observed 
(McLaughlin et al., 2002; Massimi et al., 2003; Roberts et al., 2007).   
HFKs containing wild type, E6ΔPDZ and E6ΔPKA genomes were grown in monolayer cell 
culture to 80% confluency, cells were harvested and solubilised in 8 M urea.  Western blots 
were probed with a 2D11 monoclonal antibody (anti-hDlg).  As can be seen in Figure 5.2A, 
all donor lines, contained detectable levels of hDlg by western blot analysis.  Typically 
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E6ΔPKA lines expressed levels of hDlg lower than those present in the wild type or E6∆PDZ 
lines.  In E6∆PDZ lines, which are unable to target PDZ substrates, hDlg levels were 
significantly increased compared to wild type and untransfetced cells. Western blots from 
figure 5.2A are representative of two experimental repeats carried out in 3 separate donor 
lines.  Signal intensities of hDlg levels detected from western blots from 3 separate donors 
were quantified and normalised to GAPDH levels.  Densitometric analysis of hDlg protein 
bands confirmed the differences in hDlg protein levels seen by western blot analysis.  Figure 
5.2B shows the mean Optical Density (OD) readings of three separate hDlg western blots 
from 1 donor line.  From figure 5.2B it can be seen that the hDlg densities of HFKs 
harbouring E6∆PDZ genomes are comparable to normal HFKs.  In HFKs containing wild 
type cells the mean OD reading is significantly lower than that of normal HFKs and those 
containing the E6ΔPDZ mutant genomes (p=0.04 and p=0.03 respectively).  HFKs carrying 
the E6ΔPKA mutant genomes typically display the lowest overall OD readings.  Moreover, 
the difference in density of hDlg bands observed from E6ΔPKA genomes is significantly less 
than those containing E6ΔPDZ genomes (p=0.03) 
The subcellular distribution of hDlg in monolayer cultures was also examined.  Normal HFKs 
as well as HFKs containing wild type and E6ΔPDZ or E6ΔPKA mutant genomes were grown 
over coverslips to 80% confluence and then fixed in 4% paraformaldehyde for analysis by 
immunofluorescence.  hDlg levels were analysed by probing with a 2D11 (anti-hDlg) 
antibody.  In monolayer cultures of normal HFKs, hDlg can be visualised at the cell-cell 
boundaries (Figure 5.2C).  HFKs containing wild type genomes show less peripheral hDlg 
staining than normal HFKs with E6ΔPKA displaying the weakest hDlg staining at the cell 
boundaries (Figure 5.2C). In accordance with data from western blotting analysis, HFKs 
containing E6ΔPDZ genomes display a strong hDlg staining pattern, at levels comparable to 
normal HFKs (Figure 5.2C). 
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Taken together, these results indicate hDlg as a potential target for the HPV18 E6 PBM in the 
context of a productive HPV infection, since hDlg protein levels are altered in the presence of 
the HPV18 genome.  The ability of HPV18 to degrade hDlg requires a functional E6 PBM 
since levels of the hDlg protein in HFKs containing the truncated PBM (E6ΔPDZ mutant) 
were at levels comparable to normal HFKs.  Loss of the ability to negatively regulate the 
degradation, in the context of the E6ΔPKA mutant, results in a somewhat greater loss of the 
hDlg protein than seen in wild type containing HFKs and this is confirmed by western 
blotting and immunofluorescence analysis.  In two of the donor lines, there is a shift in the 
hDlg protein band observed by western blot analysis (Figure 5.2A).  This shift may be a result 
of post translational modifications of hDlg, for example phosphorylation (Hanada et al., 1997; 
Mantovani et al., 2001). 
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Figure 5.2 hDlg protein levels are affected by PDZ binding activity.  (A) Normal 
HFKs and HFKs containing wild type, E6ΔPDZ or E6ΔPKA genomes were grown to 80% 
confluency, harvested and lysates probed with an anti-hDlg antibody (2D11). Wild type 
containing cells contain levels of hDlg protein lower than untransfected cells and those 
containing E6ΔPDZ genomes, whilst mutants which are constitutively active for binding to 
PDZ substrates (E6ΔPKA) display the lowest levels of hDlg protein by western blot analysis. 
Western blots are representative of 3 independent experiments carried out in 3 donor lines. 
(B) The relative intensities of hDlg protein levels from normal HFKs as well as those 
containing wild type, E6ΔPDZ or E6ΔPKA genomes was measured by densitometry and 
normalised to GAPDH levels (Bio-Rad). The density of hDlg protein levels from normal 
HFKs was significantly greater than those containing wild type genomes (p=0.04). Moreover, 
densitometer analysis of hDlg protein levels from E6ΔPDZ and E6ΔPKA genomes revealed a 
significant reduction in density reading of hDlg protein in wild type containing cells and 
E6ΔPKA genome containing cells, compared with E6ΔPDZ lines (p=0.03 and p=0.03 
respectively). The bar graph represents the optical density data from 3 independent 
experiments carried out in 1 donor line. (C) Immunofluorescence reflects the results seen by 
western blotting. Monolayer cultures of HFKs containing wild type genomes, E6ΔPDZ or 
E6ΔPKA genomes were grown on coverslips to 80% confluency, fixed in 4% 
paraformaldehyde and probed for immunofluorescence with anti-hDlg antibody (2D11). hDlg 
intensities are strongest for those cells containing E6ΔPDZ genomes whilst HFKs containing 
wild type or E6ΔPKA genomes display a reduced hDlg staining pattern. Images are 
representative of 3 independent experiments in 3 donor lines.  
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5.2.2 Changes to the E6 PBM do not affect the expression of hScrib, 
MAGI-1 or TIP-2 protein levels in HPV-immortalised keratinocytes 
In addition to hDlg, other PDZ proteins such as hScrib (the human homologue of the 
Drosophila tumour suppressor protein Scribble, found localised with hDlg at AJ and MAGI-1 
(localised at TJ) are also targets for degradation by the E6 PBM (Gardiol et al., 1999; 
Glaunsinger et al., 2000; Kiyono et al., 1997).  The ability of E6 to bind and degrade these 
PDZ domain-containing proteins appears to vary, with HPV16 E6 showing a preference for 
hScrib and HPV18 E6 showing a preference for hDlg and MAGI-1 (Kranjec & Banks, 2010; 
Thomas et al., 2003).  
To assess the ability of HPV18 wild type and mutant genomes to target other members of the 
PDZ binding domain family, HFKs containing wild type, or mutant (E6ΔPDZ, E6ΔPKA) 
genomes were grown to 80% confluency, lysed in a buffer containing 8M urea and the 
solubilized proteins were resolved by SDS-PAGE and subjected to western blot analysis with 
a number of anti-PDZ antibodies.  As can be seen in Figure 5.3, there appears to be no 
significant changes in the expression levels of hScrib protein between wild type and mutant 
containing HFKs and this result is consistent across 2 separate donor lines.  Moreover, no 
significant changes were observed in MAGI-1 levels in wild type or mutant HFK lines 
(Figure 5.3).  Interestingly, the levels of TIP-2- a member of the PDZ family involved in 
TGFβ signalling (Favre-Bovin et al., 2005) appear to be somewhat stabilised in the presence 
of a productive HPV infection as levels of the protein increase in cells containing wild type, 
E6ΔPDZ or E6ΔPKA genomes.  In line with other PDZ substrates such as hScrib and MAGI-
1, there appears to be no significant differences in the expression levels of the TIP-2 protein 
between wild type and E6 mutant genome containing HFKs (Figure 5.3).  Taken together, 
these data suggest that the HPV18 gene products from whole viral genomes do not 
significantly change the protein levels of the hScrib, MAGI-1 or TIP-2 in monolayer cultures.   
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Figure 5.3 PDZ binding activity does not effect the expression of hScrib, MAGI-1 
and TIP-2.  Normal HFKs as well as HFKs containing wild type, E6ΔPDZ or E6ΔPKA 
genomes were grown to 80% confluency, harvested and probed for immunoblotting with anti-
hScrib, anti-MAGI-1 and anti-TIP-2 antibodies. Western blot analysis revealed no significant 
changes in the total protein levels of hScrib and MAGI-1 expressed from normal HFKs as 
well as those containing wild type or mutant genomes. Moreover, an analysis of TIP-2 
expression levels revealed no significant changes in protein levels by western blot from HFKs 
containing wild type genomes and those containing either E6ΔPDZ or E6ΔPKA genomes, 
similar to that of hScrib and MAGI-1, however this protein appears to be stabilised in the 
presence of HPV18 genomes. Western blots are representative of 3 independent experiments 
carried out in 2 donor lines. 
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5.2.3 PTPN13 levels are not significantly changed in HPV18-transfected 
HFKs 
PTPN13 is a member of the non-receptor phosphatases family which specifically fall into a 
class of phosphatases that contain FERM (four point, one ezrin, radixin, moesin) domains 
(Spanos et al., 2008).  It is a highly modular 270 kDa protein with multiple interaction 
domains.  The protein is known to contain five PDZ binding domains and has been implicated 
in several cellular pathways that play a role in cell survival.  Previous reports have shown that 
HPV16 E6 interacts with and induces loss of the PTPN13 protein in a PDZ protein-binding 
manner (Spanos et al., 2008).  
HFKs containing wild type, E6ΔPDZ and E6ΔPKA genomes were grown to 80% confluency, 
harvested and lysed in 8 M urea for subsequent analysis by western blotting with an anti-
PTPN13 antibody.  As can be seen in figure 5.4, there is no significant change in the protein 
expression of PTPN13 between normal HFK lysates and those which contain either wild type 
or mutant (E6ΔPDZ or E6ΔPKA) genomes.  Interestingly, a band is observed in protein 
lysates from E6ΔPKA containing HFKs at approximately 175 kDa.  This band is not visible 
in lysates from normal HFKs or those containing wild type or E6ΔPDZ genomes.  The 
presence of this 175 kDa band is consistently present in E6ΔPKA lysates from three other 
donor lines suggesting that it is a common feature of HFKs expressing these genomes.  The 
origin of the 175 kDa band is unknown however it could be a proteolytic breakdown product.  
Alternatively the band could be an alternatively spliced product which is stimulated in these 
cells. 
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Figure 5.4 PTPN13 protein levels are not reduced in HFKs harbouring wild type, 
E6ΔPDZ or E6ΔPKA genomes.  Monolayer cultures of cells containing either wild type or 
mutant genomes were grown to confluency, harvested and probed for immunoblotting with an 
anti-PTPN13 antibody. Western blot analysis of normal HFKs as well as HFKs carrying wild 
type, E6ΔPDZ and E6ΔPKA genomes revealed no significant changes in total protein levels 
of PTPN13 between normal HFKs and those containing wild type or E6ΔPDZ genomes. 
PTPN13 protein levels in HFKs containing E6ΔPKA genomes were similar to normal HFKs 
and those containing wild type or E6ΔPDZ genomes, however the presence of an additional 
protein band at approx. 175 k Da was a consistent feature of HFKs carrying this mutant 
genome. Western blots are representative of 2 independent experiments carried out in 3 donor 
lines.  
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5.2.4 Loss of negative regulation of the E6 PDZ-binding domain is 
associated with reduced hDlg protein staining in organotypic raft 
cultures 
Whilst some changes in hDlg protein expression were noted in monolayer cell cultures 
containing wild type, E6ΔPDZ and E6ΔPKA genomes, the distribution of hDlg in HFKs 
containing wild type or mutant genomes stratified in organotypic raft cultures was also 
examined.  Raft cultures of normal HFKs as well as HFKs containing wild type, E6ΔPDZ or 
E6ΔPKA genomes were grown for 13 days, fixed, and paraffin embedded sections were 
probed by immunofluorescence with an anti-hDlg antibody (2D11).  Images were taken on a 
Nikon Eclipse E600 microscope at the same exposure.  As can be seen in figure 5.5A, a 
punctate pattern of localisation of hDlg protein can be seen at peripheral cell-cell contact 
regions.  A minor population of hDlg proteins, distinct from the membrane-bound form can 
also be observed in the cytoplasm of normal HFKs (Figure 5.5A).  Moreover, in the more 
differentiated suprabasal cell layers, hDlg protein is localised to the cell periphery at sites of 
cell: cell contact (Figure 5.5A).  Raft cultures of HFKs containing wild type, E6ΔPDZ or 
E6ΔPKA genomes typically showed a similar pattern of hDlg localisation in basal cells.  In 
HPV18 wild type transfected cells, a small reduction in the intensity of hDlg protein at the 
cell periphery was observed in suprabasal cell layers (Figure 5.5B).  The relative amount of 
cytoplasmic hDlg also appears to be reduced in the differentiated suprabasal cell layers in 
these cultures (Figure 5.5B).  Raft cultures containing E6ΔPDZ genomes cells displayed 
stronger hDlg staining than wild type cells, at levels comparable to untransfected HFKs in 
suprabasal cell layers and more differentiated cell layers (Figure 5.5C) with strong staining at 
cell membranes and sites of cell contact and these changes in hDlg protein intensity correlated 
with the total levels of hDlg protein detected by western blotting previously (Figure 5.5C; 
Figure 5. A).  Raft cultures of E6ΔPKA mutants, which have lost the ability to negatively 
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regulate the degradation of PDZ proteins, illustrate the most dramatic effect on hDlg protein 
levels.  HFKs containing this mutant genome contain reduced levels of both cytoplasmic and 
membrane associated hDlg protein in more differentiated suprabasal cell layers (Figure 5.5D) 
when compared with other mutants of the PDZ binding motif (E6ΔPDZ) and wild type cells.  
These results indicate that changes to the PDZ binding domain affect the levels of hDlg 
protein in differentiating cells.  Whilst a reduction in hDlg was observed in wild type raft 
cultures and those containing E6ΔPKA genomes, there is not complete loss of the protein.  
This is consistent with the retention of low levels of hDlg in cervical carcinoma cells such as 
Hela (Mantovani et al., 2001).  
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Figure 5.5 Constitutive expression of the E6 PBM correlates with a reduction in hDlg 
protein in organotypic raft cultures.  Organotypic raft cultures of normal HFKs and HFKs 
containing wild type, E6ΔPDZ or E6ΔPKA genomes were grown to 13 days, fixed in 4% 
paraformaldehyde and paraffin embedded sections were prepared for indirect 
immunofluorescence with anti-hDlg antibody (Green) and counterstained with DAPI (blue) 
for detection of nuclei. Images were taken on a Nikon Eclipse E600 microscope at the same 
exposure to avoid any bias. In normal HFKs the staining pattern of hDlg protein is strong and 
predominantly localised to the upper suprabasal cell layers in differentiating cells. The pattern 
of hDlg protein expression in E6ΔPDZ genome containing cells is similar to that of normal 
HFKs with hDlg protein expression at a similar level to that or normal HFKs. HFKs 
containing wild type genomes or the constitutively active E6ΔPKA mutation have diffuse 
pattern of staining in the basal and suprabasal cell layers. hDlg protein is detectable at the 
cell-cell junctions, similar to that of normal HFKs and E6ΔPDZ HFKs however the intensity 
of staining is reduced, particularly in the constitutively active E6ΔPKA mutant which display 
the weakest hDlg protein staining. These images are representative of 3 independent 
experiments carried out in 2 donor lines.    
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5.2.5 hScrib is not targeted for degradation by the E6 PBM in HPV18 
transfected HFKs in organotypic raft cultures. 
The results from hDlg staining of organotypic raft cultures revealed changes in the levels of 
hDlg protein between wild type and mutant genome containing HFKs.  To assess whether the 
levels of other PDZ proteins are affected in a similar manner, the subcellular distribution of 
hScrib was assessed in organotypic raft cultures.  Organotypic raft cultures were grown, fixed 
and paraffin embedded sections were subjected to immunofluorescence with an anti-hScrib 
antibody.  As can be seen in Figure 5.6, there appears to be strong hScrib staining at the 
membrane cytoskeleton/sites of cell-cell contact in normal HFKs, especially in the more 
differentiated cell layers (Figure 5.6).  The levels of hScrib are not changed significantly upon 
infection with HPV18 wild type genomes or HPV18 E6 mutant (E6ΔPKA or E6ΔPDZ) 
genomes (Figure 5.6).  These data are in line with previous western blotting data which 
showed no significant changes in the expression of hScrib protein (Figure 5.3).  Moreover, 
there appears to be no significant change in the localisation of the protein between normal 
HFKs and those containing wild type, E6ΔPDZ or E6ΔPKA genomes suggesting that hScrib 
does not act as a substrate for the HPV18 E6 PBM in differentiating cells.  Failure to observed 
any changes in hScrib could be due to substrate specificity as HPV16 E6 has been shown to 
preferentially target hScrib over HPV18 (Thomas et al., 2003).  Furthermore, the failure to 
observe any significant changes in hScrib protein expression in differentiating cells could be 
due to the fact that the E6 PBM induced subtle changes in the distribution of hScrib which 
were not readily discernible from this assay.  
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Figure 5.6 Changes to the E6PBM do not affect the expression of hScrib protein in 
differentiating cells.   Paraffin embedded sections of normal HFKs and HFKs containing 
wild type, E6ΔPDZ or E6ΔPKA genomes were stained with anti-hScrib antibody (Green) and 
counterstained with DAPI (blue) for detection of nuclei by immunofluorescence microscopy. 
A similar pattern of hScrib staining was observed in normal HFKs and those carrying wild 
type genomes, with hScrib staining being predominantly found in the upper suprabasal cell 
layers of differentiating cells at areas of cell-cell contact/cell membranes. Expression of 
mutants of the E6 PBM do not significantly change the expression or localisation of hScrib 
protein staining in differentiating cells as a similar hScrib staining pattern was observed in 
HFKs containing E6ΔPDZ and E6ΔPKA genomes.  These images are representative of 3 
independent experiments carried out in 2 donor lines.  
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5.2.6 Abrogation of the E6 PBM does not effect connexin-43 expression in 
HPV-immortlaised keratinocytes 
Connexin-43, also known as gap junction alpha-1 protein is a member of the connexin gene 
family and the encoded protein is a component of gap junctions, which are composed of 
arrays of intracellular channels that provide a route for the diffusion of low molecular weight 
materials from cell to cell (Kumar & Gilula, 1996).  Disruption of gap junction proteins is 
frequently reported in malignant cell lines and tumours.  Moreover, reduced connexin 
expression has been found in a number of different tumours (Holden et al., 1997; Saitoh et al., 
1997; Saitoh et al., 2001).  Immunohistochemistry of cervical biopsies showed reduced 
connexin-43 expression in dysplastic regions compared with normal epithelia (King et al., 
2000).  In the context of HPV, loss of connexin-43 expression has been shown to influence 
epithelial dysplasia (Aasen et al., 2003). 
Previous experiments in connexin-43 null mice have shown changes in cell growth rate, loss 
of cell adhesion and altered cell morphology (Martyn et al., 1997; Naus et al., 1999).  Data 
from this study has shown that changes in cell growth and morphology can be attributed to 
HFKs expressing a truncated E6 molecule lacking the PBM.  To determine whether these 
changes in the E6 PBM activity are influenced by the levels of connexin-43 protein 
expression, normal HFKs and HFKs containing wild type and E6ΔPDZ genomes were grown 
to 80% confluency on coverslips and fixed in 4% paraformaldehyde in preparation for 
immunofluorescence with an anti-connexin-43 antibody.  Immunofluorescence analysis of 
normal HFKs and HFKs containing wild type or E6ΔPDZ genomes show no changes in the 
expression level or distribution of connexin-43 within these cells.  From figure 5.7 it can be 
seen that the levels of expression of protein remain consistent between normal HFKs and 
those containing either wild type HPV18 or the E6ΔPDZ mutant genomes (Figure 5.7).   
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Figure 5.7 Abrogation of the E6 PBM does not affect the expression of Connexin-43.  
To assess whether changes in Connexin-43 expression are influenced by changes in E6 PBM 
activity, monolayer cultures of normal HFKs as well as those containing wild type or 
E6ΔPDZ genomes were grown on coverslips to 80% confluency, fixed in 4% 
paraformaldehyde and prepared for immunofluorescence with anti-Connexin-43 antibody 
(Green) and counterstained with DAPI (blue) for detection of nuclei. Immunofluorescence 
analysis of normal HFKs and HFKs containing wild type genomes showed a similar 
Connexin-43 expression pattern, with connexin-43 observed at the cell membrane. Expression 
of E6ΔPDZ genome containing cells does not significantly effect the expression of 
connexion-43 protein as the pattern of connexin-43 expression is similar to that of normal 
HFKs and HFKs containing wild type genomes. These images are representative of 3 
independent experiments carried out in 2 donor lines. 
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Taken together, these results suggest that connexin-43 is not targeted by HPV18 as no 
changes were observed in connexin-43 levels between wild type containing and normal HFKs 
(Figure 5.7). In addition, the abrogation of the E6 PBM does not effect the expression or 
localisation of connexin-43 (Figure 5.7) suggesting that the phenotypes observed in HFKs 
expressing this E6 mutant may not be attributed to changes in connexin-43 expression. 
5.2.7 Abrogation of the PBM does not effect expression of E-cadherin in 
HPV-immortalised keratinocytes 
As previously discussed, in epithelial cells of vertebrates, hDlg is associated with the AJ.  
Adherens junctions are protein complexes which occur at cell-cell junctions in epithelial 
tissues and serve as a bridge connecting the actin cytoskeleton of neighbouring cells 
(Hartsock & Nelson, 2008).  One of the major protein components of AJ is E-cadherin.  E-
cadherin is a calcium dependent cell-cell adhesion glycoprotein.  In epithelial cells, E-
cadherin is often found adjacent to actin containing filaments of the cytoskeleton.  Mutations 
in this gene have implications in a number of different cancers including gastric, breast and 
ovarian cancers (Wijnhoven et al., 2000).  E-cadherin down regulation decreases the strength 
of cellular adhesion within a tissue, resulting in an increase in cellular motility.  In addition, 
the disruption of AJ’s decreases the phosphorylation of E-cadherin by protein kinase CK2 and 
this process of down regulation is a common event in carcinogenesis (Serres et al., 2000).   
To determine whether the changes in the phenotypes observed between wild type containing 
and E6ΔPDZ mutant genome containing cells could be attributed to changes in E-cadherin 
expression, normal HFKs as well as HFKs containing wild type or E6ΔPDZ genomes were 
grown on coverslips to 80% confluence and assessed by immunofluorescence as previously 
described with an anti-E-cadherin antibody (Chapter 2: Materials and Methods, Section 
2.6.3).  As can be seen in Figure 5.8A, E-cadherin can be seen at the cell periphery at sites of 
cell-cell contact.  There appears to be no changes in intensity of E-cadherin staining at the cell 
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cytoskeleton between normal HFKs and HFKs containing HPV18 wild type genomes (Figure 
5.8A).  HFKs containing the E6ΔPDZ genomes have E-cadherin staining at levels comparable 
to normal HFKs and HFKs containing wild type genomes suggesting that the abrogation of 
the E6 PBM does not affect the levels of E-cadherin observed (Figure 5.8A).  
To verify the results seen by immunofluorescence, monolayer cultures of normal HFKs and 
HFKs containing wild type or E6ΔPDZ genomes were grown to 80% confluence and lysates 
were extracted for immuunoblotting with an E-cadherin antibody.  As can be seen in figure 
5.8B, the levels of E-cadherin remain unchanged between normal HFKs and those harbouring 
wild type or E6ΔPDZ genomes (Figure 5.8B).  Taken together these results suggest that E-
cadherin levels are not significantly changed in monolayer cultures containing HPV18 
genomes since no change was observed in E-cadherin levels by western blot analysis or 
immunofluorescence between normal HFKs and HFKs containing wild type genomes.  In 
addition, the data from these experiments suggests that the abrogation of the E6 PBM has no 
significant effect on the levels of E-cadherin expression since no changes were observed in 
this study.     
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Figure 5.8 Abrogation of the E6 PBM does not effect the expression of E-cadherin.  
(A) Monolayer cultures of normal HFKs and HFKs containing wild type or E6ΔPDZ 
genomes were grown to 80% confluency, harvested and prepared for western blotting with 
anti-E-cadherin antibody. No significant changes were observed in E-cadherin protein 
expression between normal HFKs and those carrying either wild type or E6ΔPDZ genomes. 
GAPDH demonstrates equal loading of the protein samples. Western blot is representative of 
3 independently performed experiments in 2 donor lines. (B) HFKs were also grown over 
coverslips, fixed in 4% paraformaldehyde and probed with an anti-E-cadherin antibody by 
immunofluorescence. These finding concur with the findings from (A). There are no 
significant differences in E-cadherin protein expression or localisation between normal HFKs 
and those carrying wild type or E6ΔPDZ genomes. Images are representative of   
independently performed experiments in 2 donor lines.   
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5.3 Discussion 
In this study the ability of HPV18 wild type, E6ΔPDZ and E6ΔPKA genomes to target known 
members of the PDZ domain containing family of proteins were examined.  The differences 
in the behaviour between wild type and mutant genome containing HFKs correlated with the 
level of one of these targets, hDlg.   hDlg has been previously shown to be important for 
regulating cell polarity and proliferation in response to cell-cell contact (Woods et al., 1996).  
E6∆PDZ genomes express a non functional PDZ binding domain and show cellular levels of 
hDlg which are comparable to normal HFKs.  Previous studies have shown that E6 processes 
hDlg for ubiquitin-mediated degradation and that this targeting is regulated by PKA (Kuhne 
et al., 2000).  The E6ΔPKA mutation, which abrogates PKA’s negative regulation, degrades 
hDlg in an E6-dependent constitutive manner, which is independent of cellular PKA levels.   
During the HPV replication cycle, PKA phosphorylation of E6 might be a means of 
regulating degradation of PDZ proteins and changes to mechanisms that regulate PKA 
activity.  Indeed, a loss of PKA recognition of HPV18 E6 stimulates an increase in the loss of 
membrane-bound hDlg-an effect that correlates with enhanced morphological transformation 
of keratinocytes (Kuhne et al., 2000; Watson et al., 2003).  
The decrease in hDlg protein levels exhibited by HFKs containing wild type and E6ΔPKA 
genomes may have been a result of a number of mechanisms.  In addition to E6-directed 
degradation, hDlg is also controlled at the transcription level (Mantovani et al., 2001) so the 
reduction in hDlg levels could be attributed to proteosomal-mediated degradation or 
transcriptional down regulation.  Interestingly, complete loss of the hDlg protein was never 
observed and only slight changes were seen in hDlg levels by immunofluorescence of 
organotypic raft cultures.  This finding is consistent with the retention of the low levels of the 
hDlg protein in cervical carcinoma-derived cells like Hela (Mantovani et al., 2001).  
Furthermore, it is known that nuclear pools of hDlg are preferentially targeted by the E6 
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onocoprotein (Massimi et al., 2003) which may also explain why complete loss of hDlg was 
never observed as it could be a specific pool of the protein which is being degraded.  Viral 
targeting of specific nuclear pools of hDlg provides strong evidence for hDlg having multiple 
functions within the cell (Roberts et al., 2007; McLaughlin et al., 2002) and suggests that 
hDlg may provide a number of functions essential for the survival in epithelial cells.  Western 
blot analysis of HFKs containing E6∆PDZ genomes revelaed a moderate increase in hDlg 
levels compared with normal HFKs.  A recent study by Accardi and colleagues demonstrated 
that the E7 protein of HPV16 was involved in promoting the accumulation of phosphorylated 
forms of the PDZ protein NHERF-1.  The accumulation of these phosphorylated forms of the 
protein were then preferetially targetted by E6 through its PDZ binding domain (Accardi et 
al., 2011).  In the same respect, the E7 protein of HPV18 could be promoting the 
accumulation of phosphorylated forms of hDlg which are unable to be targetted by E6∆PDZ 
genome containing cells (due to the lack of a PDZ binding motif) and may explain the 
increase in hDlg levels observed in these cell lines.  
The presence of a class-1 PDZ binding motif on high risk E6 molecules would, in theory, 
render all cellular class 1 PDZ domain-containing proteins as putative proteloytic substrates 
for this viral oncoprotein.   In the case of other potential PDZ substrates of E6 analysed in this 
study, no significant changes were observed in protein levels of these proteins in monolayer 
cultures of HFKs containing wild type, E6ΔPDZ or E6ΔPKA genomes by western blot 
analysis or by immunofluorescence.  This is in agreement with a parallel study of HPV18 and 
HPV16 and their ability to target other members of the PDZ domain containing family for 
degradation, including FAP1, TIP2 and PTPN13.  In each case, there was a failure to see any 
degradation of these targets by HPV18 or HPV16 (Kranjec & Banks, 2011).  The failure to 
observe any significant changes in the expression of these proteins may also reflect the 
differences in the phosphorylation status of the target protein, which could influence 
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accessibility to the E6 PBM and subsequent targeting as shown in the case of hDlg (Massimi 
et al., 2006, Narayan et al., 2009).  Moreover, it is possible that in binding proteins associated 
with cell polarity, high risk E6 proteins are actually targeting other functions of these proteins 
rather than simply mediating their degradation, such as the hDlg tumour suppressor function 
in its interaction with APC (Ishidate et al., 2000; Massimi et al., 2003) which may explain 
why no changes in the total levels of the protein were observed.   
Western blot analysis of PTPN13 protein levels from HFKs containing wild type or mutant 
genomes revealed the presence of an additional 175 kDa band in cells containing E6ΔPKA 
genomes.  This band was not present in lysates from wild type or E6ΔPDZ genomes.  The 
origin of this band is unknown however it could be a proteolytic breakdown product or an 
alternatively spliced product which is stimulated in these cells.  
In immortalised keratinocytes, E6 disrupts cell-cell association by a number of mechanisms 
including down regulation of expression levels of cell junction components or by interfering 
with pathways that assemble these structures at the cell membrane.  Analysis of the epithelial 
junction marker protein E-cadherin and the gap junction protein connexin-43 were examined 
however no significant changes were observed in expression levels of either protein between 
normal HFKs and HFKs carrying a wild type or E6ΔPDZ genomes.  It is possible that there 
may be some changes in the levels of these proteins; however the changes may be slight and 
not detectable by current the assays used.  A more comprehensive analysis of TJ function is 
required to assess the contribution of wild type and mutant genomes to the degradation and 
localisation of cell junction components, in particular the ZO-1 protein which has been shown 
to be a critical regulator of tight junction assembly (Umeda et al., 2006; Fanning et al., 2007). 
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CHAPTER 6 FINAL DISCUSSION AND FUTURE 
DIRECTIONS 
6.1 Overview of findings 
The E6 proteins of high risk HPV types have been shown to target a number of cellular 
proteins containing PDZ domains.  The interaction between HPV and PDZ proteins is 
mediated by a class I PDZ binding motif (PBM) at the C-terminus of the E6 oncoprotein.  The 
precise function of this domain in the infectious cycle of the virus or in virus-mediated 
carcinogenesis is not known although the E6 PBM has been shown to be important for E6 
transformation of rodent cells (Kiyono et al., 1997) as well as anchorage independent cell 
growth (Spanos et al., 2008) and induction of EMT (Watson et al., 2003; Spanos et al., 2008), 
both of which are hallmarks of cancer and metastatic progression.  Studies in HPV31 
transfected primary HFKs have implicated this domain in the negative regulation of cellular 
proliferation and maintenance replication of viral episomes in undifferentiated cells (Lee & 
Laimins, 2004).  More recent work by Nicolaides and colleagues in a transformed 
keratinocyte cell line transfected with HPV16 substantiate the requirement of the E6 PBM for 
episomal genome maintenance (Nicolaides et al., 2011).  
The study described in this thesis has highlighted the importance of the E6 PBM function 
during both the early and late stages of the HPV18 viral life cycle.   In addition, evidence 
from this study suggests that the function of the E6 PBM in the HPV life cycle and in 
carcinogenesis may be regulated by host cell signalling pathways.  
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6.2 Evaluating the loss of episomes in E6∆PDZ genome containing cells 
These studies have shown that primary human foreskin keratinocytes - the host cell of the 
virus- are able to support wild type genomes of the oncogenic virus HPV18.  Moreover, these 
genomes are stably maintained upon extended passaging, in agreement with similar studies of 
HPV31 (Lee & Laimins, 2004).  Interestingly, E6∆PBM episomes are gradually lost from the 
cells and this effect on viral replication correlates with the appearance of integrated forms of 
the viral genome.  These effects are independent of a constitutive E6 PBM function since 
HFKs containing E6∆PKA genomes, which are constitutively active for PDZ binding, are 
stably maintained upon extended passaging.  The molecular basis for this reduction is 
unknown; however the failure of viral episomes to persist in keratinocytes is a conserved 
feature of other high risk types including HPV16 and HPV31 (Nicolaides et al., 2011; Lee & 
Laimins, 2004).  p53 has been shown to be a potential suppressor of the maintenance 
replication of HPV genomes following infection (Lepik et al., 1998).  In this light, Nicolaides 
and colleagues suggest that the tight regulation of E6 is crucial for the maintenance 
replication in basal cells and that in the absence of an E6 PBM, levels of E6 are not stabilised, 
which may have implications on the ability of E6 to target other cellular proteins such as p53 
(Nicolaides et al., 2011).   
In this study no changes in the expression level of E6 proteins were observed between cells 
carrying the PBM deleted HPV18 genomes and the wild type genome containing cells in 
monolayer cultures or when stratified in organotypic raft cultures, suggesting that the 
episomal reduction observed is not attributed to significant changes in E6 stability.  The 
differences in E6 stability observed between different HPV types could be attributed to 
differences in cell systems used to analyse the viral life cycle or HPV subtype.  The ability to 
detect the E6 protein in vitro and in vivo has previously been notoriously difficult, however 
the development of antibodies which detect the E6 protein have been a major benefit to 
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understanding this protein.  Future work may be to look at the subcellular distribution of the 
E6 protein in HFKs containing wild type, E6∆PDZ and E6∆PKA genomes.   
As previously mentioned the maintenance replication of HPV genomes is not well tolerated in 
cells and requires the viral proteins to alter a number of cellular proteins including p53, Rb 
and PDZ proteins amongst others.  Previous work has shown that these activities are tightly 
regulated in a way that loss of one function often influences the action of another (Park & 
Androphy, 2002).  In a similar manner, the ability of E6 to bind to PDZ proteins may act to 
create a balance with another viral protein activity and a consequence of the inability of the 
E6 protein to target PDZ substrates may be episomal loss.  The molecular basis for this 
episomal clearance is not understood and is an important area of future investigation.  
Further analysis of the HPV18 genome containing cell lines indicated that cells harbouring 
HPV18 genomes unable to target PDZ substrates were defective in normal mitotic 
progression and this correlated with an increase in the number of atypic nuclei in cell cultures 
containing these E6∆PDZ genomes.  Previous studies have shown that during cytokinesis 
there is dramatic accumulation of hDlg within the midbody (Massimi et al., 2003; Unno et al., 
2008).  The presence of hDlg at the midbody suggests that hDlg may play a functional role in 
the process of cytokinesis.  Centrosome abnormalities in response to HPV E6 expression have 
been reported previously and primarily lead to the development of multiple nuclei as well as 
micronuclei and large multi-lobed nuclei which may have formed as a consequence of a 
persistent block of cytokinesis (Duensing et al., 2000; Duensing et al., 2001).  This may be 
explained in part by the ability of HPV E6 proteins to relax G2/M checkpoint control, thereby 
allowing an increased proportion of cells to enter mitosis.  In cells containing E6∆PDZ 
genomes there is an increased frequency of atypic nuclei (particularly bi-nucleate and multi-
nucleate cells) compared with matched cultures containing wild type or E6∆PKA genomes.  
Overexpression studies of hDlg and hScrib have shown that when hDlg and hScrib are 
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overexpressed there is an inhibition of S-phase entry and proliferation (Hanada et al., 2000; 
Ishidate et al., 2000; Nagasaka et al., 2006).  Furthermore, the studies from Unno and 
colleagues show that overexpression of hDlg constructs in Hela cells that contain HPV18 E6 
cause defects in cytokinesis including cellular multinucleation (Unno et al., 2008).  In this 
light it is tempting to speculate that targeting of hDlg by the E6 PBM is required to overcome 
a defect in cytokenesis in HPV containing cells.   Moreover, since maintenance of HPV 
episomes is linked to mitotic tethering of the viral DNA (Sekhar et al., 2010), our 
observations may be relevant to the phenotype of these cells with regards episome 
persistence. 
One experiment to consider would be to introduce a knockdown of the known PDZ targets 
e.g. silencing of hDlg in E6ΔPDZ lines which fail to target PDZ substrates, to evaluate the 
rescue of the episomal loss phenotype and determine which, if any of the PDZ substrates are 
responsible for the phenotypes observed.  During this thesis, stable cell lines (in total 14 cell 
lines) were generated containing individual shRNAs to hDlg in cells containing E6ΔPDZ 
genomes.  Upon analysis of hDlg protein expression by western blotting significant depletion 
of hDlg was not observed (data not shown); however due to time constraints these cell lines 
were not analysed further.  In future analyses it will be important to extend the passage of 
these cell lines to determine if the mutant HPV18 genomes persist in the presence of the 
shRNA – it is possible that a small pool of hDlg has been targeted; also further knock-downs 
should be prepared using multiple pools of the shRNAs as well as shRNAs to other PDZ 
substrates such as hScrib and MAGI-1. 
The reduction in episomes observed in HFKs containing E6ΔPDZ genomes also correlates 
with a loss of the E2 gene in a PCR integration assay.  Integration is a consequence of failure 
to maintain episomal forms of the genome.   The mechanism behind the integration observed 
in HFKs containing E6∆PDZ genomes is unclear however it could be a result of the positive 
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selection of cells with integrated copies of the genome over cells with episomes that are not 
maintained.  A previous analysis in the HPV16-containing cervical keratinocyte cell line W12 
has shown a selection of HPV16 integrants in cells with reduced numbers of episomes (Pett et 
al., 2006).  In agreement with the results from this thesis, parallel studies in HPV16 and 
HPV31 of E6 mutants which are unable to bind to PDZ substrates also show cells containing 
these E6 mutants appear to integrated upon extended passaging (Nicolaides et al., 2011; Lee 
& Laimins, 2004).  Previous studies have shown that cells containing integrated copies of the 
HPV genome acquire a selective growth advantage over cells harbouring episomal copies of 
the viral genome (Pett et al.,  004).  Interestingly, although the mutant genome E6∆PDZ has 
been shown integrate; HFKs containing E6∆PDZ genomes still proliferate slower than wild 
type cells indicating that the E6 PBM does control growth in some manner.  The mechanisms 
for this control have yet to be established.  
In this study, HFKs containing E6ΔPDZ genomes showed a significant reduction in their 
growth, even when compared to normal HFKs.  Conversely, abrogating the negative 
regulation of the PDZ domain by means of the PKA mutation results in a significantly faster 
growth than normal HFKs and HFKs containing wild type genomes.  Previous work by 
Ishidate and colleagues has highlighted the importance of APC and hDlg in regulating cell 
proliferation.  In this study they show that the C-terminal domain of APC interacts with the 
PDZ domain of hDlg to form a complex, and this complex is important in negatively 
regulating cell cycle progression (Ishidate et al., 2000).   Moreover, inhibition of cell cycle 
progression was abolished when the PDZ domain of hDlg was mutated (Ishidate et al., 2000). 
Based on these data it is possible that constitutive targeting of PDZ substrates such as hDlg 
may disrupt the formation of a complex with APC and contribute to the phenotypes observed.    
One of the major activities of the E6 oncoprotein is its ability to inhibit apoptosis, which is 
largely thought to occur through its interactions with p53, Bak and pro caspase 8 (Filippova et 
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al., 2007).  A study by James and colleagues has shown that HPV16 E6 can also inhibit 
apoptosis in a PDZ-dependent manner (James et al., 2006).  A similar study by Zhan and 
colleagues identify Scribble as important in this process as a depletion of Scribble in 
mammary epithelia was shown to inhibit apoptosis (Zhan et al., 2008).  FACS analysis of 
HFKs containing wild type or mutant HPV genomes did not identify any significant sub G1 
peaks, however as there is evidence that these PDZ proteins are important in regulating 
apoptosis, and so further examination should be considered.   
On this basis of these findings, it is tempting to speculate that loss of PDZ targeting by 
phosphorylation of the E6 PBM could promote chromosomal integration of the viral DNA.  If 
this is indeed the case then changes in the cellular signalling pathways such as PKA signalling 
may be a risk factor for malignant progression. 
6.3 Signalling pathways implicated in the phenotypes observed 
A number of the PDZ substrates targeted by the E6 oncoprotein have been implicated in the 
regulation of several signalling pathways in various systems including Wnt, Notch, NF-ΚB 
and STAT signalling pathways.  The precise mechanism by which the polarity regulators 
control signalling is still unclear.  Moreover, how misregulation of these signalling pathways 
are associated with some of these phenotypes observed including loss of episomes, cell 
proliferation, differentiation and invasion is not fully explained.  
NF-ΚB activation has been implicated in the pathogenesis of many cancers (Dolcet et al., 
2005), with roles in a number of different processes related to transformation and oncogenesis 
including proliferation, migration, angiogenesis and prevention of apoptosis.  Studies by 
James and colleagues revealed that HPV16 E6 was able to activate NF-ΚB in airway epithelial 
cells (James et al., 2006) and this was dependent upon the presence of the E6 PBM.  NF-ΚB 
activation in HPV-infected cells is likely to play a role in the proliferative capacity of cells by 
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protecting them from apoptosis, which is reflected in the diminished ability of HPV18 E6 
mutants which are unable to bind to PDZ proteins (E6ΔPDZ) to proliferate and cause 
epithelial hyperplasia in organotypic raft cultures.  An appreciation of which NF-ΚB pathways 
are affected by the E6 PBM and what PDZ substrates are targeted is crucial to the 
understanding of how these PDZ dependent mechanisms contribute to the phenotypes 
observed.  
Upregulation of Notch signalling has already been implicated in a number of different cancers 
including T-cell leukaemia (Clark et al., 2007; Roy et al., 2007).  Studies in Drosophila have 
shown that the Lgl polarity protein is involved in the asymmetric distribution of Numb, an 
inhibitor of Notch signalling (Wirtz-Peitz et al., 2008).  Moreover studies of Lgl null mice 
display enhanced hyperplasia which was associated with increased Notch signalling 
(Klezovitch et al., 2004).  Haematoxylin and eosin staining of organotypic raft cultures 
revealed distinct differences in the morphology of HFKs containing wild type HPV18 
genomes or mutants of the E6 PBM.  E6ΔPKA containing HFKs which are constitutively 
active for binding and degrading PDZ substrates were associated with increased hyperplasia.  
Future work could focus on the contribution of Notch signalling to the phenotypes observed 
by silencing Numb in cells which are unable to bind to PDZ substrates (E6ΔPDZ) and see 
whether the same phenotypes are observed from HFKs containing E6ΔPKA genomes.  
Alteration of Wnt signalling has been shown to be a major factor in the outcome of a number 
of different cancers including colorectal cancers (Clevers, 2006).  hDlg was first implicated in 
Wnt signalling when it was shown that it could bind a negative regulator of Wnt signalling, 
APC (Matsumine et al., 1996).  As previously mentioned, the binding of hDlg to APC has 
been shown to be important for the effects of hDlg on the cell cycle (Ishidate et al., 2000) and 
migration (Etienne-Manneville et al., 2005).  This study has shown that changes to the 
HPV18 E6 PBM have consequences on cell growth.  Constitutive binding of the E6 PBM was 
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associated with a significant increase in growth rates of keratinocytes compared with HFKs 
containing either wild type or E6ΔPDZ genomes and this correlated with lower levels of the 
hDlg protein by western blot analysis and immunofluresence microscopy of monolayer 
cultures and paraffin embedded sections.  Based on these data, it is possible that the changes 
in growth and invasion observed in HFKs containing E6ΔPKA genomes could be attributed 
to a loss of binding of hDlg to APC, which may implicate Wnt signalling as a potential 
pathway for further studies.  
As well as having roles in Wnt signalling, hDlg as well as other PDZ substrates have been 
shown to be important in the function of a number of G-protein coupled receptors (GPCR) 
including the serotonin 2A receptor, mGlu receptor and the tumour marker TEM5 (Xia et al., 
2000; Yamamoto et al., 2004; Funke et al., 2005).  The regulation of these GPCRs often 
requires direct binding of the PDZ substrate to the receptor.  GPCR signalling is regulated by 
mPins (Sans et al., 2005; Yasumi et al., 2005) which has been shown to be a potent tumour 
suppressor in Drosophila neuroblasts (Lee et al., 2005).  GPCR signalling has been shown to 
regulate a number of different pathways including the cAMP signalling pathway.  GPCR 
signalling activates cAMP dependent protein kinase in a feedback loop which requires 
activated cAMP to phosphorylate the receptor.  Loss of GPCR signalling has been shown to 
be associated with tumourigenesis in vitro and in vivo (Schafer et al., 2004).  Data from this 
thesis has shown that changes in cell growth were attribute to changes in PKA signalling as 
treatment of HPV containing keratinocytes with a number of activators and inhibitors of PKA  
resulted in changes in the growth of HPV transfected keratinocytes, suggesting that this 
pathway could be important in determining a mechanism for the phenotypes observed.  
The life cycle of HPV requires the establishment of a persistent infection with low copy 
episomes in infected basal cells.  HPV genomes persist in infected cells by evading the host’s 
innate and adaptive immune responses by a number of different mechanisms.  The 
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JAK/STAT pathway is a major pathway which regulates the innate immune response.  Recent 
studies by Hong and colleagues have shown that suppression of STAT-1 expression by HPV 
E6 was necessary for virus genome amplification and maintenance of episomes (Hong et al., 
2011) and that E6AP binding was required for this suppression, indicating an important role 
for this activity in pathogenesis.  Data from the study described in this thesis has shown that 
the HPV18 E6 PBM is required for the efficient establishment and maintenance replication of 
episomes in donor HFKs.  Moreover, HPV genomes which are unable to bind to PDZ 
substrates (E6ΔPDZ) fail to amplify their genomes when suspended in 1.5% methylcellulose. 
Although STAT-1 suppression may not be involved in the phenotypes observed in this study, 
it is possible that other members of the IFN-stimulated gene factor 3 (ISGF-3) complex such 
as STAT-2 and IFN regulatory factor 9 could be selectively suppressed and that this 
suppression requires an E6-PDZ interaction.   
The malignant potential of the high risk HPV types is largely attributed to the transforming 
potential of the HPV E6 and E7 oncoproteins.  It is well established that these proteins work 
cooperatively.  The E7 protein is responsible for the inactivation of Rb and activation of E2F 
which drives S phase genes.  As a result of unscheduled DNA replication, apoptosis is 
triggered which is counteracted by the E6 oncoprotein by degradation of the tumour 
suppressor protein p53 (Scheffner et al., 1990; Huibregtse et al., 1991).  Based on this 
observation, it is possible that the degradation of PDZ substrates may also be a consequence 
of the cooperative functions of E6 and E7.  Recent studies have shown that the HPV16 E6 and 
E7 proteins work together to target the PDZ protein, NHERF-1 which is involved in 
signalling and transformation (Accardi et al., 2011).  HPV16 E7 was shown to promote the 
accumulation of phosphorylated forms of NHERF-1, which was preferentially targeted by 
HPV16 E6.  In the same manner, high risk E7 and/or other E6 functions may be responsible 
for the accumulation of other PDZ substrates which can be preferentially targeted by the E6 
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PBM, also the virus may induce these specific PDZ substrates for a specific part of the life 
cycle and they are then only targeted by E6 at times when not functional – hence the 
regulation of the E6 PBM by phosphorylation.  
 
6.4 A physiological role for PKA phosphorylation in HPV infected cell 
Loss of conditional regulation of the E6 PBM within HPV18 genomes (E6∆PKA) was 
associated with a significant increase in cell growth compared to cells carrying the wild type 
genomes.  This suggests that changes in PKA signalling in cells carrying wild type genomes 
may lead to changes in growth characteristics.  Indeed, the treatment of HFKs harbouring 
wild type genomes with specific stimulators of PKA signalling (e.g dibutyryl-cAMP) 
impeded keratinocyte cell growth, whilst increased growth occurred upon inhibition of PKA 
signalling using the competitive inhibitor H89.  The positive effects on cell growth were 
verified upon stratification of the E6∆PKA cells in organotypic raft culture which showed 
significant increased hyperproliferation of suprabasal cells compared to wild type genome 
containing cells. 
Conditional regulation of E6-PDZ targeting was also linked to cell invasion.  Cells containing 
the E6∆PKA genomes-which are unable to respond to PKA and thus constitutively active for 
PDZ targeting, showed increased invasion on collagen compared to wild type genomes that 
could still be regulated by PKA.  A study by Watson and colleagues showed that using an 
identical mutation of E6, constitutive activation of the E6 PBM in cells which are unable to 
respond to PKA was associated with an increased EMT phenotype and actin cytoskeleton 
disorganisation (Watson et al., 2003).  Cell invasion is the final step in the process of EMT 
which involves alteration of the epithelium structure and disruption of the basal lamina 
(Goode & Perrimon, 1997).  In this light it is tempting to speculate that the phenotypes 
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observed may be due to an EMT.   Moreover, it is unclear what effect the abrogation of the 
E6 PBM function has on cell invasion.  In the same study by Watson and colleagues, changes 
to the epithelial phenotype of cells containing a mutant which is unable to bind to PDZ 
substrates (Thr156Glu) was less marked, however there was still evidence of some EMT 
characteristics such as actin stress fibre formation (Watson et al., 2003).  Of course in this 
study a deletion of the E6 PBM was not examined and it is possible that the phosphomimic 
mutation Thr156Glu retains a degree of PDZ-binding.  Future studies may focus on the 
requirement of an intact PBM to the invasive phenotypes observed. 
This study has highlighted the importance of a regulated, functional PBM during the life cycle 
of HPV18 and link E6 PBM function to maintenance replication of viral episomes and growth 
regulation of episome-containing cells.  Moreover, changes in activity of E6 PBM are 
associated with alteration in expression levels of some but not all known PDZ substrates 
including hDlg.  It has been 15 years since hDlg was shown to be targeted by the E6 PBM of 
high risk papillomaviruses (Kiyono et al., 1997; Lee et al., 1997).  Since then a number of 
other substrates of the E6 PBM have been identified including the most recent NHERF-1 
protein (Accardi et al., 2011).  A comprehensive analysis of all known PDZ substrates of E6 
is required to determine which PDZ substrates are responsible for the phenotypes observed in 
this study.  It is worth bearing in mind that other potentially important PDZ targets may exist 
which as yet are undiscovered.  Interestingly, western blot analysis of the tyrosine 
phosphatise, PTPN13 in cells containing a constitutively active PDZ domain revealed an 
additional band at approximately 175 kDa and this was present in multiple donor containing 
these mutant genomes.  The origin of this band is unknown however it is of interest that it is 
present in all donor lines which express the constitutively active mutant.  It is possible that the 
additional band represent an alternatively spliced product or proteotlytic breakdown product.  
Further investigation is required to determine the origin of this product.    
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An alignment of HPV sequences from high risk and low risk types, revealed that all of the 
HPV types within the alpha genus recognised as high risk types (Group 1 and 2, Figure 3.1) 
(Bouvard et al., 2009) contain a PBM at the extreme C-terminus.  Moreover, of the types 
frequently found in cancer (Group 1, Figure 3.1) a PKA consensus motif (RXXT) overlapping 
the E6 PBM is a conserved feature, however this recognition motif is not found in viruses that 
contain an E6 PBM and not defined as fully carcinogenic.  The conservation of this PKA 
recognition site within a distinct group of HPV types could therefore represent a molecular 
signature for carcinogenesis since mutation studies within the context of complete HPV18 
genomes (E6ΔPKA) resulted in increased cell growth and invasion.  Interestingly, HPV types 
defined as classified as probably, or possibly carcinogenic (Groups 2A and 2B respectively), 
do contain a PKA recognition motif within the extreme C-terminus of E6, however overlap 
with the PBM is infrequent; only HPV68 and HPV67 from Groups 2A and 2B respectively 
contain a PKA recognition motif which overlaps with the E6 PBM.  Future studies may 
identify whether phosphorylation may alter the interactions between E6 and PDZ substrates in 
these HPV types and others. 
Crystallization studies of E6 PBM-PDZ interactions have shown that the interaction between 
E6 PBM and its substrates occurs within the substrate groove of PDZ molecules between βB 
strand and the αβ helix (Zhang et al., 2007) with the main chain carboxyl group of the E6 
peptide anchored within the motif of the PDZ protein (Zhang et al., 2007).  Studies by Zhang 
and others have shown that arginine 153 contributes to the binding of MAGI-1 PDZ1 but not 
to the binding of hDlg or MAGI-3 PDZ1 (Thomas et al., 2008; Zhang et al., 2007).  
Moreover, mutation of the R
154→G greatly reduced the ability of E6 to bind hDlg and MAGI-
1 and induce their degradation (Zhang et al., 2007) suggesting that additional factors in the E6 
sequence or structure can determine the specificity of binding and indicate that PDZ target 
selection may be influenced by other residues.  A number of studies have shown that minor 
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differences in the E6 PBM can significantly affect PDZ domain targeting (Thomas et al., 
2005; Zhang et al., 2007).  It is possible that the changes made within the PKA-RM may have 
altered substrate selection and it will be important for future studies to verify that the mutant 
has a similar degradation profile of PDZ targets such as hDlg, MAGI-1, -2 , -3 and hScrib as 
the wild type E6 protein. 
Like HPV E6, a number of other cellular proteins with PDZ binding motifs are negatively 
regulated by phosphorylation.  A study by Chung and colleagues showed that casein kinase II 
is able to phosphorylate the serine residue within the PDZ motif of the NR2B subunit of 
NMDAR -a glutamate receptor which plays a critical role during neural development.  
Phosphorylation by CKII was shown to disrupt the interaction between PSD-95 or SAP 102 
and NR2B, resulting in a decrease in the surface expression of NR2B in neurons (Chung et 
al., 2004).  Moreover, studies from the Choi and Chetkovich laboratories have shown that 
PKA phosphorylation of the PDZ ligand of the transmembrane receptor regulatory protein 
STARGAZIN abrogates its binding to the PDZ substrate PSD-95 (Chetkovich et al., 2002; 
Choi et al., 2002).  Similarly, phosphorylation of the PDZ motif on Kir2.3 ion channels 
disrupts the binding with PSD-95 at complexes in the hippocampus (Cohen et al., 1996).  
Other proteins with PDZ motifs which are negatively regulated by phosphorylation include 
the C terminal ligands of the GluR2 receptor which when phosphorylated by PKA and PKC 
in vitro and in vivo, abrogates the binding to the glutamate receptor-interacting protein GRIP 
(Matsuda et al., 1999; Chung et al., 2000).  Other protein/PDZ interactions which are 
inhibited by phosphorylation are listed in Table 6.1.  
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Table 6.1 Phosphorylation of the PDZ domain modultes protein interactions 
 
Whilst many studies have reported that phosphorylation of the C-terminal PDZ domain of 
proteins, negatively regulates PDZ interactions, a number of studies have shown that 
phosphorylation can promote or have no effect upon PDZ interactions.  A study by Von and 
colleagues demonstrated that calmodulin dependent kinase II and PKA phosphorylation of 
FATZ3 and FATZ1 respectively mediated the interaction with the PDZ proteins of ZASP, 
Cypher and other Enigma family protein members (Von et al., 2009).  Conversely 
phosphorylation of the NR2C subunit of NMDAR by PKA and PKC did not affect binding to 
PSD-95 (Chen et al., 2006).   
It is important to note that other viruses may also regulate their interactions by 
phosphorylation of the PDZ domain.  Recent studies have shown that CKII phosphorylation 
of the HTLV-1 PDZ binding motif abolishes Tax-1 binding to hDlg indicating that 
phosphorylation of the PBM is an important mechanism which is shared amongst other virus 
types (Bidoia et al., 2010).  Data on the phosphorylation sites of PDZ domains and the roles 
of phosphorylations of these domains will be useful to determine a regulatory mechanism for 
PDZ mediated interactions.  Future studies may focus on how the phosphorylation of the E6 
PBM affects the binding of E6 to all known PDZ substrates, i.e. does it enhance, suppress or 
have no effect on binding specific PDZ domain containing proteins.  Moreover, 
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phosphorylation of the E6 PBM may result in the binding to other novel proteins which are 
not yet defined (Li et al., 2011).  
6.5 Final Statement 
These novel studies have shown that the E6 PBM, a conserved motif amongst high risk HPV 
types, has a crucial role in the early and late stages of the HPV18 life cycle.  Interestingly, 
those HPV types that have a strong association with human cancers have evolved a strategy to 
regulate this domain by phosphorylation, and the data described in this thesis indicates that 
the conditional regulation of this domain is of physiological relevance to the HPV replication 
cycle and maintenance of viral episomes.  Moreover, these studies provide evidence to 
suggest that changes in PKA signalling in cells infected with high risk HPV types has 
consequences on viral pathogenesis.  Loss of PKA signalling in these studies using intact 
HPV genomes is associated with increased cell proliferation and cell invasion; both hallmarks 
of carcinogenesis.  Thus changes in PKA signalling and phosphorylation of E6 during specific 
stages of the life cycle and/or malignancy can be expected to regulate this activity of E6.  In 
addition, a change to the E6 PBM function in the viral genome-containing cells was 
associated with changes in expression of substrates of the E6 PBM including hDlg and 
PTPN13. 
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